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Abstract
In this work conjugates of poly amines have been designed and synthesised for 
therapeutic evaluation against cancer cells and trypanosomal targets.
The positive charges carried by endogenous polyamines at physiological pH give 
them high affinity for DNA leading to groove-binding. A dedicated cellular polyamine 
uptake system has been characterised which is upregulated in rapidly proliferating cells 
(e.g. many cancers). Anthracene and acridine are cytotoxic DNA intercalators. This 
cytotoxicity was enhanced by the design and synthesis of conjugates with polyamines to 
give stronger DNA binding through bifunctional modes of DNA interaction 
(simultaneous intercalation and groove binding), and potential cellular uptake by the 
polyamine transporter.
Regioselective protection of the tetraamine spermine allowed nucleophilic 
conjugation to the 9- position of the polyaromatic, either through an amide (anthracene 
and acridine) or by direct substitution of a phenoxide (acridine), by a primary amine. 
Acridine conjugates were also synthesised with a variety of spacers between the acridine 
and the spermine moieties. These conjugates were used in cytotoxicity assays by M. A. 
Qarawi, University of Bath, in vitro against B 16 murine melanoma cells. The most 
cytotoxic conjugate was a 9-aminoacridine with a 5-aminopentanoic acid derived spacer 
with a cytotoxic EC50 of 2.7x1 O' 7 M.
Further conjugates were prepared replacing spermine with tetraamines with 
different configurations of methylene groups. These compounds were produced by solid 
phase organic synthetic techniques and employed the 4-pentenoyl protecting group for 
the first time in solid phase polyamine synthesis.
Syntheses were designed for 23- 24- and 28-membered macrocyclic analogues of 
cadabicine, a spermidine containing plant natural product. Polyamine protection 
controlled the polyamino regiochemistry and macrocyclisation was achieved by forming 
diphenyl ether bonds through SNAr displacement of an ortho-nitro activated fluorine by 
a phenol. These conjugates will be tested as inhibitors of trypanothione reductase, a key 
medicinal target against trypanosomal parasites.
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1.1 General Introduction to Poly amines
Polyamines are structurally simple low molecular weight aliphatic amines. They 
are cellular components, essential for normal growth and replication (Tabor and Tabor, 
1964). The two key endogenous polyamines are the tetraamine spermine 1 (bis-A^.A2- 
(3-aminopropyl)-l,4-diaminobutane; 4,9-diaza-l,12-diaminododecane) and the triamine 
spermidine 2 (Af-O-aminopropyO-M-diaminobutane; 4-aza-l,8-diaminooctane). The 
closely related diamine putrescine 3 (1,4-diaminobutane) is also of importance both as 





Spermidine 2 Putrescine 3
These compounds are essentially fully protonated at physiological pH (7.4) (Table 1.1) 
and it is the string of positive charges along their length which lies behind much of their 





Spermidine 2 Putrescine 3
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Table 1.1 Measured p/fa values for simple amines
Amine p /fa’s
Putrescine 3 10.80, 9.63a
Spermidine 2 11.56, 10.80, 9.52b
Spermine 1 11.50, 10.95,9.79, 8.90b
Propylamine 10.54“
Butylamine 10.60“
(a. Albert and Serjeant, 1984; b. Takeda et a i,  1983)
Nature has evolved a system of biosynthetic and interconversion enzymes which 
keep intracellular poly amine concentrations constant, normally in the (iM range (Tabor 
and Tabor, 1984). At times of rapid cellular growth and division, the concentrations of 
endogenous polyamines can rise to mM levels, a situation particularly apparent in 
cancer cells (Tabor and Tabor, 1984). There also exists a polyamine transport 
mechanism (Felschow et al., 1995) which allows cells to scavenge exogenous 
polyamines from their environment which they can substitute for those created by de 
novo synthesis, a system which may also be reversed to allow cells to excrete excesses 
(Grillo and Colombatto, 1994). Their crucial cellular roles and specific enzymatic and 
transport pathways make poly amines desirable targets for therapeutic intervention. The 
plethora of poly amine conjugates found throughout the plant and animal kingdoms 
means there are many natural products which can be assessed for therapeutic activity 
through interaction with macromolecular biological anions (e.g. proteins, DNA), as 
inhibitors of enzymes with polyamine or polyamine derived substrates or through 
interference with intracellular polyamine levels.
3
The importance of the specific polyamine structures to cellular processes becomes 
apparent when the amount of energy expended in their biosynthesis is considered. If 
they simply fill a role of charge neutralisation, then metallic cations would be more 
energy efficient replacements. If the spacing between the positive charges is also of 
importance, then potentially a polylysine could substitute. Research is still ongoing and 
the knowledge of the specific mechanisms of polyamine action is continually being 
updated. Due to their physiological activities, both endogenous and synthetic 
polyamines as well as polyamine containing conjugates are of considerable interest in 
the field of medicinal chemistry. Much work has been published on polyamine based 
therapies against cancers and against protozoal diseases. Small molecule polyamine 
conjugates from certain spiders and wasps have been shown to block cation channels, 
leading to interest in them both as pharmacological tools and as treatments for 
neurodegeneration.
Polyamines form the backbone for iron scavenging siderophores used by microbes 
to sequester the iron they require from their environment. These compounds and their 
analogues are of interest to investigate iron transport in cells and the role of iron in 
infection as well as treatments for diseases associated with iron imbalance. Triamines 
have been used in conjugates to effect site-selective DNA and RNA cleavage, the acid- 
base cooperativity between adjacent amine groups being the key to their activity. The 
affinity of polyamines for DNA has been the basis for a number of synthetic conjugates 
which condense and deliver DNA particles to cells in order to express genes. This is a 
key strategy in gene therapies which could eventually treat genetically caused illnesses 
such as cystic fibrosis. For reviews of medicinal chemistry research in these areas, see: 
Marton and Pegg, 1995 and Blagbrough et al., 1997.
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1.2 Polyamine Biosynthesis
The polyamine biosynthetic pathway has been characterised by a number of key 
enzymes which synthesise or metabolise polyamines, maintaining their required 
intracellular concentrations (Fig. 1.1) (Marton and Pegg, 1995). In mammals, synthesis 
begins from the a-amino acid L-ornithine, which itself is derived from DNA-encoded L- 
arginine. L-Ornithine decarboxylase (ODC) performs decarboxylation to yield the 
diamine putrescine 3. S-Adenosylmethionine (AdoMet) is decarboxylated by S- 
adenosylmethionine decarboxylase (AdoMetDC) to give a species (dcAdoMet) which is 
an aminopropyl donor. In conjunction with spermidine synthase and then spermine 
synthase, putrescine 3 is successively aminopropylated to give spermidine 2 and then 
spermine 1 .
In the metabolic pathway there are two key enzymes. Spermidine/spermine-iVy- 
acetyltransferase (SSAT) acetylates a propylamine moiety in either spermine or 
spermidine to give a substrate for polyamine oxidase (PAO) which then cleaves the 
acetylated propylamine. Both putrescine 3 and Ay-acetylspermidine can be readily 
excreted from the cell and putrescine 3 can also be degraded by diamine oxidase. 
Inhibitors have been found for all of the enzymes in both the catabolic and metabolic 
pathways and have been used in therapeutic regimes (Marton and Pegg, 1995). The 
polyamine biosynthetic pathway is strongly repressed in the presence of polyamines so, 
when depletion begins to occur, the catabolic enzymes make large compensatory 
increases in their activity. There is a rapid cycling of the enzymes, ODC has a half-life 
of 2 0  minutes, so often inhibitors have to be administered for extended periods of time 
for continued effectiveness. Overall these inhibitors are cytostatic rather than cytotoxic 
making polyamine inhibitors more useful as compounds to be co-administered alongside 
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(after Marton and Pegg, 1995)
1.3 Poly amine Transport
Many cell types have been shown to possess dedicated polyamine uptake 
mechanisms which are distinctly separate to amino-acid transport systems (Morgan, 
1990; Seiler and Dezeure, 1990; Grillo and Colombatto, 1994). The polyamine 
transporter is upregulated under circumstances where cells require greater polyamine 
quantities than can be produced by de novo synthesis. It can be induced by endogenous 
hormones and growth factors as well as by depleting the cell of polyamines by 
biosynthetic enzyme inhibitors. The transporter is upregulated in cancer cells and in 
cells which have been stimulated to proliferate (Seiler et al., 1990) and it is regulated by 
the concentrations of intracellular polyamines. It has been shown that induction of the 
system actually involves synthesis of new transporter protein rather than modifying 
existing protein in a way which modulates polyamine affinity (Mitchell et al., 1992). 
Excess of intracellular spermine 1 or spermidine 2 is considered to be the signal to 
terminate the uptake by causing the production of a short-lived regulatory protein 
(Mitchell et al., 1992). Investigations have been carried out to investigate the variability 
in structure of synthetic polyamines which are recognised and transported (Porter et al., 
1984; Felschow et al., 1995 and 1997). This work is of particular importance for the 
design of polyamine derived anti-cancer agents which can be designed to use this system 
(Cohen and Smith, 1990; Marton and Pegg, 1995). Also, in related studies, the toxicity 
of the dipyridinium species paraquat (A,A-dimethyl-4,4'-dipyridinium) 4 has been
shown to be via a specific transporter (Smith et al., 1982; Brooke-Taylor et al., 1983). 
This gives a basis for the lung specific toxicity observed in paraquat 4 poisoning.
Paraquat 4
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1.4 Novel Polyamine Natural Products
Polyamines have been isolated from many natural sources. There are an especially 
large number of plant alkaloids containing polyamine moieties (Guggisberg and Hesse, 
1983 and 1998). Many of these natural products are of interest to medicinal chemists, 
providing leads in the development of novel therapeutic agents, illustrated below by four 
examples of polyamines isolated from plants or cultures.
The sterol sulfate-spermidine conjugate squalamine 5 (Moore et al., 1993), 
isolated from the liver and gallbladder tissues of the dogfish shark Squalus acanthias, 
shows antitumour, antimicrobial and fungicidal activities. It also induces osmotic lysis 




Pseudoceratidine 6 , is a terminally diacylated spermidine derivative which has 
been isolated by the research group of Tsukamoto from the marine sponge 
Pseudoceratina purpurea (Tsukamoto et al., 1996). It has potential as an anti-fouling 
agent in the paint applied to ship hulls to inhibit the undesirable growth of both 
macroscopic and microscopic organisms (Ponasik et al., 1996 and 1998).








Spergualin 7 is a peptide conjugate of spermidine 2 isolated from culture filtrates 
of Bacillus laterosporus (Nishizawa et al., 1988). It shows antibiotic and antitumour 
activity and minor modifications to the structure yield potent immunosupressive 
compounds with effectiveness in preventing organ rejection after transplant (Umeda et 
al., 1987; Nishizawa et al., 1988).
OH O OH H
xHN N
Spergualin 7
Kukoamine A 8  is a spermine conjugate terminally di-acylated with dihydrocaffeic 
acid isolated from Lycium Chinese (Chantrapromma and Ganem, 1981). It has been 
shown to have antihypertensive activity (Funayama et al., 1980) and more recently to be 
a potent, selective inhibitor of trypanothione reductase vide infra, a key target in current 






1.5 Polyamine Antiparasitic Conjugates
Parasitic disease continues to be a major problem for world-wide health. Malaria
threatens half of the global population and the incidence of strains of protozoa resistant
to the current drugs is ever increasing (Marton and Pegg, 1995). The acquisition and the
use of polyamines are sufficiently different in such parasites compared to in mammals
9
that therapies based on polyamine mechanisms are attractive. DFMO 9 is an 
irreversible inhibitor of ODC, the enzyme which generates putrescine 3 from L- 
ornithine at the beginning of polyamine biosynthesis. Malaria causing parasites of the 
genus Plasmodium develop in mammalian erythrocytes. In this environment, there are 
low levels of polyamines which the parasite can easily sequester, so it must synthesise 
its own to provide enough to facilitate the synthesis of the proteins required for its 
growth and development (Assaraf et al., 1984; Whaun and Brown, 1985). DMFO 9 
inhibition of putrescine 3, and hence polyamine biosynthesis in in vitro models leads to 
the arrest of parasite development at an early stage (Assaraf et al., 1984). Exposure to 
putrescine 3 leads to a reversal of the effects, spermidine levels rise and development 
resumes. Unfortunately, in vivo DMFO 9 proves to be less effective. It has been 
suggested that parasites can take up putrescine 3 from plasma by increasing transport 
across the cell membrane of the infected erythrocytes (Singh et al., 1997). In order to 
counter this, investigation has recently been started into combination therapy with N 1, 
A^-bis(7-chloroquinolin-4-yl)butane-1,4-diamine (BCBD) 10, an inhibitor of the 
putrescine uptake mechanism (Singh et al., 1997).
DFMO 9 BCBD 10
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Another compound which shows good activity against P. falciparium in vitro and 
cures P. bergi infections in mice is the terminally di-benzylated tetraamine 11 (Bitonti et 
al., 1989). Its development came about through structure-activity studies sparked by the 
success shown by dialkylated tetraamines against cancer cell lines (Edwards et al.,
1991) vide infra. Polyamine 11 is used in conjunction with DFMO 9 which stimulates 
its uptake by the parasite. As with the anti-cancer compounds, once in the cell it is 
thought to displace natural polyamines from critical binding sites disrupting normal 
cellular processes. Although less active than chloroquine 12, this treatment is more 




Other genera of parasites causing human disease are Trypanosoma and 
Leishmania. T. brucei gambiense causes sleeping sickness, T. cruzi causes South 
American Chaggas disease and Leishmania species cause Leishmaniasis. DMFO 9 has 
been used to treat T. brucei infections (Marton and Pegg, 1995). The parasite’s ODC 
enzyme turns over less rapidly than that of the mammalian host, which is desirable, but 
it is less sensitive to DFMO 9. Despite this, DFMO has proved to be effective and in 
fact is the only new drug to be licensed to treat sleeping sickness in the last 40 years
11
(Marton and Pegg, 1995). The reason for its success probably lies with the differences 
in the way the parasite biosynthesises and uses polyamines compared to its host. At the 
simplest level, DFMO 9 will halt trypanosomal development through polyamine 
deprivation leaving it susceptible to attack by the host’s immune system. Two other 
contributory factors might be the build up of massive concentrations of AdoMet and the 
cessation of the synthesis of trypanothione 14.
In the parasitic system, AdoMetDC is not regulated in the same way as in 
mammalian systems, so that, when polyamine biosynthesis ceases, AdoMet continues to 
build up and is not metabolised (Byers et a l, 1991). Glutathione 13 is the tripeptide 
TGluCysGly which is present at mM concentrations to protect mammalian cells from 
toxic free-radicals and electrophiles, including those generated in vivo during xenobiotic 
metabolism. Trypanothione 14 is the parasitic equivalent of mammalian glutathione 13 
(Fairlamb and Cerami, 1992). Trypanothione is a ^w-glutathione conjugate with 
spermidine which cannot be produced if polyamine synthesis is halted. It has a dithiol 
14 which is oxidised to a disulfide bridge 15 in the presence of active oxygen species.
In order to regenerate trypanothione 14 the enzyme trypanothione reductase (TR) is used 
to cleave the disulfide bond. It has been shown that glutathione disulfide (the 
mammalian equivalent of trypanothione disulfide 15) is not processed by trypanothione 
reductase and equally it has been proven that trypanothione disulfide is not processed by 
mammalian glutathione reductase (Krauth-Siegel et a l,  1987). This has lead to the 
belief that enzyme inhibitors can be designed which inhibit TR but do not affect 
glutathione reductase. Inhibition of TR would severely compromise the parasitic 
defence system against free-radicals, either naturally occurring or introduced by a drug 







Trypanothione 14 Trypanothione disulfide 15
One method of anti-trypanosomal treatment is the administration of 5-nitrofurans 
such as nifurtimox (Walsh et al., 1991) which undergo redox cycling with NAD(P)H 
generating more oxygen radicals than the trypanothione system can cope with.
For treatment with DFMO 9 to be successful the patient must be hospitalised for 
14 days with intravenous DFMO for 6  h each day (Marton and Pegg, 1995).
Fortunately, DFMO has low toxicity so there are few toxic effects from such long 
exposure, but it is expensive to produce, a major problem to the impoverished African 
nations where sleeping sickness is endemic. A more effective inhibitor of polyamine 
synthesis is Abe Ado 16 which inhibits the AdoMet enzyme. The most dramatic change 
shown in trypanosomes treated with AbeAdo is a greatly elevated concentration of 
AdoMet which is thought to be the cause of the antitrypanosomal effect (Byers et al.,
AbeAdo 16
An important organism where DFMO 9 is not an effective treatment is T. cruzi. 
Investigations of this trypanosome have shown that during certain stages of its life-cycle 
it does not produce putrescine from either ornithine, as in mammals, or from arginine, a 
process common in most species except mammals and yeast (Tabor and Tabor, 1984). 
Instead, it synthesises polyamines from putrescine 3 and cadaverine (1,5-diamino- 
pentane) 17 which it scavenges from its host organism. Spermidine and spermine are 
synthesised as well as the equivalent tri- and tetraamines from cadaverine 17.
As DFMO 9 has little effect, enzyme inhibitors for trypanothione reductase (TR) 
have become target combative agents. It has been known from the beginning of the 
twentieth century that trivalent aromatic arsenicals can be used to treat parasitic 
infections (Walsh et a l,  1991). Even after 80 years of use, the mechanism of action has 
only just been elucidated. The arsenic binds to trypanothione linking the thiols to form 
a macrocycle which is then an inhibitor of TR (Walsh et al., 1991). The problem with 
the arsenical and nitrofuran drugs is their human toxicity so a specific inhibitor for TR 
would be anticipated to be much more acceptable, having little or no affinity for the 
mammalian glutathione reductase. TR inhibitors have been described, mostly taking the 
form of terminally substituted spermine and spermidine derivatives. The initial lead
Cadaverine 17
was the plant natural product kukoamine A, Ay,A^-bis(dihydrocaffeoyl)spermine 8  
(Ponasik et a l,  1995). Other potent inhibitors include //-alkylated tetraamines diphenyl 
18 and dinaphthyl 19, and the A-alkylated dinaphthyl triamine 20 (O’Sullivan et al., 
1997).
So far these compounds have only been shown to have trypanocidal activity in 
vitro and have failed to demonstrate any in vivo activity. They are still being 
investigated and have the potential to yield compounds with good activities and low 
host toxicities.
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1.6 Polyamine Conjugates in the Treatment of Diarrhoea
In 1964, Tabor and Tabor reported that relatively high concentrations of spermine 
1 and spermidine 2 are found in the gastrointestinal tract (Tabor and Tabor, 1964). 
Acting on this information, Tansy and co-workers were keen to characterise the 
physiological activity of polyamines in the gut, so initial investigations were carried out 
with polymers derived from ethylenimine, commonly available polyamine containing 
compounds with a variety of industrial uses (Melamed et a l ,  1977). Branched-chain 
polymers were shown to inhibit gastric emptying in rats whilst linear structures had 
negligible physiological activity. From these results, it was thought that polyamines 
might find use as appetite suppressants or in prolonging the action of orally 
administered drugs. However, further experimentation employing oral administration to 
dogs showed a severe retching response (Tansy et a l,  1977). Investigations were also 
carried out with small molecule polyamines and synthetic close analogues (Belair et a l, 
1981). Amongst these compounds, the naturally occurring polyamines were found to 
have a profound effect on gastric emptying whilst synthetic analogues were shown to 
have significantly lower activities.
In the course of HIV related infections, there is the frequent occurrence of serious 
diarrhoea either as a result of infection or as a side effect from certain drugs. So far this 
diarrhoea has been difficult to treat, existing drugs giving only partial responses and the 
therapy is accompanied by a high relapse rate. A new approach to treatment has been 
the use of synthetic polyamines, developed by Bergeron and co-workers (Bergeron et 
a l,  1996), to slow gut motility. After initial structure-activity assessment, DEHSPM 
was found to show anti-diarrhoeal activity in a castor-oil induced diarrhoea model in 
rats and has now been used to treat patients in the clinic. The drawback with this 




In vivo studies have shown that DEHSPM 21 is first metabolised by N-de- 
ethylation. Normally, the next stage in polyamine metabolism would be removal of the 
3-aminopropyl moieties through the action of SSAT and PAO. However, the remaining 
homospermine contains only 4-aminobutyl fragments and so is not metabolised, this 
leads to accumulation in the patient's tissues. This problem has been resolved by 
synthesising compounds substituted with hydroxyl groups (on tetrahedral carbon atoms 
of ^-configuration) on methylenes located y-to the ethylated amines 22. These alcohol 
functional groups offer potential sites for enzymatic conjugation or oxidation leading to 
further metabolism and elimination. Studies showed that dioltetraamine 22 retains its 
gastrointestinal activity and has significantly reduced chronic toxicity, although the 
exact mechanism of degradation is not known (Bergeron et a l ,  1996). These results 
illustrate the way in which toxicity associated with polyamines can be reduced without 
the loss of therapeutic effects.
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1.7 Polyamine Ion Channel Blockers
Spermine 1 is found in the venoms of certain spiders where it accompanies a 
range of small molecule phenols (Fischer and Bohn, 1957; Gilbo and Coles, 1964). 
From these venoms, many structurally novel polyamine amides 23-28 have now been 
isolated (for recent reviews of these argiotoxins, see: Blagbrough and Usherwood, 
1992; Schafer, et al., 1994) and characterised pharmacologically (for reviews, see: 
Usherwood and Blagbrough, 1991; Carter, 1995; Mueller et al., 1995). These low 
molecular weight polyamine containing toxins (argiotoxins) are potent and selective 
non-competitive antagonists of glutamate receptors, blocking the cation-selective 
channels associated with this excitatory a-amino acid (both NMD A- and non-NMDA 
glutamate receptors). Therefore, they have potential as pharmacological probes and as 
lead compounds for the design of drugs to treat neurodegeneration, especially stroke 
(Parks et a l,  1991; Blagbrough and Usherwood, 1992; Carter, 1995). However, 
unsymmetrical polyamine amides require total syntheses for sufficient material to be 
available for detailed pharmacological characterisation as well as for complete 
confidence in the structural assignments.
The novel poly amine FTX-3.3 29 (Blagbrough and Moya, 1994) and the 
polyamine amide sFTX-3.3 30 (Moya and Blagbrough, 1994) are important 
pharmacological tools for modulation of voltage-sensitive calcium channels (VSCC). 
These polyamines block VSCC with differential inhibition in mature rat cerebellar 
Purkinje cells (Dupere et al., 1996) and antagonise P-, N- and L-type VSCC in a 
voltage-dependent manner (Norris et al., 1996). Other pharmacological evidence for 
cation channel block comes from one endogenous role of cytosolic spermine 1  and 
spermidine 2 as gating molecules for inward rectifying potassium channels (Ficker et 




















The venom of a solitary parasitic wasp (Philanthus triangulum) contains 
thermospermine 31 (a regioisomer of spermine) conjugated to L-tyrosine in PhTX-4.3.3 
32. This unsymmetrical polyamine amide is essentially equipotent with synthetic 
spermine-containing analogue PhTX-3.4.3 33. Poly amine amides (philanthotoxins) are 
potent blockers of the cation channels gated exogenously by nicotine and endogenously 
by acetylcholine or glutamate. That they are cation channel blockers is not surprising 
given their structures, essentially fully protonated at physiological pH. The pATa data for 
PhTX-3.4.3 33 have recently been published: 11.4, 10.4, 9.5 and 8.5, although the third 
measured pATa (9.5) also accounts for the phenolic functional group, and therefore an 
increase in acidity from pH 10.4 to 9.5 finds both the secondary amine nearer to the 
tyrosine residue, and the phenoxide of tyrosine gaining protons (Jaroszewski et al., 







1.8 Polyamine Containing Ion Chelators
In all forms of life, except for a few species of bacteria, iron plays an important 
role, principally in metabolic processes where the interconversion between the + 2  and 
+3 oxidation states is utilised in a variety of redox proteins. In the environment, iron 
generally occurs at the ferric oxidation level which is largely insoluble and hence 
presents the problem to micro-organisms of how to obtain the iron they require. 
Microbes have solved this problem by generating iron chelator systems (siderophores) 
which complex ferric iron allowing it to be accessed (Bergeron, 1984). Many 
siderophores contain polyamine or polyamide moieties, e.g. desferrioxamine B 34, 
parabactin 35 and agrobactin 36. Phytosiderophores are low molecular weight ion 
chelating compounds endogenous to plants. They facilitate iron solublisation and 
transport in a manner analogous to the microbial siderophores. The phytosiderophore 
nicotianamine 37 (Scholz et a l,  1992; Matsuura et a l,  1994) is a triamine which 
contains a primary, a secondary and a tertiary amine functional groups. These polyamine 
based compounds are potential treatments for haemochromatosis (p-thalassaemia), 











HO' H CO,H H CO,H
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R = H, Parabactin 35 
R = OH, Agrobactin 36
Nicotianamine 37
21
1.9 Polyamine Conjugates as Artificial RNAase and DNAase
Komiyama and co-workers have recently published work on the design and 
synthesis of synthetic catalysts which hydrolyse RNA with the aim of developing 
systems which mediate site-selective scission. Originally, the catalysts were based 
around transition metal chemistry, but recent developments have incorporated 
oligoamines, such as ethylenediamine, which will efficiently hydrolyse RNAs 
(Yoshinari et al., 1991). The mechanism of action in this cleavage is by intramolecular 
acid-base co-operation between an ammonium cation and an uncharged amine. In order 
to make a site-selective RNA cleaving agent, diethylenetriamine has been linked to a 19- 
mer piece of synthetic DNA 38, designed in order that the DNA sequence is 
complementary with the RNA sequence, adjacent to the desired site for scission.
Ethylenediamine is used here for its acidity, rather than as a metal ion chelator. 
The pA'a’s of ethylenediamine are 9.2 and 6.5 (Yoshinari et al., 1991), or 9.92 and 6 .8 6  
(Albert and Serjeant, 1984). However, “that intramolecular co-operation between two 
amino residues plays a dominant role is strongly evidenced” with “remarkable 
acceleration of RNA hydrolysis by simple oligoamines as highly potent catalytic 
moieties for artificial ribonucleases” (Yoshinari et al., 1991). DNA intercalators 
(anthraquinones) substituted with metal chelating moieties (ethylenediamines), and 
complexed to cupric ions, induce the chain cleavage of double stranded DNA (Ihara et 
al. 1994). Other artificial ribonucleases have been designed on a poly amine or 
amine/imidazole template, with acridine used to effect RNA intercalation (Shinozuka et
H
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In vitro, poly amine interactions with naked DNA cause precipitation, protection 
from denaturation by heat or shearing and formation of particles (Tabor and Tabor, 
1984). Further studies have shown the quantitative relationship behind these 
interactions demonstrating that DNA is condensed when about 90 % of the negative 
charges on the sugar-phosphate backbone have been neutralised; an event predicted by 
the counter-ion theories of Manning (1978). When such experiments are performed in 
dilute solutions of DNA there is compaction into discrete particles identifiable as rods, 
spheres or toruses under the electron microscope (Gosule and Schellman, 1976).
When DNA is exposed to dilute solutions of polyamines, transformations are 
observed between structural forms. Initially, it was assumed that the nature of 
polyamine-DNA interactions was solely through electrostatic attraction between 
ammonium cations and the anionic phosphate (Tabor and Tabor, 1964). Recent work 
has shown that this is not normally the case and that there are preferential polyamine 
binding sites associated with the major and minor grooves of DNA. The locations of 
these sites have often proved elusive as the binding is not long lived with frequent 
migration of poly amines between sites. For this reason, NMR spectroscopic and even 
X-ray studies have often proved inconclusive. Polyamines do not contain chromophoric 
moieties and conjugation to chromophores or photoaffinity labels will affect the mode 
of binding to some extent. Computer molecular modelling has gone a long way in 
identifying preferential binding sites (Haworth et a l,  1991) along with UV spectroscopy 
and DNA footprinting. In GC rich regions, there is a binding site in the major groove, 
identified by molecular mechanics and by experiment showing spermine 1 blocks inter­
strand cross-linking by 2,5-diaziridinylbenzoquinone 39, a DNA cross-linker with a 
preference for a specific GC site (Yuki et al., 1996).
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2,5-Diaziridinylbenzoquinone 39 
The formation of hydrogen bonds between DNA bases and polyamines when 
bound cause bending of the double helix (Feuerstein et al., 1986 and 1990). Higher 
concentrations of polyamines can cause changes in the helical structure, typically with 
transformations between Z and B (Behe and Felenfeld, 1981) or B and A (Jain et a l , 
1989) forms, depending on the exact conditions. These transitions typically occur at 
polyamine concentrations comparable to those in the intracellular environment. 
Polyamines, along with histones, fulfil crucial roles defining the structure of chromatin 
and protecting DNA (Marton and Pegg, 1995). Depletion of nuclear polyamines leaves 
DNA much more susceptible to digestion by DNAase enzymes suggesting a change in 
the chromatin structure and relaxation of DNA to a less compacted form (Basu et a l,
1992). Histones account for 50 % of the charge neutralisation of chromosomal DNA 
(Matthews, 1993). Polyamines can provide charge neutralisation for the remainder 
through either non-specific interactions or interactions at their preferred binding sites. 
By modulating acylation of the histone and polyamine populations, cells can control the 
bending of DNA, a process which may be important at times of nucleosome formation 
and gene expression. Both histone H4 and spermidine are acylated by histone 
acetyltransferase, in the same region of chromatin. High levels of acylated histone H4 
are associated specifically with transcription (Waterborg et a l, 1984) leading to the 
hypothesis that there is a synergistic interaction between acylated histone and 
spermidine in this process (Matthews, 1993).
1.11 Gene Therapy
Gene therapy is the correction of a genetic fault (e.g. cystic fibrosis) by delivering 
DNA containing a correct copy of the defective gene across a cellular membrane and 
thence to the cell nucleus. Some sort of compaction and charge neutralisation system is 
required to package the foreign DNA into a suitable form for cellular uptake. Once 
inside the cell, the DNA must escape the lysosome and migrate to the nucleus where it 
can be incorporated into the genetic material and express the correct gene.
Polyamines have been shown to compact DNA into forms suitable for uptake into 
cells, but initial studies with spermidine and spermine showed that although the DNA 
was suitably compacted, the polyamine/DNA interactions were readily reversible 
making them unsuitable transfection candidates (Behr, 1993). Structure-activity studies 
with a range of polyamine conjugates have shown that the most suitable systems consist 
of a poly amine covalently bound to a lipid (lipopoly amines) (Behr et a l ,  1986; Byk et 
a l,  1997). Dioctadecylamidoglycylspermine (DOGS, Transfectam) 40, and 
dipalmitoyl-phosphatidylethanolamine spermine (DPPES) 41 were the first polyamine 
based lipid (lipopolyamine) gene delivery vectors (Behr et a l,  1989); RPR120535 42 is 








These molecules contain spermine covalently bound to two hydrophobic chains. 
When mixed with DNA, these polyamine-incorporating vectors cause condensation and 
formation of self-organised compact nuclear particles with an excess coat of cationic 
lipid. It is interesting to note that Transfectam 40 does not require the use of 
chloroquine 12 or an other weak base for successful transfection. In previous non­
polyamine transfection systems the presence of such a base has been required to buffer 
the lysosome and to protect the DNA from degradative lysosomal enzymes. It is 
possible that the buffering capacity of the modified spermine fulfils this role, an 
interpretation which is supported by considering the p £ a  values published for 
Transfectam 40 which are 10.5, 9.5, 8.4 and 5.5. It may indeed be significant that the 
fourth (lowest) of these pKa. values corresponds to the internal pH of the acidic 
lysosome (Remy et al., 1994). For a recently published overview of synthetic 
polyamine gene delivery agents, see: Miller, 1998.
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1.12 Polyamine Conjugates in the Treatment of Cancer
Due to the fundamental roles poly amines play in cellular growth, it is not 
suprising that polyamine conjugates or compounds which interfere with polyamine 
pathways are the focus of significant attention as potential anti-cancer agents. Rapidly 
proliferating cancer cells require large quantities of intracellular polyamines to maintain 
their growth rate. A first line of attack is the use of inhibitors against the enzymes in the 
polyamine biosynthetic pathway. Difluoromethylornithine (DFMO) 9, an inhibitor of 
the ODC enzyme (Metcalf et al., 1978; Bacchi et a l , 1987), showed initial promising 
activity in animal tumour models, but has failed to show significant activity in clinical 
trials, either when used alone or in conjunction with other agents. One exception was 
the combination of DFMO 9 and methylglyoxal-bis(guanohydrazone) (MGBG) 43, an 
inhibitor of AdoMetDC, which produced significant responses in patients with glial 
tumours (Marton and Pegg, 1995). Unfortunately, liver toxicity has proved to be a 
significant problem with this treatment.
Overall, the problems associated with the use of DFMO and other inhibitors as the 
key therapeutic agents are associated with the rapid turnover of the target enzymes, 
making it necessary to administer continuously the inhibitors during treatment, and the 
resourceful nature of the cell in locating the polyamines it requires. Polyamines can be 





Spermidine 2 and putrescine 3 are produced from the back conversion pathway from 
spermine 1 (SSAT, PAO), and also spermine stored in other cells can be exploited. 
These problems can be minimised by feeding patients on specially produced polyamine- 
free food, administration of antibiotics to limit the number of microbes in the gut and by 
inhibiting the metabolic pathway. Possibly a more important role for DFMO 9 is as a 
component co-administered with drugs which are designed to be taken into cells by the 
polyamine transporter. The inhibition of polyamine biosynthesis which DMFO 9 causes 
leads to a corresponding upregulation of the transporter as the cells try to maintain their 
intracellular polyamine concentrations. This can lead to an enhanced uptake of drug 
conjugate.
Some of the simplest and most effective synthetic polyamines to show anti-cancer 
activity have been developed by Porter, Bergeron and their co-workers. Initial activity 
of A-alkylated spermidine (Porter et a l,  1982 and 1985) and spermine derivatives 
(Bergeron et a l, 1988) was reported in vitro against L I210 leukaemia. These 
compounds were designed with three aspects in mind: they should be recognised and 
gain entry to the cell by the polyamine transporter, they should competitively replace 
endogenous polyamines in the cell, and they should function differently to endogenous 
polyamines at sites of polyamine activity. Studies were continued with series of 
triamines and tetraamines with various methylene backbones and patterns of N- 
alkylation (Bergeron et a l, 1989 and 1994). The most effective of these compounds 
were found to be terminally A-ethylated tetraamines DENSPM 44, DESPM 45, 
DEHSPM 21 which displayed IC50 values of 1.3 pM, 0.2 pM and 0.06 pM respectively 
over 96 h, in in vitro cultures of L1210 cells. DENSPM 44 is the subject of phase I 













These compounds utilise the transport apparatus and deplete intracellular 
polyamine pools. Their accumulation can upregulate SSAT increasing the rate of 
metabolism of spermine 1 or spermidine 2 (Fogel-Petrovic et al., 1993) and reduce the 
activities of ODC and AdoMetDC. Although there is a significant variation in the time 
it takes for cellular incorporation, probably due to different affinities to the transporter, 
over a period of 24 h the total amount of cellular polyamine normalised for the nitrogen 
content remains constant. If one molecule of (synthetic) tetraamine is incorporated, then 
one molecule of spermine 1 is metabolised and excreted. It has been demonstrated that 
these compounds do not have the activity displayed by endogenous polyamines with 
respect to chromatin and DNA stabilisation. Replacing natural polyamines with 
DEHSPM in vitro left cellular DNA more susceptible to attack by DNAase enzymes in 
a manner similar to that seen when the cell is totally depleted of its polyamine content. 
This leads to the conclusion that DEHSPM 21 is not stabilising the chromatin in the way 
required for normal transcription and gene expression. More recently, the analogous 
dialkylated triamines have been re-evaluated. Although initially discarded due to lesser 
cytotoxic activity than corresponding tetraamines, these compounds are again the
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subject of experiment in animal models due to their significantly smaller toxicities, a 
factor important when long durations of treatment are required (Bergeron et al., 1997).
Another approach to the development of anti-tumour compounds is the covalent 
linking of cytotoxic agents, whose activity is mediated through direct interaction with 
DNA, to a polyamine. The resulting conjugate will be transported into the cell through 
the polyamine transport mechanism (if recognised) and the polyamine should further aid 
DNA binding of the cytotoxic component at its DNA target site. Chlorambucil 46 is a 
nitrogen mustard-containing compound which is used in the clinic to treat a number of 




Chlorambucil 46 has been conjugated to both spermidine 2 and, spermine 1 
resulting in DNA cross-linkers with the potential to carry up to 3 or 4 positive charges at 
physiological pH (Cohen et al., 1992; Cullis et al., 1995). In vitro experiments have 
established that these polyamine conjugates are recognised by cellular uptake systems; 
the spermidine conjugate 47 displayed -35 times more cytotoxicity than chlorambucil 
46 alone. These conjugates 47 and 48 alkylate DNA in the same positions as 
chlorambucil 46 indicating that the polyamine moiety is not affecting the mechanism of 
alkylation (Cullis et al., 1998). However, in vivo studies did not display the high levels 
of activity predicted by the in vitro assays (Cullis et al., 1995).
A more promising approach to the design and synthesis of polyamines containing 
a reactive functional group capable of DNA alkylation has recently been described by 
Callery and co-workers (Li et al., 1996). They have prepared spermidine 49 and 
spermine 50 analogues with the primary amines replaced by aziridine functional groups 
to give a bis-alkylating agent bound to a polyamine backbone.
50
Studies showed these compounds to be transported into cells and to cross-link 
DNA. The in vivo activity of spermine analogue 50 was comparable to that shown by 
other bis-alkylating agents in the same assay, making it a lead compound with the 
potential for further development.
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1.13 Aims
The aims of this research are to produce conjugates of polyamines which have 
been designed to have potentially medicinally interesting properties. Two key areas 
have been studied: cytotoxic agents targeted against tumours, and inhibitors of the 
trypanothione reductase enzyme to treat trypanosomal diseases.
The affinity of polyamines for DNA and their transport mechanisms make them 
ideal targeting agents for cytotoxic agents with mechanisms of action associated with 
DNA. The transport mechanisms are known to be both flexible enough to recognise 
modified polyamines and to be upregulated in rapidly proliferating cancer cells. This 
gives an enhanced uptake of drug in cancer cells. The poly amine binding to DNA, once 
in the cell, will bring the conjugated cytotoxic moiety close to its site of action 
enhancing its activity. In these studies, poly amines have been conjugated to cytotoxic 
agents which intercalate between DNA base pairs. Conjugates have been prepared by 
“classical” solution chemistry employing the use of amine protecting groups to ensure 
efficient, specific synthesis as well as by the more recently developed solid-phase 
synthetic chemistry techniques.
Natural product leads have been used to identify compounds with potential 
trypanothione reductase activity. Typically, these compounds are polyamines diacylated 
with cinnamic acid derivatives. In these studies, such analogues have been synthesised 
in which the 6 -membered aromatic rings from the cinnamic acids are linked via a 
diphenyl ether bridge making macrocycles with ring sizes between 23- and 28-members. 
The synthetic challenges in this work include the reaction of unsymmetrical polyamines 
in a regiospecific way, the efficient formation of diphenyl ether bonds and the ring 
closure of various sizes of macrocycle.
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Chapter 2
Polyamine Conjugates of Anthracene- and 
Acridine-9-carboxylic Acids
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Polyamine Conjugates of Anthracene- and Acridine-9-carboxylic Acids
DNA intercalators are generally planar, aromatic, polycyclic compounds (e.g. 
ethidium 51 and propidium 52) which are able to bind between the planar heterocyclic 
base pairs, perpendicular to the axis of the double helix (Wilson, 1996). This binding is 
brought about by K-n stacking interactions between the systems of delocalised electrons 
in the intercalator and in the DNA base rings. In order to create an intercalation site in a 
DNA duplex, there is a separation of base pairs resulting in the lengthening of the DNA 
strand and a decrease in the torsional twist, causing unwinding near the location of the 
intercalation site. These effects are not observed when compounds with groove-binding 
modes of interaction are exposed to DNA (Wilson, 1996). The changes in shape mean 
that many intercalating compounds, such as daunomycin 53 and adriamycin 54, display 
cytotoxic activities as transcription is impeded and hence cell replication can no longer 
be performed (Neidle and Sanderson, 1983). The disruption near the site of 
intercalation is possibly recognised by repair enzymes which cause either single- or 
double-stranded scission in order to relieve the conformational strain.
C1
52 Propidium R
53 Daunomycin R = H
/  \
54 Adriamycin R = OH
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By attaching substituents to intercalating moieties which point away from the 
DNA helix, inhibition of DNA associated enzymes can be achieved. Notable examples 
are the topoisomerase DNA processing enzymes which can interact with intercalator 
side chains. The function of the topoisomerases (Sinha, 1995; Berger et al., 1996; 
Withoff et a l ,  1996) is to control the degree of twisting in closed circular DNA either by 
making a single strand break, in the case of topoisomerase I, or a double strand break, in 
the case of topoisomerase II and allowing twisting of the strands. Both enzymes operate 
mainly on supercoiled DNA converting it into different topoisomers, but they will 
operate on linear DNA in regions exhibiting torsional stress. Whilst there is an 
intercalator present, topoisomerase II may make a break in the DNA close by, in order to 
try to relieve some of the excess of strain generated by the intercalation pocket. A three- 
way complex can then be formed between the intercalator and DNA and by part of the 
intercalator protruding into one of the grooves interacting with topoisomerase. This 
ternary complex is stable and prevents the enzyme from rejoining the DNA strand (Lui, 
1989; Spicer et al., 1997).
Topoisomerases are known to be overexpressed in many proliferating tumour cells 
types making them ideal targets for cancer chemotherapy (Heck et al., 1988). The 
marine natural products eilatin 55 and shermilamine B 56 are examples of 
pyridoacridine intercalators with inhibitor activity against topoisomerase II (Hagan et 
al., 1997).





One other way in which compounds can interact with DNA is by binding in either 
the major or the minor grooves. Compounds which exhibit these modes of binding 
include polyamines, as discussed in Chapter 1, and structures such as netropsin 57 and 
distamycin 58 (Wilson, 1996), propamidine 59 (Nunn et a l , 1993; Nunn and Neidle, 
1995) pentamidine 60 (Sansom et al., 1990; Edwards et al., 1992; Greenidge et a l ,
1993), DAPI 61 (Barcellona and Gratton, 1996) and berenil 62 (Jenkins et al., 1993).
Groove-binding compounds typically contain amine and ammonium ion groups 
for hydrogen and electrostatic bond formation. Hydrogen bonds are formed between 
amines and carbonyl groups on the DNA bases and electrostatic bonding occurs between 
the ammonium cations and the anions on the DNA sugar-phosphate backbone. There is 
also the possibility of the formation of van der Waals bonds between moieties such as 
methyl groups in thymine residues and carbons on the groove-binding chain furthest into 
the groove. Groove binders tend to be chain-like and, if not flexible like spermine, then 
they have a crescent shape which will, in general, follow the curvature of the groove.
Recently, details have been published of conjugates between groove-binders and 
anti-cancer agents, such as intercalators and DNA alkylating moieties (Lee et al., 1993; 
Xie et al., 1995; Wyatt et a l , 1997). Although the majority of groove binders are not 
noted for cytotoxic activity, many do possess specificity for certain DNA sequences and 
they have also been shown to interfere with both topoisomerases I and II. Site-specific 
intercalating drugs (Eliadis et a l ,  1988) have potential for targeting DNA in cancer cells 
and, by attaching an intercalator, the activity of topoisomerases in these cells may be 
modulated. An example of such a conjugate is a hybrid of netropsin 57 and the anti­
tumour acridine amsacrine 63. This conjugate 64 has been shown to have groove 
binding and intercalating modes of action in chromatin preparations, has topoisomerase 
II inhibitory activity, has reasonable growth inhibition in vitro, but displays only 
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Polyamines are ideal candidates for conjugation with intercalators. As well as 
targeting the DNA grooves, they are also flexible, possess a dedicated cellular uptake 
system and there is increasing evidence of their DNA site selectivity (Yuki et al., 1996). 
Flexibility may be a requirement for efficient bifunctional modes of conjugate-DNA 
interaction as there is a corner to be turned between the intercalator, perpendicular to the 
helix, and the groove binder lying in a roughly parallel orientation to that axis. This 
could be a problem experienced with conjugates containing more rigid groove-binders 
such as netropsin 57. The problem of cellular transport could be one reason why 
netropsin conjugate 64 showed only moderate in vivo activity.
The intercalators chosen for this work were the hydrocarbon anthracene 65 and the 
analogous pyridine derived acridine 6 6 .
9 9
The first two targets were conjugates between the 9-position of these aromatics 
and a terminal amine on spermine, through an amide linkage. These compounds, 67 and 
6 8 , have three positive charges along the polyamine chain at physiological pH making 
the groove-binding moiety a spermidine rather then a spermine mimic. Initial studies 
using linear dichroism, circular dichroism and data interpretation facilitated by 
molecular modelling had been carried out at the University of Bath and with outside 
collaborators, and these studies showed that the conjugates would indeed show 
bifunctional DNA binding modes (Adlam et a l,  1994; Rodger et a l ,  1994 and 1995).
H H
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In order to synthesise sufficient quantities of the targets 67 and 6 8  in an efficient 
manner, careful attention was paid to the polyamine moiety, especially the problem of 
how to introduce the aromatic chromophore at a specific position. Much synthetic work 
has been published on building up polyamines with protecting groups on specific 
amines (Ganem, 1982; Bergeron, 1986; Fiedler and Hesse, 1993; Blagbrough and Geall, 
1998; Pak et a l ,  1998). Usually the synthesis starts with a diamine and the polyamine 
chain is built from suitably protected fragments, often employing nucleophilic
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substitution of halogens, Michael conjugate additions or reductive aminations. Fig 2.1 
shows the general method developed by Bergeron and co-workers (Bergeron et al., 
1994) for synthesising terminally N-ethylated symmetrical and unsymmetrical 
tetraamines. The mesitylenesulfonyl is used as a protecting group. The proton on the 
nitrogen in such sulfonamides is sufficiently acidic to be abstracted by NaH generating 
an anion which will attack electrophilic centres, in this case the carbon adjacent to a 
halogen in the fragment of polyamine to be added.
Fig. 2.2 shows the use of Michael additions with acrylonitrile to extend diamines 
by two propylamine units affording natural and unnatural tetraamines after catalytic 
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Fig. 2.3 shows the work of Fiedler and Hesse (1993) demonstrating that by careful 
selection of conjugation methods and protecting groups then polyamines can be built in 
an orthogonally protected manner allowing specific amine groups to be unambiguously 
unmasked. Hesse has used these techniques towards the syntheses of many naturally 
occurring poly amine conjugates and their analogues. These syntheses are time 
consuming, but sometimes necessary if the spacing pattern of the amino groups is not 
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In our initial studies, the polyamine we used was spermine 1 which is readily 
available (commercially). Rather than starting from a diamine and building the 
polyamine through the addition of fragments with protecting groups already in place, a 
strategy for their selective introduction to spermine was developed. Fig. 2.4 shows the
I 9 ^strategy for synthesising N  , N  , AMri-Z-protected spermine 71 leaving one terminal 
primary amine ready for acylation. In the first reaction, a Boc group is introduced on 
one primary amine. This reaction relies on the greater nucleophilicity of primary amines 
over nucleophilic, but sterically hindered secondary amines.
A threefold excess of spermine 1 was reacted with of Boc anhydride in THF, the 
excess of polyamine being added in order to favour monoacylated products over di- or 
triacylated products. Spermine 1 was initially dissolved in THF and the solution cooled 
to 0 °C before the addition of Boc anhydride in order to ensure that there was no rapid 
rise in temperature due to any exothermic reaction. A significant temperature rise could 
affect the selectivity of the acylation leading to a greater proportion of acylated 
(carbamoylated) secondary amines. After an hour at this temperature the reaction 
mixture was stirred for a further 18 h at 20 °C, to ensure complete reaction. After work­
up, TLC, visualised by dipping the plate in acidic ninhydrin reagent, showed unreacted 
spermine on the baseline, one major product spot and three minor products. In order to 
separate the desired product from A^-Boc-spermine and di-Boc products, careful 
chromatography was required. Due to the highly basic nature of these compounds and 
the acidity of the hydroxyl groups on silica gel, if column chromatography is attempted 
using mixtures of organic solvents then the material either streaks or sticks to the 
baseline. Addition of a base to the eluant solves this problem as the added base 
competes with the product for the acidic sites effectively deactivating them. Cone. aq. 
NH3 was found to give the best results in TLC experiments, and, when used in the
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eluant for flash column chromatography, good separation was achieved. In order to 
separate the Ay-Boc-spermine 10:4:1, then 6:4:1 and finally 4:2:1 (Cf^CL/MeOH/conc. 
aq. N H 3 ) were used to give the compound 69 in 15 % yield with respect to spermine.
Ay-Boc-spermine 69 was then reacted with 3.3 equiv. benzyl chloroformate for 
18 h under Schotten-Baumann conditions. The reaction mixture was extracted with 
CH2CI2 and the residue from the extracts was shown to be the tetra-protected polyamine 
70 and it did not require any further purification by TLC and NMR. The Boc group was 
removed by the action of TFA in a 1:1 mixture with CH2CI2 at 0 °C. The reaction went 
cleanly and after evaporation of the solvents in vacuo the residue was purified by flash 
column chromatography, again using conc. aq. N H 3 in the eluant, to yield N l, N 2, A3-tri- 
Z-spermine 71 in quantitative yield (Fig. 2.4).
In order to add the intercalating aromatic chromophore to the protected polyamine, 
9-anthracene and 9-acridinecarboxylic acids (72 and 73) were used. There are a 
plethora of ways to make amide bonds in the literature mostly stemming from peptide 
syntheses (Bodansky e ta i ,  1976; Bodansky, 1984 provides a good overview). For this 
synthesis, the commonly used dicyclohexylcarbodiimide (DCC) was used in a solution 
containing a catalytic amount of 1-hydroxybenzotriazole (HOBt). This method has the 
advantage that the major by-product from the acylation is dicyclohexylurea (DCU) 
which has low solubility so the majority of it can be easily removed from the reaction 
mixture at the end of the reaction by filtration. This simplifies the subsequent 
chromatographic purification of the amide product. After recovering the desired 
amides, the final step required is to remove the Z protecting groups. This was attempted 
by the commonly used procedure of hydrogenolysis in the presence of a catalytic 
amount of Pd adsorbed onto carbon. This method of Z removal should be quantitative 
and yield clean products after filtration of the reaction mixture to remove the catalyst.
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74 X = CH
75 X = N 10 % Pd/C 
MeOH
67 X = CH
6 8  X = N Fig.
2.5
Tri-Z-spermine 71 was coupled to anthracene-9-carboxylic acid 72 using DCC as 
the coupling (dehydrating) agent in the presence of a catalytic amount of HOBt (Fig. 
2.5). The reaction was carried out with equimolar quantities of the acid and amine in 
CH2CI2 and was seen to be progressing within 30 min as a white precipitate of DCU 
was formed. After 18 h, TLC showed one major product which was visible with both 
UV light and ninhydrin reagent and was also less polar than either of the starting 
materials, of which there were only small amounts remaining. That the product 74
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stains with ninhydrin despite the fact that the amines within it have all been 
functionalised to amides is probably due to decomposition (likely deprotection) or 
possibly some amide hydrolysis of the compound when the TLC plate is heated.
The desired product 74 was isolated in a good yield (76 %) by flash silica column 
chromatography, in this case without the need for NH3 in the eluant as all the amine 
groups were now masked. The Z protecting groups were removed by hydrogenolysis at 
atmospheric pressure in the presence of catalytic 10 % Pd on C. After 12 h of reaction, 
TLC analysis showed there to be starting material still remaining and it was therefore 
necessary for the reaction mixture to be exposed to H 2 for a further 1 2  h before the 
reaction was complete. It had been initially hoped that this reaction would yield pure 
product after the careful purification of the starting material in order to avoid a 
potentially difficult purification of this triamine 67. The TLC after work up showed that 
a purification step was required so the residue was successfully subjected to column 
chromatography and the residue from the column was lyophilised. The desired product 
67, isolated in 93 % yield, was a white foam found to be highly hygroscopic. The 
structure of the product was confirmed by *H and 13C-NMR and by both low and high 
resolution FAB-MS. However, it was not possible to get an elemental analysis of C, H 
and N with sufficient accuracy. This is found to be the case with polyamine conjugates 
generally. They are hygroscopic and will react with carbon dioxide in the air to give 
carbonic acid salts. Both of these factors account for the disturbance of elemental 
composition.
Coupling acridine-9-carboxylic acid 73 with amines is more problematic than the 
analogous anthracene reactions due to the presence of both a tertiary amine (a pyridine 
nitrogen) and a carboxylic acid group. These functionalities act in a zwitterionic fashion 
giving the compound a partially ionic character which makes it particularly hard to 
solubilise in convenient organic solvents. After investigating a range of solvents DMF
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appeared to be the best, although solubility was still limited. In DCC type coupling 
reactions, the concentration of the reaction mixture needs to be high to ensure fast, 
efficient reaction. Rather than using a large quantity of DMF to solubilise all of the 
acridine-9-carboxylic acid 73 and ending up with low concentrations of this and the 
other reagents, a suspension was made so that a small quantity of the acid would go into 
solution and react to give a soluble product and then more acid would be solubilised to 
replace that which had reacted. The reaction was carried out over 48 h with TLC 
monitoring after which time most of the starting materials appeared to have been 
consumed. After work up and chromatography, the major product was shown to be the 
desired product 75, isolated in 53 % yield. This conjugate was deprotected by catalytic 
hydrogenation over 24 h and the required target was isolated in 91 % yield after column 
chromatography. The product 6 8  was a buff coloured foam after lyophilisation and, as 
with the anthracene analogue 67, was found to be hygroscopic.
A potential problem with these analogues relates to how much of the polyamine is 
in contact with the DNA groove. There is a turn to be made between the intercalator 
perpendicular to the helical axis and the groove running in a direction parallel (and 
around) this axis. The polyamine will be flexible enough to turn into the groove, but 
there may not be an optimal interaction particular between the charged secondary amine 
closest to the chromophore. In order to alleviate this potential problem, another target 
76 was designed incorporating a spacer between acridine and spermine.
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Initially, a 5 carbon spacer was chosen, this residue being derived from the amino 
acid 5-aminopentanoic acid (5-aminovaleric acid). This unit should be long enough to 
show a measurable increase in activity through tighter DNA binding if a linear spacer is 
required without being too long and causing unfavourable entropic effects.
To synthesise this target 76 a scheme was proposed (Fig. 2.6) where the amine of 
the 5-aminopentanoic acid 77 is Boc protected 78 and then the free acid is coupled to 
tri-Z-spermine 71. TFA is then used to remove the Boc group from conjugate 79 and 
the chain extended polyamine 80 is then ready to react with acridine-9-carboxylic acid 
73 in the same manner described in Fig. 2.5.
Due to the acidic and basic natures of the functionalities, 5-aminopentanoic acid 
77 is also zwitterionic (like 73) giving rise to solubility problems. THF was chosen as 
the solvent to carry out the Boc protection step as the starting material has some 
solubility in it, and the product is freely soluble. Boc anhydride was added to a 
suspension of amino acid in THF and the reaction was stirred, with TLC monitoring, for 
48 h after which time all of the starting material appeared to have been consumed. The 
predominant product was separated by column chromatography, in 82 % isolated yield, 
and the proton and carbon NMR spectra clearly showed the incorporation of the Boc 
group. At 8  1.40 ppm a singlet in the ^H-NMR integrated for 9 protons corresponding 
to the methyl protons in the butyl group and in the 13C-NMR signals at 8  28.3, 79.0 and 
156.3 ppm corresponded to the methyl, tertiary and carbonyl carbons. This product 78 
was coupled over 48 h in 38 % yield to tri-Z-spermine 71 using DCC and catalytic 
HOBt to give the fully protected chain extended polyamine 79. This moiety was then 
subjected to TFA in CH2CL at 0 °C in order to remove the Boc group and unmask the 
primary amine 80, reaction being evident from the increased polarity of the product on 
the TLC plate and its enhanced colour when stained with ninhydrin. NMR experiments 
confirmed the deprotection reaction had cleaved the Boc group in an isolated yield of 8 8  
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The chain extended polyamine 80 was then coupled to acridine-9-carboxlic acid 
hydrate 73 in DMF with DCC and catalytic HOBt (0.05 equiv.). The reaction was run 
for 48 h with TLC monitoring and after work-up was purified by silica gel 
chromatography to give amide 81 in 31 % yield. This Z-protected intermediate was then 
subjected to hydrogenolysis to unmask the amine groups and the desired target 76 was 
isolated as a buff coloured hygroscopic foam in 80 % yield after chromatography.
The synthetic conjugates were initially assessed for cytotoxic activity by M. A. 
Qarawi at the University of Bath. The assay was in vitro against B 16 murine melanoma 
cells using the MTT procedure first reported by Mosmann (1983) (Alley et a l, 1988). 
The assay was carried out using 8 x 1 2  well microtitre plates which could be read by a 
spectrophotometer. Each row of 8  wells contained the same configuration of cells 
and/or drug allowing for eight independent determinations per experiment. Rows were 
set up containing either cells in media or polyamine conjugate in media to act as 
controls during spectrophotometric measurement and the remaining rows contained 
cells and polyamine amide at various concentrations. The cells were incubated with the 
polyamine compounds, typically for 48 h, and were then washed. The cells were then 
incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) for 
3 h. Cells which remain viable at this time metabolise the MTT to a formazan 
derivative which has a blue colour. After incubation, DMSO was added to solubilise all 
of the formazan and photometric analysis was used to assess the amount of formazan 
present and hence the number of viable cells. To demonstrate that activity seen in the 
assay was due to bifunctional modes of interaction of the covalently linked conjugates 
also assayed were spermine, anthracene and acridine-9-carboxylic acids (72 and 73) and 
1:1 mixtures of the two acids with spermine 1. The results of the assays are shown in 
Table 2.1.
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Also synthesised was a model amide 82 which is a conjugate of propylamine and 
acridine caboxylic acid, prepared by DCC/HOBt coupling between the acid and the 
amine. It was designed to help assess the cytotoxic activity due to the acridine moiety 
and hence its strength of interaction with DNA. In measuring this, the significance of 




Table 2.1 Results of the MTT assay
Compound M ean EC50 (M) SE (±)
9-anthracenecarboxylic acid 72 > 1.2 x 10 '3 -
9-acridinecarboxylic acid hydrate 73 > 8 .0x1 O' 4 -
spermine 1 4.5x1c4 1 .8 x l0 '4
1:1 spermine:9-anthracenecarboxylic acid 2.6X1C4 8 .0 x 1' 5
1:1 spermine:9-acridinecarboxylic acid 3.9x10^ 8 .Ox 1C5
9-anth-CO-3.4.3 67 2 .0 x l0 ‘5 7.0x1 O' 6
9-acrid-CO-3.4.3 6 8 5.4xl0 ' 6 l . l xl  O' 6
9-acrid-CO-4-CO-3.4.3 76 1.9xl0 ' 6 2.7x10 ' 7
Table 2.1 shows the concentration of each compound (E C 5 0 ) required to kill 50 % 
of the cells exposed to it.
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The synthesised conjugates showed greater activity than either of their component 
parts either alone or as a mixture. Of the conjugates, the acridine compounds showed 
greater activity than the anthracene conjugate and of these, the compound with the five 
carbon spacer showed the best activity. This preliminary study shows the compounds to 
be cytotoxic, but gives no information about the precise mode of cytotoxic action of 
these compounds. Further studies are required to determine activity against a wider 
range of cell lines, in vivo activity and overall toxicity, interaction with the polyamine 
transporter and activity against topoisomerase enzymes.
Nevertheless, this initial evidence of the increase in cytotoxicity with more 
binding modes (both intercalation and groove-binding) is proof that this approach has 
application in the development of new cytotoxic compounds and is of importance 
towards the development of new potential chemotherapeutic agents. In these initial 
studies, we have devised a route for the controlled preparation and purification of 
unsymmetrical poly amines and their amides which allows the terminal conjugation of a 
variety of different species to a primary amine. These results in the preparation of novel 
conjugates of polyamines and DNA intercalators will be used in the design and 
synthesis of more cytotoxic polyamine conjugates. For example, it is known that 9- 
aminoacridines are more cytotoxic than acridines bearing other simple substituents. It 
would be of interest to make further conjugates without the amide, with the polyamine 
directly attached to the acridine through an amine bond.
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Chapter 3
Polyamine Conjugates of 9-Aminoacridine
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Polyamine Conjugates of 9-Aminoacridine
Aminoacridine derivatives have been used in clinical medicine since before the 
turn of the 20th century (Denny et a l . 1983). They first came to light as by-products of 
the aniline dye industry when they were found to have anti-malarial and anti-bacterial 
activity (Denny et a l,  1983). In the 1930’s and 40’s aminoacridines were found to bind 
preferentially to DNA and RNA, and certain derivatives were introduced as biological 
stains. Around this time, 9-aminoacridines were found to have some activity as growth 
inhibitors of certain tumours (Denny et a l,  1983). From this time onwards, there have 















Conjugation to nitrogen mustards gave a range of DNA alkylating agents (e.g. 85)
in which the high affinity of the acridine for DNA brings the mustard group (a P~
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haloamine; an aziridinium ion precursor) close to its site of action (Denny et a l ,  1983). 
However, the clinical utility of such compounds has been precluded by their high 
mutagenic activity. Another series of 9-aminoacridines which underwent much 
evaluation, particularly in Poland, were those with a 1-nitro substituent (e.g. nitracrine 
87) (Denny et al., 1983). These compounds were shown to have both reversible and a 
smaller proportion of irreversible interactions with DNA, indicating some form of 
covalent bonding occurring. The precise nature of this interaction has not been 
elucidated. Clinical trials involving nitracrine 87 have been undertaken in both Poland 
and the USA, but ended up rejecting its usage due to issues of toxicity. Analogues of 
these compounds (e.g. 8 6 ) continue to be investigated by Barker and co-workers 
(Monge et al. 1994a and b).
9-Aminoacridine has also been conjugated to DNA groove-binders to give 
analogues (64 and 8 8 ) with site specific modes of binding (Eliadis et al., 1988;Bailly et 
al., 1992), however these compounds have yet to display good in vivo activity.
Another 9-aminoacridine analogue with therapeutic interest is the tetrahydro 
derivative tacrine (84). This compound has been shown to be beneficial in the treatment 
of Alzheimer's disease and other forms of neurodegeneration. The mechanism of action 
is the inhibition of cholinesterase, hence maintaining the level of the neurotransmitter 
acetylcholine (Dawson, 1989; Eagger e ta l ,  1991).
To date, medically the most successful 9-aminoacridine against cancer is 
amsacrine 63. This compound has emerged from an extensive programme of synthesis 
and evaluation under the direction of Cain in New Zealand. The results from this work 
have largely been published in J. Med. Chem. from the late 1960’s onwards (for an 
overview, see: Denny, 1993) and studies with this 9-aminoacridine conjugate are 
continued today by Denny and co-workers. Amsacrine has successfully completed trials 
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The studies on amsacrine 63 and its analogues established that they intercalate into 
DNA and that the strength of this interaction directly correlates with anti-tumour activity 
both in vitro (Ferguson and Baguley, 1981) and in vivo (Baguley et al., 1981). The 
methanesulfonamide group is important for water solubility and stability of the 
compound as well as for biological activity (Atwell et a l ,  1972). The 3'-methoxy group
is important for anti-tumour activity. If it is moved to the adjacent 2'-position then this
analogue is completely inactive against L1210 leukaemia cells in vitro (Cain et a l,  
1975). It has been predicted that, when bound to DNA, the anilino ring protrudes into 
the minor groove and the methoxy substituent points tangentially away from the helical 
axis (Wilson et al., 1981). In this position it is free to interact with adjacent proteins 
such as the topoisomerase enzymes. Amsacrine 63 has been shown to be an inhibitor of 
topoisomerase II trapping the cleavable complex. Studies have shown that, in close 
analogues of amsacrine, the ability to stabilise this complex has more importance than 
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The compounds described in Chapter 2 were 9-carbonyl anthracene or acridines 
67, 6 8  and 76, families of compounds not specifically noted for their anti-tumour 
activity. In order to produce compounds with enhanced cytotoxic activity compounds 
89-91 were designed without the amide linkage, but instead having a secondary amine 
linking acridine with a polyamine. These compounds are 9-aminoacridines. At 
physiological pH, they will carry close to four positive charges, three on the amino 
groups mimicking spermidine 2  and one associated with the acridine ring nitrogen and 
also the secondary amine at the 9-position. It is not clear exactly where the majority of 
this positive charge resides as there is easy flow of electrons through the aromatic 
system, and especially around the central pyridine ring of the acridine (c.f. the 
conjugated system of the nucleophile 4-A,A-dimethylaminopyridine, DMAP 92).
As with the 9-carbonyl polyamine conjugates (67, 6 8  and 76), consideration was 
given to flexibility in the region of linkage. Again, targets were therefore proposed with 
a five carbon spacer 90, and also a ten carbon unit 91 was included to see if increasing 
the length of the spacer provided any advantage in binding affinity to DNA and 
therefore in cytotoxicity.
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The syntheses of these compounds were designed bearing in mind that, in 
acridine, the nitrogen at the 1 0 -position (the pyridine nitrogen) will activate suitable 
leaving groups at the 9-position for nucleophilic substitution. Such reactions are well 
known for both 2- 93 and 4- 94 (but not 3-) halo substituted pyridines, the ring nitrogen 
temporarily stabilising the anionic intermediate (McMurry, 1992) (Fig. 3.1).
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stabilised anion Fig. 3.1
9-Chloroacridine 96 would be an ideal starting point for the synthesis, but it has 
low stability once synthesised and therefore the more stable, but still sufficiently 












Substitution reactions with 9-phenoxyacridine 97 have been previously described 
in the literature (Dupre and Robinson, 1945; Eliadis et a l , 1988) for a number of 
nucleophiles, including amines. However, there is no precedent for such reactions 
employing Z-protected di- or polyamines as the nucleophiles. For this substitution, 9- 
phenoxyacridine 97 is simply gently heated in phenol, as the solvent, together with the 
required nucleophile. For the first target 89, a conjugate of tri-Z-spermine 71, the final 
deprotection will be carried out by catalytic hydrogenolysis to remove the Z groups.
The synthesis started with 9-(10if)acridone 95 which was converted into 9- 
chloroacridine 96 by treatment with thionyl chloride in the presence of a catalytic 
amount of DMF (Fig. 3.2). The starting acridone 95 contains a vinylogous amide which 
could potentially exist as two tautomers, the favoured form being the keto rather than
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the enol. This is comparable to the analogous 2- or 4-hydroxypyridine 98 compounds 
which also exist as the a - or y-pyridones when in ethanolic solution, however in the 






solution phase vapour phase
Fig. 3.3
The reactants were heated for 30 min then the mixture was basified by pouring the 
reaction mixture into an ice cold solution of dilute aqueous NH3. The product 96 was 
recovered by extracting with CH2CI2 and, as it displayed satisfactory NMR 
spectroscopic data, it was used without further purification. The mass spectra of 9- 
chloroacridine 96 showed the expected isotope peaks associated with molecules 
containing 35C1 and 37C1. Within 24 h of this preparation, the material was converted 
into 9-phenoxyacridine 97. Sodium hydroxide was dissolved in phenol being stirred at 
SO °C and then 9-chloroacridine 96 was added in one portion. After 1.5 h at this 
temperature the reaction mixture was poured into aq. 2M sodium hydroxide and this 
mixture was stirred for a further 18 h. The product 97 precipitated and was collected by 
filtration. After drying in vacuo over P2O5, NMR spectroscopic analyses showed the
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compound to be pure and ready to be reacted as the required electrophile. It was found 
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Fig. 3.4
The phenoxide 97 was displaced by the amino group in tri-Z-spermine 71 by 
m ixing equimolar quantities in molten phenol at 80 °C (Fig. 3.4). This reaction mixture 
was stirred at this temperature for 18 h with TLC monitoring. After this time, there was 
an obvious product spot on the TLC plate which showed up strongly under UV light and 
was coloured bright yellow to the naked eye. The reaction mixture was diluted with 
CH 2CI2 and the resulting solution was washed with aq. 2M sodium hydroxide in order to 
remove the phenol (leaving group and solvent). The product was purified by flash
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column chromatography on silica gel and was recovered as a bright yellow viscous oil. 
NMR spectroscopic analysis clearly showed that the polyamine had been conjugated to 
the acridine and that the protecting groups were still intact (99). Hydrogenolysis to 
remove the protecting groups followed and, after work up, TLC showed that 
chromatography was required to purify the product 89.
Due to the presence of several amino groups, TLC required conc. aq. N H 3  to move 
the compound from the baseline. However, when flash column chromatography on 
silica gel was attempted using 4:2:1 C^CL/M eOH/conc. aq. N H 3 , TLC of the 
recovered fractions revealed only a high running spot which showed strongly under UV 
light and a polar polyamine spot with no UV activity, staining when heated with 
ninhydrin. The aq. NH3 in the eluant was causing the product 89 to decompose on the 
column. Using alternative organic bases in the eluant either gave the same result or 
failed to move the product down the column so an alternative solid phase was sought. 
Neutral alumina which had been deactivated was found to be suitable. The alumina was 
deactivated to Brockman grade 4 by adding 10 mL of water to every 100 g of neutral 
alumina and shaking in a sealed container for 16 h. A gradient of eluant polarity was 
run through the column starting with 20 % MeOH in CH2CI2 and ending at 100 %, 
required to prevent co-elution of by-products with the target 89 compound. The 
acridine-spermine conjugate 89 was finally isolated in 8 8  % yield as a bright yellow 
hygroscopic foam.
The conjugate with the 5-carbon spacer 90 was synthesised in an analogous 
fashion to the compound without a spacer 89. The chain extended tri-Z-spermine 80, as 
described in Chapter 2, was condensed with 9-phenoxyacridine 97 in molten phenol and 
the resulting conjugate 100 was isolated in 49 % yield after chromatography. 
Deprotection by catalytic hydrogenolysis and then chromatography on Brockman grade
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Fig. 3.5
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In order to synthesise the compound containing the 10-carbon spacer 91, the 
spacer 103 first had to be made before being linked to tri-Z-spermine 71 (Fig. 3.5). The 
spacer was to be built from two 5-aminopentanoic acid 77 units. This amino acid was 
protected on the carboxylic acid functionality by conversion into methyl ester 1 0 1  and 
then it wras coupled with the Boc protected 5-aminopentanoic acid 78 described 
previously. Ester hydrolysis would unmask the acid group ready for another amide 
formation step, this time with tri-Z-spermine 71. The fully protected chain extended 
polyamine 104 would then be subjected to TFA mediated cleavage of the Boc group to 
leave it ready to be conjugated to acridine 105.
5-Aminopentanoic acid 77 was converted smoothly into the hydrochloride of its 
methyl ester 101 by heating under reflux in acidified methanol. The product, a white 
solid, was recrystallised from methanol and was identified by the appearance of the 
required methyl peak at 5 3.68 ppm in its !H-NMR and by a melting point (140-141 °C) 
matching closely with the literature (145-146 °C, Oelofsen and Li, 1968). This 
compound was coupled with A-Boc-5-aminopentanoic acid 78 by DCC/HOBt coupling 
in CH2CI2. NEt3 was added to the reaction mixture to free the acid from its salt in situ. 
The coupled product 102 was isolated in 45 % yield after chromatography and was then 
subjected to alkaline hydrolysis with aq. KOH in dioxane. After 2 h, TLC showed that 
the ester had been fully cleaved and an acidic work-up yielded the desired carboxylic 










106 R = Z 91 R = H
Fig. 3.6
Coupling with tri-Z-spermine 71 went in 36 % yield after purification and 
cleavage of the Boc group yielded the mono amine 105 in quantitative yield. Coupling 
with 9-phenoxyacridine 97 was successfully achieved as outlined above by stirring the 
reactants at 80 °C in phenol yielding the protected intermediate 106 in 50 % yield. The 
final compound 91 was recovered after hydrogenolysis and subsequent purification on 
deactivated alumina in 81 % yield as a yellow hygroscopic foam (Fig. 3.6).
The compounds described so far should exhibit good affinity for DNA and display 
bifunctional modes of DNA interaction, but the one feature they may not have is a 
region which will protrude from the groove and give an area of potential interaction 
with DNA associated proteins, especially topoisomerases. To address this issue, two 
further targets 107 and 108 were identified having the aromatic pharmacophore of 
amsacrine 63 linked to spermine 1.
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107 R = H
108 R = OMe
One target has a 4-aminobenzoic acid derived spacer 107 between the acridine and 
polyamine and the other includes a methoxy group 108, identified as being important for 
amsacrine structure-activity relationships, ortho to the amine (aniline) linkage. In the 
planned synthesis of these analogues, it was decided to conjugate the spacer first to the 
acridine rather than the spermine moiety in a fashion similar to that used in the 
published synthesis of amsacrine 63 (Denny, 1993). In this way, tri-protected spermine 
is not introduced until the penultimate stage. As preparing this protected polyamine is 
time consuming in terms of the chromatography required, it is more efficient to 
synthesise the aromatic system first, thus minimising the amount of polyamine lost 
through reactions not giving quantitative yields. The syntheses were started from 4- 
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Fig. 3.7
The carboxylic functionalities were initially protected in 80 % yield by treatment 
with thionyl chloride which had been previously reacted with methanol at 20 °C (Fig.
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3.7). After 18 h stirring, neutralisation, then extraction and recrystallisation gave pure 
samples of the required esters 111 and 112. Conjugation to the 9-position of acridine 
was brought about by nucleophilic displacement of chloride from freshly prepared 9- 
chloroacridine 96. This employed the procedure described by Denny (1993) towards the 
synthesis of amsacrine. Previously, we had chosen phenol as the leaving group as 9- 
phenoxyacridine is stable at 20 °C over long periods of time (> 1 year). For these 
reactions using an aniline nucleophile, it was decided to follow the literature precedent 
and use freshly prepared 9-chloroacridine 96 for each reaction. The reactants were 
stirred together in anhydrous methanol and methanesulfonic acid was added to the 
reaction mixture. There was an immediate change in colour from yellow to deep 
orange-red. After 18 h, the reaction mixture was neutralised, extracted and the products 
were purified by flash column chromatography on silica. The ^-N M R  spectrum clearly 
showed extra aromatic signals at 8  6.80 ppm (CH3 and CH5) and 7.82 ppm (CH2 and 
CH6) due to the incorporation of the six-membered ring to the acridine. These 
compounds are an orange colour, whilst the starting acridine compound is yellow. The 
change in the system leads to increased conjugation in the aromatic chromophore and a 
shift of the absorption maxima to longer wavelengths. It is also noteworthy that the 
nucleophilic nitrogen is an aniline, and contains a para-substituted electron withdrawing 
group, these groups acting in a complementary manner to increase further the red-shift 
(bathochromic). Furthermore, the nucleophilicity of this moiety will be significantly 
reduced by the electron withdrawing group, and unsubstituted anilines are poor 
nucleophiles. Therefore, the successful synthesis of the desired targets 113 and 114 in 
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The esters 113 and 114 were saponified by the action of aq. KOH in dioxane and 
once protonated and purified, the free acids 115 and 116 were linked to tri-Z-spermine 
71 by DCC-HOBt coupling (Fig. 3.9). Initial attempts at coupling were carried out over 
24 h, but after this time significant amounts of the intermediate formed between DCC 
and the acid were isolated. This intermediate must have significant stability as it 
survived chromatography. After 48 h of reaction, modest amounts of the desired amides 
117 and 118 could be isolated.
The final deprotection of the conjugates 117 and 118 was attempted, as previously 
described, by catalytic hydrogenolysis. The analogue without the methoxy group 107 on 
the anilino ring deprotected after 24 h and was isolated in 61 % yield after 
chromatography as an orange hygroscopic foam. When this procedure was applied to 
methoxy analogue 118 there was no recovery of the desired product 108 and there was 
considerable breakdown of the starting material as indicated by TLC. As there were 
many product spots, no attempt was made to identify them. Attempts were also made at 
hydrogenation with Pearlman’s catalyst (Pd(OH)2/C) both using MeOH and AcOH as 
solvents, but only similar disappointing results were achieved. An alternative method of 
Z  group removal is by the action of trimethylsilyl iodide (TMSI) and this was attempted 
but, as predicted, this method also bought about (9-demethylation. This novel analogue 
119 was purified, characterised and was tested with the other compounds.
As the removal of Z groups was proving to be problematic, it was decided to use a 
slightly less rigorous protection strategy to synthesise the required 3'-methoxy analogue 
108 (Fig. 3.10). The tetracyclic acid 116 was coupled to ^-Boc-sperm ine 69 using 
DCC and catalytic HOBt. The greater nucleophilicity of the primary amine over the 
secondary amines was relied upon to yield the required di-acylated polyamine 1 2 0 .
After work-up and column chromatography, the desired compound 120 was isolated in
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37 % yield. TFA in CH2CI2 was used to remove the Boc group and successfully yielded 
the desired target compound 108 as its polytrifluoroacetate salt. TLC and analytical 
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The 9-aminoacridine conjugates were assayed for cytotoxic activity against B 16 
murine melanoma cells by M. A. Qarawi in the M IT  assay as described above (Chapter 
2). The results of these assays are shown in Table 3.1.
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Table 3.1 Results of the MTT assay of 9-aminoacridines
Compound M ean E C 50 (M) SE (+)
Acrid-3.4.3 89 1 .0 x 10 ‘6 5.6xl0 ' 7
Acrid-4-CO-3.4.3 90 2.7xl0 ‘7 1.2 x 10 '8
Acrid-4-CO-4-CO-3.4.3 91 3.0xl0 ' 5 2.0x1 O' 5
Acrid-aniline-CO-3.4.3 107 9.2xl0 ‘6 2.3xl0‘6
Acrid-(HO-aniline)-CO-3.4.3 119 9.0x10-5 3.0x10 ' 5
Acrid-(MeO-aniline)-CO-3.4.3 108 4.9xl0 ' 6 5.7xl0 ' 7
Table 3.1 shows the concentration of each compound (EC50) required to kill 50 %
of the cells exposed to it.
The 9-aminoacridine-spermine conjugate 89 showed improved cytotoxic activity 
over the 9-carbonyl analogue. This was predicted as certain 9-aminoacridines have been 
shown to have notable antitumour activity, but amidoacridines do not. The addition of a 
5-carbon spacer increased the activity and gave the most potent compound in this study. 
When the spacing between the intercalator and polyamine was increased to ten there 
was a drop in cytotoxic activity. The compounds having the amsacrine aromatic core 
displayed activity of about the same order as the 9-amidoacridines in this assay. The 
most cytotoxic compound was the 3'-methoxy analogue 108 closely followed by the
unsubstituted (3-hydrido) 107. There was a drop off of about an order of magnitude of 
activity in the hydroxy analogue 119.
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These 9-aminoacridine-polyamine conjugates are promising leads as we have 
achieved over an order of magnitude greater cytotoxic activity than the 9-amido 
compounds previously described (Chapter 2). These compounds offer ideal frameworks 
for the investigation of both DNA binding and cytotoxic modes of action, particularly 
their interaction with topoisomerases and other DNA associated proteins. We have 
demonstrated that polyaromatic-polyamine conjugates with multiple modes of DNA 
binding have enhanced cytotoxic activity over either of their components which have 
only single modes of DNA interaction.
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Chapter 4
Solid Phase Approaches to the Synthesis of 
Polyamines and Polyamine Amides
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Solid Phase Approaches to the Synthesis of Polyamines and Polyamine Amides
Despite the well developed repertoire of protecting group manipulations described 
above (Chapters 2 and 3) and in the literature, (for reviews, see: Greene and Wuts, 1991; 
Kocienski, 1994; Schelhaas and Waldmann, 1996), the synthesis of polyamines, 
especially unsymmetrically substituted polyamines, can still be time consuming and at 
times low yielding. If the polyamine required is not available naturally, it must be built 
up in a stepwise fashion. At all times protecting groups must be carefully chosen in 
order to allow orthogonal introduction and deprotection for access to specific amines for 
further conjugation. Generally, a chromatographic purification is required after each 
synthetic step to remove undesirable by-products (e.g. acylation or alkylation at 
unwanted positions) and unreacted starting materials. A potentially more rapid 
approach to the synthesis of polyamines and polyamine conjugates is by the use of solid 
phase organic synthesis (SPOS) (Nash et a l , 1996; Byk et al., 1997; Kellam et al.,
1997; Tomasi et al., 1998; Page et al., 1998). A strategy can be envisaged whereby the 
terminal primary amine of a suitable protected diamine or polyamine is attached to a 
resin and then the free primary amine is reacted sequentially either to lengthen the 
polyamine chain or for the addition of other moieties (e.g. acridine) on the way to 
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The major advantages of SPOS over more traditional synthesis are that the 
intermediate purification steps are not necessary and yields are higher. Each step in the 
synthetic sequence is usually driven to total completion by the use of large excesses of 
reagents, a situation which is not always possible in solution phase synthesis. At the end 
of the reaction time, the resin is filtered and the excess of reagents is washed away by 
repeated passage of solvent over the resin. When all of the reactions are completed, 
there is a cleavage step and, if necessary, a single chromatographic purification to yield 
the desired product. A further advantage of SPOS is the possibility of using 
combinatorial approaches to build quickly libraries of compounds by splitting the resin, 
reacting each portion with a different reagent, recombining then splitting and reacting 
again. The major disadvantage associated with SPOS is that the reactions employed 
must give only one product since, after multiple steps, reactions with side products will 
quickly multiply the number of compounds on the resin leading to poor yields and 
difficult separations after cleavage. For the same reasons, all reactions must be 
quantitative or as close to 100 % reaction as possible. There are also a number of 
practical considerations which must be taken into account when conducting SPOS. 
Solvent systems must be chosen carefully to ensure that the resin swells efficiently. If 
the reaction solvent does not allow the resin to swell sufficiently, the reagents will not 
be able to penetrate to all of the bound substrate and there will be incomplete reaction. 
There is also the issue of how the courses of the reactions are monitored. The use of 
TLC is not normally convenient as it requires the cleavage of a small quantity of the 
substrate from the resin which is time consuming and depletes the quantity of resin over 
several successive steps. This problem has led to the development of specific 
techniques for reaction monitoring e.g. FTIR and gel-phase 13C-NMR (Look et al., 
1994).
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Having synthesied spermine amide conjugates with acridine by solution phase 
techniques, six targets 121-126 were designed having polyamines with different 
configurations of methylene groups acylated with acridine on either a primary or a 
secondary amine. These compounds were to be synthesised by SPOS methodology 
from a common starting material, the mono-protected triamine N1-Boc-N}-(3- 
aminopropyl)-1,3-diaminopropane.
121 R1 = Acr, R2 = H
122 R1 = H, R2 = Acr
123 R1 = Acr, R2 = H
124 R1 = H, R2 = Acr
Acr =
125 R1 = Acr, R2 = H
126 R1 = H, R2 = Acr
The solid support chosen for this work was Wang resin {para- 
benzyloxybenzylalcohol polystyrene) (Wang, 1973; Lui et al., 1981; Sieber, 1987) 
which has 0.65 mmol of hydroxyl groups per g of resin. The benzylic hydroxyl is 
reacted with 4-nitrophenyl chloroformate which is then reacted with the amine to be
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linked to the polystyrene (Fig. 4.2). The linkage thus formed is a carbamate so the 
amine is protected and w ill not react further during the SPOS synthetic manipulations 
(D ixit and Leznof, 1977). This carbamate is cleaved under acidic conditions which  
rules out any acidic reagents in the synthetic scheme, but it also m eans that as the 
polyam ine chain is lengthened, amines which need protection can be m asked by Boc  
groups. At the end o f the synthesis, exposing the resin to TFA w ill c leave both the resin 























Reactor is rocked on its side whilst 
the reaction is in progress
Anhydrous
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Towards the synthesis of the target compounds 121-126, Wang resin was reacted 
with 10 equiv. of both 4-nitrophenyl chloroformate and A-methylmorpholine. Due to 
the nature of the resin, reactions cannot be stirred in a conventional mechanical fashion 
as the beads are broken up and destroyed, so the reaction vessel is constantly rocked or 
agitated in order to ensure even distribution of reagents. The reaction was done on 5 g 
of resin in a glass reactor with three necks, one sealed with a septum and two with 
sinters and taps (Fig. 4.6, for a photo see Fig. 4.3). This arrangement allowed the 
introduction (via a cannula) and removal of anhydrous solvents allowing the activated 
product to be washed in an inert atmosphere. The reactor had a dimpled base which 
disperses reagent amongst the resin and it was coated with a layer of silicon (sigmacote) 
before introduction of the resin to prevent the resin from sticking to the glass.
After thorough washing of the resin with a range of anhydrous solvents, the resin 
was reacted with half quantities of the same reagents for a reduced time to ensure that 
the reaction was complete. After washing and drying the resin (40 °C over P2O5) it was 
reacted with A^/ -Boc-A^/-(3-aminopropyl)-l,3-diaminopropane 181 (see Chapter 5 for 
synthesis) in CH2CI2. As the reaction progressed and the amine displaced the 4- 
nitrophenol leaving group, the reaction mixture turned a bright yellow colour. After 16 
h the resin 127 was washed, this time without the need for anhydrous conditions. In 
order to remove the final traces of 4-nitrophenol, it was necessary to agitate the resin for 
an extended period of time (typically 18 h) in THF-H2O (1:1) as part of the washing
O
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process. In order to monitor the success of the reaction, a small sample (-15 mg) was 
taken and ground up with solid, anhydrous KBr. The absorbance of this mixture was 
measured with an FTIR instrument and the appearance of a broad band at 1680-1700 
cm ' 1 was clearly visible indicating the presence of the carbamate functional group.
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Fig. 4.7
The completion of the reaction was also verified by measuring the 13C-NMR 
spectrum of the resin as a gel in CDCI3 (Fig. 4.7).
Before extending the polyamine, some trial reactions were carried out to 
investigate the best method for introducing the acridine moiety. The initial idea was to 
use acridine-9-acyl chloride 128. This was prepared from the carboxylic acid 73 which 
was reacted with thionyl chloride in the presence of a catalytic amount of DMF (Fig.
4.8). Several attempts were made to acylate the free amine on the resin bound triamine 
127 with this acid chloride. Reactions were tried using Af-methylmorpholine or NEt3 as 











Unfortunately, it is not possible to monitor the progress of the reaction by FTIR as 
the resin masks the regions where the new IR bands appear. In each case, the resin was 
treated with TFA in CH2CI2 to cleave the product and, in each case, only unreacted 
poly amine was isolated as identified by TLC. Two further methods of activating the 
acridine-9-carboxylic acid 73 were tried (Fig. 4.8). The first was with 2- 
mercaptothiazoline (Nagao e ta i ,  1980 and 1984). This heterocycle was reacted with a 
portion of the acid chloride in the presence of triethylamine and a trace of DMAP 92. 
The reaction was monitored by TLC until all of the acid chloride had been consumed 
then the resulting solution 129 was used to treat the resin 127. This method also failed 
to yield any acylated product after cleavage. The final method of acylation to be tried 
was by the use of HOBt activation. Acridine-9-carboxylic acid 73 was reacted with 
DCC and a stoichiometric amount of HOBt in DMF. The resulting solution of activated 
acid 130 was used to acylate the resin 127. This time, after TFA mediated cleavage of 
resin 131, there was an obvious polyamine-chromophore conjugate in the residue (Fig.
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4.9). A flash column was necessary to separate this product from unreacted triamine, 
that may have been cross-linked on the resin. The isolated product showed ‘H- and i3C- 












In order to extend the polyamine chain on the resin, reductive amination reactions 
were proposed. The amino position to be chain extended is exposed to an A-protected 
amino-aldehyde or A-protected amino-ketone in the presence of a reducing agent. An 
imine is formed between the resin bound amine and the carbonyl, then reduction yields 
the secondary amines from the aldehyde or ketone (Fig. 4.10).
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-NH,
Resin and linker 
R = protected polyamine chain
PG = amine protecting group
.PG
V - H
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The protecting group on the new terminal amine can then be removed generating a new 
site for either chain extension by a further reductive amination, or alternatively for 
acylation.
Due to the acid labile nature of the carbamate linker to the resin, the protecting 
group on the amino-aldehyde/ketone has to be chosen so that it can be cleaved in a non- 
acidic fashion. The Z group which was used as a protecting group orthogonally to Boc 
in Chapters 2 and 3 is not suitable for SPOS as the typical method of cleavage is by 
catalytic hydrogenation. The catalyst is a Pd species adsorbed on C and there is no 
obvious way of separating the solid catalyst from the resin after reaction. In this work, 
the use of the azido and pent-4-enoyl (Pnt) groups were investigated. The azido group 
can be reduced by action of PPh3 to give an amino group (Carboni et al., 1993). The Pnt 
group has not previously found use in the SPOS synthesis of polyamines. Its use was 
reported initially by Fraser-Reid and co-workers in solution-phase towards the synthesis 
of p-glucosaminides (Madsen et a l , 1995). The Pnt group has also found use in the
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synthesis of oligonucleotides both in solution and solid phase syntheses (Radhakrishnan 
et al., 1995 and 1997). It is cleaved by action of I2 , usually in a 1:1 THF/H2O solvent 











Three carbonyl compounds were chosen for reductive amination reactions, 5- 








The reducing agent chosen to investigate these reactions was borane-pyridine 
complex (BAP). There was some literature precedent for the use of BAP, but this was 
to make tertiary rather than secondary amines (Kahn et al., 1996).




Each reductive amination was carried out with 10 equiv. of aldehyde/ketone and the 
same amount of BAP (Fig. 4.12). In the case of the azido containing compounds 133 
and 134, the progress of the reaction could be monitored by the appearance of an azido 
band, located at 2090 cm ' 1 in the IR. The spectrum for the reaction with the Pnt 
protected amine 135 showed no change as the resin peaks masked any new absorbances. 
These reactions were all on 2 g of resin and of 48 h duration, carried out under argon
86
with agitation. The quantity of resin meant that it was most convenient to perform the 
reactions in a 50 mL round bottom flask, (for a photo see Fig. 4.4) The flask was pre­
treated with sigmacote before introduction of the resin to ensure it did not stick to the 
glass. After the reaction time, each resin was thoroughly washed and dried and was then 
split into two portions. One half was reacted with a tenfold excess of Boc anhydride to 
protect the newly formed secondary amine (Fig. 4.13).
Boc20
R =
3 1 3 6
3 1 3 7
1 3 8
R =
N ,  1 3 9
3 1 4 0
.Pnt 1 4 1
Fig. 4.13
As the quantities of resin now being used were around 1 g per reaction it was 
unnecessary to use a glass reactor. A convenient alternative is a plastic, 20 mL syringe 
with a filter at the end (Fig. 4.14, for a photo see Fig. 4.5). The resin is placed into the 
syringe and the plunger replaced. Solvent can then be sucked up and, more importantly, 
removed by simply drawing up or pushing down the plunger, the filter preventing the 
resin from leaving the syringe. In this way, reagents can quickly be introduced then the 
end of the syringe is fitted with a cap. Simple rotation of the syringe ensures dispersion 






After the Boc protection step, the two resins bearing the azido functionalities (139 
and 140) were reacted with PPh.i in THF with a small amount o f H 2 O in order to reduce 
the azides to amines (Fig. 4 .15). The course o f the reaction was easily fo llow ed  by 
m onitoring the disappearance o f  the azide peak in the IR characteristically at 2090  cm " 1 
(Fig. 4 .16).
139 R = Me
140 R = H
142 R = Me






Azide peak disappears 
during PPh3 reduction
- Wavenumber/ cm*1 
Fig. 4.16
Two days were required for complete reaction and after washing and drying then 
each resin was acylated with a solution of HOBt activated acridine-9-carboxylic acid 
130 in DMF. These reactions were performed over 19 h and during this period the 
acylating reagent was replaced once (Fig. 4.17).
The resin bearing the Pnt protected amine 141 was reacted with h  in a 1:1 mixture 
of THF and H2O. Ten equiv. of I2 were used and the reaction was run for 18 h. When 
the resin 144 was washed after reaction, as well as the usual range of solvents, a 
saturated solution of aq. Na2S2 0 3  was used to remove traces of I2. This resin was then 
acylated in the same way as the previous two with HOBt activated acridine-9-carboxylic 
acid 130 (Fig. 4.17).
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These three resins (1 4 5 -1 4 7 ) were then exposed to TFA to bring about cleavage of 
the functionalised poly amines from the resin (Fig 4.17). The residue from each 
deprotection was purified by flash column chromatography on silica gel. Products were 
isolated from each resin with spectral characteristics fitting with the desired conjugates, 
1 2 1 ,1 2 3  and 125 . Unfortunately the yields were low, a problem which was probably 
due to poor acylation reactions. The chromatography of the residues from the cleavages 
showed only one product in each case having both a polyamine and acridine moiety. If 
the problem had been due to slow or inefficient reductive amination reactions, then it 
would be expected that a quantity of the acylated triamine would also have been 
detected. Clearly, work still has to be done to investigate the problems associated with 
the acridine acylation step and to improve it to an acceptable level.
After the reductive amination steps, another synthetic route was followed towards 
the amides 1 2 2 ,1 2 4  and 126. The resins 1 3 6 ,1 3 7  and 138  were acylated with HOBt 
activated acridine-9-carboxylic acid 1 30  in DMF as previously described then the 
protecting groups were removed (Fig. 4.18). In the case of the two azides 1 4 8 ,1 4 9 ,  this 
was by action of PPI13 and in the case of the Pnt protected amine 1 5 0  this was by 
exposure to I?. After washing and drying, these three resins 1 5 1 -1 5 3  were subjected to 
cleavage by TFA. The residues from these reactions all showed uncoupled polyamines 
and none of the desired conjugates, 1 2 2 ,1 2 4  and 126 , by TLC and by *H-NMR. Again 
the problem is most likely due to failure of the acylation reactions. The exact reason 
why these reactions are so reluctant is not entirely clear although there may be problems 























R' = NH0 124
2 126
Solid phase synthesis of polyamines is a quick and efficient way of making a 
larger number of compounds for biological evaluation. This study has proven the 
feasibility of building unsymmetrical polyamine chains whilst anchored to a solid 
support and the selective unmasking of amines to reveal selectively sites for 
conjugation. More time spent on improving the acylation stages reported in this work 




Synthesis of 23-, 24- and 28-Membered 
Polyamine Containing Lactams
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Synthesis of 23-, 24- and 28-Membered Polyamine Containing Lactams
In Chapter 1 it was stated that a number of polyamine containing natural products 
and synthetic conjugates have potential in the treatment of certain parasitic infections. 
One specific target enzyme in trypanosomal parasites is trypanothione reductase (TR) 
which performs a crucial role in protecting the infective organism from oxidative stress 
produced by free-radicals (Walsh et a i, 1991; Fairlamb and Cerami, 1992). In Fig. 5.1 













spdT - trypanothione 
GSH - glutathione 13 
spd - spermidine 2
Fig. 5.1
(after Fairlamb and Cerami, 1992)
In the search for compounds which will inhibit TR, and hence have medicinal 
potential, the plant natural product kukoamine A has been identified as having useful 
activity (Ponasik et al., 1995). A comparison between kukoamine A 8 and 
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Kukoamine A 8 is a positively charged spermine conjugate whereas trypanothione 
disulfide 15 is a positively charged spermidine conjugate. Both polyamine chains are 
terminally A-diacylated. Kukoamine A 8 has a largely open-chain structure whilst 
trypanothione 15 is a 24-membered macrocycle. Detailed searches of the literature 
reveal several compounds e.g. codonocarpine 154  (Doskotch et a l ,  1971 and 1974), 
cadabicine 1 5 5  (Ahmad et al., 1985 and 1987) and capparisine 1 56  (Ahmad et al., 
1987), all plant natural products, which contain spermidine moieties in 24-membered 
rings.
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R = H, R 1 = OMe; Codonocarpine 154 Cadabicine 155
R = OMe, R 1 = H; Capparisine 156
Similar to kukoamine A 8, these compounds contain a polyamine which is acylated on 
the primary amines by cinnamic acid (3-phenylpropenoic acid) derivatives. In the case 
of the cyclic compounds 154-156, a macrocycle has been formed by a diphenyl ether 
linkage bridging between two aromatic carbons, one from each cinnamate residue. It is 
interesting to note that whilst apparently structurally the same, apart from the pattern of 
oxygenation around the aromatic rings, there is in fact a difference in the carbon 
skeleton between cadabicine 155 and codonocarpine 154 and capparisine 156. In 
cadabicine 155, the propylamine residue in the spermidine 2 moiety has been acylated 
by a cinnamate which has a para substitution pattern between the vinylic carbon and the 
cyclic ether bearing carbon. This relationship is meta in the other two compounds 154 
and 156. If the acylation pattern is examined on the butylamine side of the spermidine 
moiety, then the pattern is reversed. These compounds have potential as inhibitors of 
TR. They will bear the same charge at physiological pH and they all are 24-membered 
rings (Fig. 5.2). Cadabicine 155 was chosen as the compound to be synthesised with the 
aim of testing it for TR inhibitory activity. It was first isolated from Cadaba farinosa in 
1985 (Ahmad et a l , 1985) and has subsequently been isolated from Crataeva nurvala 









Both molecules contain a
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Conformation of cadabicine 155 
from X-ray single crystal analysis 
(Ahmad et a l, 1985)
Fig. 5.3
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Both plants are commonly found in Pakistan, and parts of both have been reported 
to have medicinal properties. Previous studies have led to the isolation and 
identification of other alkaloids in these plants (Ahmad et al., 1985). The structure of 
cadabicine 155 was identified by spectral methods including ‘H- and 13C-NMR, IR, UV 
and mass spectrometry and finally an X-ray crystal structure (Fig. 5.3) was also obtained 
(Ahmad etal., 1985).
There are a number of reasons why it is interesting and important to come up with 
a total synthesis of this natural product. From a chemical point of view, this compound 
possesses a number of synthetic challenges. The regiochemistry of the spermidine must 
be controlled as the target is unsymmetrical. There must be a method for differentiating 
between the two terminal amines. The diphenyl ether must be formed, a potentially 
difficult carbon-oxygen bond forming step. The macrocycle must be closed, an 
entropically unfavourable process. From a practical point of view, an efficient synthesis 
would allow the required amounts of compound to be easily to hand, as the naturally 
extracted product is scarce in the scientific community.
At the commencement of these studies, the literature was searched for procedures 
for forming diphenyl ethers. There are broadly three approaches which have been 
followed, thallium trinitrate promoted phenolic oxidative couplings (Rama Rao et al., 
1995), Ullmann reactions (Lindlev, 1984; Rama Rao et al., 1995) and SNAr reactions 
involving the displacement of an ortho-nitro activated fluorine (Zhu, 1997).
Before the 1980’s, the most commonly utilised method in the literature for the 
formation of diaryl ethers was by copper assisted couplings of phenols with aryl halides. 
The ipso displacement (i.e. attack at an aromatic position bearing a substituent) of aryl 
halides with nucleophiles was first reported in 1901 by Ullmann and has since been 
widely used and further modified. The variety of nucleophiles, reaction conditions and 
results from mechanistic studies have been reviewed by Lindley (1984). The simplest
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examples of diaryl ether formation have been carried out with powdered copper as the 
catalyst. A typical example is the formation of 2-methoxydiphenyl ether. 2- 
Methoxyphenol is reacted with sodium hydroxide to give the corresponding phenolate 
which is dried and then heated to 200 °C in air for 2 h with bromobenzene and copper 
powder. The product is isolated in 62 % yield; this is greater if phenol is used and is 
often lower or negligible if reactants with greater functionality are used. The active 
catalyst in this reaction is thought to be a copper oxide which forms when the copper 
powder reacts with air, as copper(I) oxide and copper(II) oxide have both been shown to 
be better catalysts than elemental copper. Investigations have shown that a wide variety 
of copper compounds will catalyse this reaction and it has also been shown that the 
choice of base, solvent, temperature and duration of reactions can be crucial for getting 
the reaction to work, the exact combination depending upon the nature of the reactants. 
Mechanistic studies that have been carried out indicate the formation of a copper 
phenoxide. The aryl halide can then ligate with the copper bringing the reacting species 
into close proximity, the requirement for ligation possibly showing the need for careful 
solvent choice. The diagram below (Fig. 5.4) shows a mechanism proposed by 
Weingarten (1964).
The harsh reaction conditions often cause low yields due to the effects of 
substituents on the aromatic rings causing decomposition. Despite this, careful 
manipulation of reaction conditions has led to some utility in the synthesis of natural 
products including (±)-vertaline 157 (Hart and Kani, 1982) (Fig. 5.5). The diphenyl 
ether was accessed by preforming the desired copper phenoxide with NaH and Cul and 
treating it with either the bromide or iodide of the other aromatic species. The reaction 
was heated under reflux for 3 h in pyridine yielding the desired ether in 38 % yield along 
with recovered starting material and a small amount of an undesired reduction product.
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CuBr + KOPh CuOPh + KBr



























Another elegant synthesis has been described by Wasserman and co-workers 
(1983); an Ullmann reaction is at the start of their synthesis of the natural product 
chaenorhine 158. This compound is a polyamine conjugate with a certain structural 
similarity to cadabicine 155. The diphenyl ether unit comes from two cinnamate 
moieties and the polyamine is spermine 1 which has been acylated on nitrogens N l and
2 3N  and has been acetylated on N  . In the biosynthesis, the remaining primary amine 
appears to have come round and attacked one of the cinnamates in a 1,4-conjugate 
fashion to form two macrocycles and the associated oxygen has been maintained at the 
carbonyl oxidation level. In Wasserman’s synthesis, Fig. 5.6, the diaryl ether was 
formed in 61 % yield by reaction between the required phenol and aromatic bromide in 
the presence of NaH, CuCl and pyridine heated under reflux. A preformed poly amine 














It is interesting to consider the biosynthesis of plant natural products such as 
chaenorhine. Many compounds have been isolated from plant sources containing 
spermine and spermidine and amongst these a large subset are acylated on one or more 
amine groups by cinnamic acids (Guggisberg and Hesse, 1983 and 1998). These 
cinnamamides have a variety of patterns of oxidation around the six-membered aromatic 
rings. Further biosynthetic reactions add to structural diversity. Kukoamine A 8 is a 
spermine 1 conjugate which has been acylated twice by caffeic acid (3,4-dihydroxy 
cinnamic acid) and then the alkene bonds have been reduced. Chaenorhine 158 is a 
spermine conjugate which has been acylated on amines 1 and 2 by two cinnamic acids 
which have then undergone an etherification to form a diaryl ether link. Amine 3 has 
been acetylated and amine 4 has performed a Michael-type (1,4) addition to an alkene in 
one of the cinnamates to form a further ring.
Recent synthetic work has widened the utility of the Ullmann reaction as a number 
of researchers have addressed the synthetic challenges provided by a number of natural 
peptidic compounds containing oxidatively coupled residues, normally derived from 
two tyrosine units (Rama Rao et a l, 1995). Not only are these compounds of interest to 
the organic chemist, but they also often display good antibiotic and anticancer biological 
activities. For a review of a number of synthetic methods towards these compounds, 
see: Rama Rao et al. (1995). Evans and co-workers have published several syntheses 
of peptidic compounds containing diaryl ethers, e.g. in 1989 the syntheses of tripeptides 
OF4949-III159 which is of interest as an anti-cancer agent and K-13 160 which is an 
ACE inhibitor (Evans and Ellman, 1989). These 17-membered macrocycles were built 
from a common diphenyl ether unit 161 produced from the intermolecular Ullmann 
reaction between two differentially protected cinnamate esters. The remainder of the 



















RA-VII (R = Me) 162 and Deoxybouvardin (R = H) 163
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Further work has been published by Boger and co-workers relating to the synthesis 
of the antitumour antibiotics RA-V II162, deoxybouvardin 163 and related compounds 
(Boger et a l ,  1993; Boger and Zhou, 1995). These hexapeptides contain a 14- 
membered cyclophane and an 18-membered peptide ring (Boger et a l,  1992). The 
initial approach taken was to form a diaryl ether linkage as an open-chain, and then to 
use a peptide coupling to close the small, 14-membered ring before attaching the larger 
peptide ring (18-membered) (Boger et al., 1993). This approach failed as the small ring 
164 could not be closed, the only product being dimeric, formed from two of the diaryl 
units 165 (Fig. 5.7). Success was achieved by using the Ullmann reaction as a 
macrocyclisation step to form the 14-membered ring 166. In all cases the base used was 
NaH, but varying the substituents on the reactants led to more efficient reactions with 





From the time this work was published, the majority of syntheses of diphenyl 
ether containing natural products have used the ether bond formation as the cyclisation 
step. Boger has described the synthesis of related ring systems including models of 










Vancomycin is an arylglycine rich heptapeptide which is conjugated to sugar 
residues. It is one member in a family of such antibiotics which differ in the peptidic 
structure as well as in the nature of the sugar groups appended. Vancomycin is currently 
used as a last resort against bacterial infections resistant to other antibiotics, although 
recently certain bacterial strains are appearing with vancomycin resistance. The 
elaborate structure has long been of interest to chemists as a synthetic challenge. The 
interaction between vancomycin and proteins has been well investigated by Williams 
and co-workers, largely through NMR studies (Williams, 1984, Williamson et a i,
1984). With the recent advance in diaryl ether forming methodologies, successive 
fragments of the structure have been prepared and this work has culminated with the 
publication, as this thesis nears completion, of the total syntheses of vancomycin 
aglycone simultaneously by the research groups of Evans (Evans et a l,  1998a and b)
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and Nicolaou (Nicolaou 1998a, b and c). The key to making the diphenyl ether rings in 
vancomycin 167 has not been by the use of Ullmann reactions, but by SwAr substitution 
reactions. Zhu and co-workers have pioneered the development of macrocyclisations 
using the displacement of an ortho-nitro activated fluorine with a phenolic oxygen (168 
to 169). Zhu has published applications of this methodology towards the synthesis of 
ring fragments of vancomycin 167 (Beugelmans et al., 1996; Vergne et a l ,  1997) and 
the structurally related antibiotic teicoplanin (Bois-Choussy et al., 1996 and 1997) as 
well in the synthesis of K-13 160 (Beugelmans et a i,  1994) and deoxybouvardin 163 




The advantages of this reaction over cyclisations by the Ullmann method are that 
the reaction is mild, requiring no more than a weak base in a polar, aprotic solvent to 
bring about reaction, and it is high yielding once the correct combination of base and 
solvent are established. There has been speculation about the mechanism of this 
reaction and why it proceeds so favourably along an entropically disfavourable path. It 
was initially proposed that there might be a n-n stacking interaction between the 
electron rich phenolic ring and the electron deficient fluoro-nitro ring. Computer 
modelling studies have been published predicting such an interaction showing the 
reacting centres to be close enough together to promote reaction (Zhu, 1997). However, 
there are two pieces of evidence which dispute this as being the key interaction driving 
the reaction. Firstly, these cyclisations can be run at concentrations (up to 1 M)
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significantly higher than typical macrocyclisation conditions, e.g. typically reaction 
concentrations of 0.004 M have been reported by Boger for Ullmann ring formations 
(Boger et a i, 1993). Despite using a high concentration reaction mixture, the sole 
product is the intramolecularly formed ring and no intermolecluar dimerisation or 
polymerisation as might be expected. The second piece of recent evidence is the fact 
that aryl-alkyl ether bonds can be formed between alcohols and aromatic ortho-nitro 
fluorines. These reactions have been demonstrated to proceed in good yield, without the 
benefit of any interactions between the two aromatic moieties (La'ib and Zhu, 1998).
A literature search was performed for syntheses of cadabicine 155 and no 
successful procedures were found. Some work has been published on the synthesis of
codonocarpine 154 using an Ullmann reaction to build the diphenyl ether unit followed
1 2by coupling of regioselectively protected N  , N  -di-Boc-spermidine (Humora et al., 
1980). Cleavage of the Boc groups and an amide forming step yielded the required 24- 
membered macrocycle. Other workers had followed a similar route towards cadabicine, 
but failed to bring about the lactamisation step (Nogradi et a l, 1994). As the majority 
of these published diphenyl ether forming macrocyclisations (vide supra) are for ring 
sizes in the 14-18 membered range, it was of interest to see if such methodology could 
be applied to forming larger rings sizes. In making small rings (3- or 4-membered), the 
energetics of forming strained systems is disfavouring whereas in a larger system it is 
the entropic difavourability of bringing the widely spaced (remote) ends together which 
could be the limiting factor.
Our initial model studies using the Ullmann approach to the cyclisation were 
disappointing, the reactions being low yielding with the formation of a lot of brown 
decomposition products. These made chromatography difficult and any interesting 
products formed were not easy to purify. Due to these problems it was decided to look 





In the first instance, rather than trying to make a spermidine containing ring, the 
symmetrical triamine A-(3-aminopropyl)-l,3-propanediamine 178 was substituted 
making the target a 23-membered macrocycle 170. Using this as a model compound 
simplified the synthesis, as the issue of the regiochemistry of the triamine was not 
relevant at this stage. This compound has a methoxy group in place of the hydroxy in 
cadabicine 155, a necessary protecting group which would be removed in the final 
synthesis of the natural product, and a nitro group which is required to activate the 
adjacent carbon for nucleophilic substitution. A Boc group is protecting the secondary 






The open-chain precursor 171 to the target 170 requires the terminal diacylation of 
the suitably protected triamine by two cinnamic acids. 3-Hydroxy-4-methoxycinnamic
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acid (isoferulic acid) 173 was synthesised by Knoevenagel condensation following 
literature procedures (Blase and Banerjee, 1995).
H^ °
malonic acid












3-Hydroxy-4-methoxybenzaldehyde 172 was heated to reflux for 1 h with malonic 
acid and piperidine in pyridine to give the desired trans cinnamic acid 173 in 92 % yield 
(Fig. 5.8). The *FI-NMR spectrum proved the isolated cinnamic acid to be the desired 
trans rather than the cis isomer as signals at 5 6.24 and 7.45 ppm, corresponding to the 
two alkene protons, are split by 16 Hz. Typically trans coupled protons give coupling 
constants between 12 and 18 Hz whilst those with a cis relationship display 0-12 Hz 
(Williams and Fleming, 1987). In order to make the 4-fluoro-3-nitrocinnamic acid 176, 
first 4-fluorobenzaldehyde 174 was nitrated under standard conditions giving only the 
desired mono-nitrated product 175. Unfortunately, attempted Knoevenagel 
condensation with this aldehyde gave many products as visualised by TLC, so it was 
decided to change the order of the reactions. 4-Fluorobenzaldehyde 174 was smoothly 
converted into the cinnamic acid 177 by the standard procedure and was then nitrated by 
the action of conc. nitric acid giving the required orr/zo-fluoronitrophenyl substitution 
pattern 176 in 85 % yield.
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For the protection of iV-(3-aminopropyl)-l,3-propanediamine 178 , the 
trifluoroacetyl protecting group was used to discriminate between the primary and 
secondary amines (Fig. 5.10). Trifluoroacetyl, when introduced by stirring the triamine 
with ethyl trifluoroacetate, has overall selectivity for primary amines (O’Sullivan et a l, 
1995; Xu et al., 1995). Two equivalents were stirred with the triamine 178  in THF for 
1 h at 25 °C before Boc anhydride was added (Fig. 5.10). This was allowed to react 
with the unmasked secondary amine 179  for 18 h, after which time conc. aq. N H 3 was 
added to the reaction mixture until the pH was above 11. The action of the NH3 cleaves 
the trifluoroacetyl groups, but not the Boc group which is base stable and acid labile. 
After 24 h, TLC indicated that the reaction was complete, so it was worked up and the 




Cinnamic acids 173 and 176 were then coupled to the triamine in a sequential 
fashion. First attempts were with isoferulic acid 173  using DCC and catalytic HOBt 
using 2  equiv. of the diamine 181 and dilute reaction mixtures to favour the mono- 
acylated product 182 . This reaction was slow and low yielding, so other possibilities for 
making the amide bond were investigated. Attempts to activate the acid by conversion 
into its acid chloride by action of thionyl chloride and catalytic DMF were not 
successful as the reaction created a number of by-products when investigated by TLC. 
Coupling was also tried by activating the acid as its pentafluorophenyl ester (DCC, 
HOBt, pentafluorophenol). Couplings with this reagent gave approximately the same 
yield as DCC alone. The best method tried was by using 2-mercaptothiazoline as an 
activating agent (Nagao et al., 1980 and 1984) (Fig. 5.11). The amides formed from 
acids by treatment with this reagent (in this case by action of DCC/catalytic DMAP) are 
susceptible to nucleophilic attack by primary amines. These compounds are also bright 
yellow, this colour disappearing when these intermediates are quenched with amines 
allowing the progress of a coupling reaction to be visually assessed. In this instance, the 
2 -mercaptothiazoline activated isoferulic acid was synthesised in 1 h with 1.5 equiv. of 
DCC, a catalytic amount of DMAP and 1.1 equiv. of 2-mercaptothiazoline. Once the 
yellow colour had appeared, and TLC indicated all of the starting materials had been
consumed, the reaction mixture was filtered to remove the insoluble DCU, and the 
filtrate was added immediately to a stirred solution of 2  equiv. of the diamine 181.
After 10 h the yellow colour had disappeared and TLC indicated that the reaction had 
run its course. After careful flash column chromatography on silica gel, the desired 
amide 182 was isolated in 75 % yield.
4-Fluoro-3-nitrocinnamic acid 176 was coupled to the remaining primary amine 
using the same protocol except this time a 1:1 ratio of activated acid to amine was used. 
The cyclisation precursor 183 was recovered in 69 % yield after chromatography.
Macrocyclisation was bought about by use of a standard procedure developed 
towards the synthesis of vancomycin fragments (Zhu et al., 1997) (Fig. 5.11). The 
precursor 183 was stirred in anhydrous DMF with 5 equiv. of CsF for 18 h. TLC 
showed the formation of a slightly more polar product which stained a different colour 
when exposed to FeCl3. This compound was isolated by chromatography on silica gel 
and was examined spectroscopically. The lH-NMR shows a change in the splitting in 
the aromatic region. Signals which displayed fluorine coupling in the open chain 
analogue no longer did after the cyclisation. The proton on the carbon ortho to the 
carbon bearing fluorine was a doublet of doublets at 6  7.71 ppm showing a 2 Hz 
coupling to fluorine and a 8  Hz coupling to an ortho proton. After cyclisation this 
signal displays only the proton-proton coupling. The ,3C-NMR spectra also give an 
indication of the change which has occurred. In the precursor, the aromatic carbon 
attached to fluorine has an obvious signal at 5 158.2 ppm which is split into a doublet of 
258 Hz. This signal has moved and there is no sign of this, or any of the carbons which 
previously displayed C-F coupling patterns, being split. The fluorine has been displaced 
by the phenolic oxygen. To confirm this the FAB-MS and FAB-HRMS of desired 
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After the success of this 23-membered ring formation, attention was turned to the 
24-membered ring as found in cadabicine. To protect the spermidine required in this 
synthesis, the published formation of a hexahydropyrimidine adduct with formaldehyde 
was exploited (Ganem, 1982). The favourable formation of this 6 -membered ring 184  
occurs when spermidine 2  is stirred for 1 h with 0.95 equiv. of aq. formaldehyde in a 
quantitative fashion Fig. 5.12. This adduct allows for the differentiation of the primary 
amines in spermidine as in this cyclic form there are two amines which can be acylated, 
a primary and a secondary, and these have different nucleophilicities. The more 
nucleophilic primary amine was reacted with the 2 -mercaptothiazoline activated 
isoferulic acid at an initial temperature of -78 °C. On addition of the acylating agent, 

































The cold temperature was employed to ensure the kinetically favoured primary acylation 
occurred rather than acylation at the secondary amine. The desired amide 185  was 
recovered after chromatography in 55 % yield. The hexahydropyrimidine ring was then 
opened by application of the Knoevenagel procedure, heating the adduct with malonic
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acid and pyridine in anhydrous EtOH for 18 h. The monoacylated spermidine 186 was 
recovered in 79 % and was then acylated with activated 4-fluoro-3-nitrocinnamic acid 




















Before cyclisation the secondary amine was protected with a Boc group by reaction with 
Boc anhydride (89 %) to ensure that the free amine did not interfere with cyclisation.
As with the 23-membered ring 170, CsF mediated cyclisation this time in 71 % yield in 
DMF (Fig. 5.13). The reagents had to be thoroughly dried before reaction or the starting 
material 187 remained unreacted. That the cyclisation had occurred was confirmed by 
TLC and NMR spectroscopy as well as by reverse-phase HPLC in which the residual 
reactant 187 was clearly seen separately to the product 188 peak. There was a 
significant line broadening in the ^ -N M R  signals in the cyclised compared to the non- 
cyclised compound which could be expected due to the loss of free rotation in the 
macrocycle. Mass spectroscopy and HRMS were also used to confirm the identity of 
the product (595.2793 found, 595.2768 required for MH+),. TFA was used to cleave the 
Boc group from the secondary amine and then attention was turned to the methyl ether. 
In cadabicine there is a hydroxyl at this position so an O-demethylation step is required. 
Initially reactions were attempted with TMSI, but despite trying a range of temperatures, 
the reactions gave either recovered starting material or decomposition products. The 
transformation was successfully mediated by action of BBr^ over 3 h at -78 °C. After 




This compound 189 is a key intermediate in the total synthesis of cadabicine 155,
requiring only the removal of the nitro group. It provides the opportunity for structure-
116
activity studies to be performed with cadabicine analogues, particularly screening for 
inhibitors of TR. The final transformation into cadabicine could be achieved by careful 











































Having synthesised 23- and 24-membered polyamine amide macrocycles there 
remained the question “how big can these rings be?” As a step towards answering this 
question, a target compound 194  was designed having the tetra-amine spermine 1 in 
place of spermidine 2 in the ring, thus making it a 28-membered macrocycle. The 
synthesis of the cyclisation precursor was analogous to the strategy employed with N-(3- 
aminopropyl)-1,3-propanediamine 1 78  since spermine is symmetrical (Fig. 5.14).
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A^A^-DiBoc-spermine 192 was isolated in 55 % yield and was then sequentially 
coupled to the two acids, 3-hydroxy-4-methoxycinnamic acid 173 then 4-fluoro-3- 
nitrocinnamic acid 176. Attempts to bring about cyclisation were at first unsuccessful. 
No reaction was observed with CsF both in DMF and DMSO so the base was changed 
to K2CO3. No reaction was observed in DMSO until it was run with the addition of 18- 
crown- 6  when there was a slow formation of a product spot as shown by TLC. It is 
assumed that this reagent is enhancing the nucleophilicity of the oxygen which was 
previously too low for reaction. As there was still a significant quantity of starting 
material 193 left after 24 h the reaction was re-run at 50 °C at which temperature 
cyclisation was complete after 5 hours (Fig 5.15). The macrocycle 194 was identified 
spectroscopically (NMR, FAB-MS, FAB-HRMS, found 752.3895, 752.3871 required 












Finally TFA in CH2CI2 to strip off the Boc protecting groups and yield the 
diamine 195 after chromatography (Fig. 5.16).
The utility of SnAr reactions has clearly been demonstrated with respect to the 
synthesis of polyamine macrocyclic alkaloids in a practical, high yielding fashion. It 
should find ready application in the synthesis of further compounds in the cadabicine 
and codonocarpine classes. For the first time, macrocyclic lactams of 23-, 24- and 28- 
members have been prepared. Rather than using intermolecular Ullmann chemistry to 
close the diphenyl ether bond, this was chosen as the site of disconnection for aromatic 
intramolecular nucleophilic substitution. We have prepared novel large-ring 







All chemicals were purchased from the Sigma-Aldrich-Fluka Chemical company 
(Gillingham, Dorset) and used without further purification. All solvents were either 
GPR or HPLC grade purchased from BDH (Poole, Dorset) and were used without 
further distillation. Anhydrous solvents were prepared with reference to procedures 
described in “Purification of Laboratory Chemicals” (Perrin et al., 1988). Water refers 
to singly distilled water. All solvent ratios are given as volume/volume. All reactions, 
unless otherwise stated, were performed under an atmosphere of anhydrous N2 gas. 
When anhydrous reagents were used all glassware was first dried at 120 °C, in vacuo. 
Thin layer chromatography (TLC) was performed routinely to monitor reaction progress 
and chemical purity. TLC was performed on pre-coated plates (Merck TLC aluminium 
sheets silica 60 F254). Visualisation was with UV light (254 nm or 366 nm) and acidic 
ninhydrin reagent (0.3 g ninhydrin in 100 mL rc-butanol and 3 mL acetic acid), alkaline 
potassium permanganate reagent (3 g potassium permanganate, 20 g potassium 
carbonate, 5 mL 5% aq. NaOH, 300 mL water) or iodine vapour as appropriate.
Flash column chromatography was performed according to the method of Still et 
al. (1978) using sorbasil C60-H silica gel purchased from Prolabo, (Eccles, Manchester) 
or ca. 150 mesh neutral alumina purchased from Sigma-Aldrich-Fluka. Columns were 
packed as a slurry in the eluting solvent and pressure was applied by hand bellows.
Reverse-phase HPLC was carried out using a 5 pin C8 inertpak column using a 
JASCO PU980 pump and a JASCO UV975 variable UV detector.
Melting points (MP) were determined using a Reichert-Jung Thermo Galen 
Kopfler block and are uncorrected. Infra-red spectra were recorded either as a thin
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liquid film or as a KBr disc using a Perkin-Elmer 782 instrument. Ultra-violet spectra 
were obtained from solutions in methanol using a Perkin-Elmer Lambda 3 spectrometer. 
'H-NMR spectra were recorded at 270 or 400 MHz using either a Jeol GX270 or a Jeol 
EX400 spectrometer respectively. 13C-NMR were recorded at either 67.8 (GX270) or
100.8 MHz (GX400). Assignments were assisted by the use of 135- and 90-DEPT 
carbon pulse experiments as well as ^ ^ H  and 2D correlation spectra. Chemical
shifts (5) are expressed in parts per million downfield from tetramethylsilane as internal 
standard. Coupling constants (J) are in Hertz and multiplicities are denoted by the 
abbreviations: s-singlet, bs-broad singlet, d-doublet, t-triplet, q-quartet, quin-quintet and 
m-multitplet. Assignments are listed as: 8  (number of protons, multiplicity, coupling 
constant, assignment).
Mass spectra were obtained using a VG autospec spectrometer. Electron impact 
ionisation (El) spectra were recorded typically using an ionising potential of 70 eV. 
Positive and negative FAB spectra were recorded using 3-nitrobenzyl alcohol as the 
matrix.
In vacuo refers to the use of a water aspirator, pressure (typically 15-30 mmHg). 
For the in vacuo removal of solvents a Btichi rotary evaporator was used and for drying 
solids in vacuo a vacuum desiccator was used with P2O5 as the drying agent unless 
otherwise stated.
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Amide bond formation by DCC/HOBt condensation - General Procedure A.
The carboxylic acid (1 equiv.), the amine (1 equiv.), DCC (1.5 equiv.) and a catalytic 
amount of HOBt (0.05 equiv.) were dissolved in an organic solvent and stirred at 20 °C. 
The precipitate was filtered off and the filtrate was evaporated in vacuo. The residue 
was purified by flash column chromatography on silica gel to yield the desired amide.
Removal o f Z-protecting groups by hydrogenolysis - General Procedure B.
A solution of Z-protected amine in MeOH was added to 10 % palladium on carbon.
The mixture was hydrogenated at atmospheric pressure for 24 h and then filtered 
through celite. The filter cake was washed with MeOH (3 x 20 mL) and the combined 
filtrate was evaporated in vacuo. The residue was purified by flash column 
chromatography to yield the desired deprotected amine.
General method 1 fo r resin cleavage - General Procedure C.
The resin was swollen with CH2CI2 and CH2CI2/TFA (1:1) was added. The reaction 
mixture was stirred for 2 h at 20 °C and then the reaction mixture was filtered. The 
filter cake was washed well with CH2CI2 and then MeOH. The combined filtrate and 
washes were evaporated in vacuo.
General method 2 fo r resin cleavage - General Procedure D.
The resin was swollen with CH2CI2 and CH2CI2/TFA (1:1) was added. The reaction 
mixture was stirred for 1 h at 0 °C and then the reaction mixture was filtered. The filter 
cake was washed well with CH2CI2 and then MeOH. The combined filtrate and washes 
were evaporated in vacuo.
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General method fo r  azido reduction - General Procedure E.
Triphenylphosphine (340 mg per g of resin, 1.30 mmol) was dissolved in THF (5 mL) 
and water (10 drops). This solution was added to the resin and the reactor was sealed 
and agitated for 24 h. The resin was washed with THF ( 4 x 5  mL) and the procedure 
was repeated using the same quantities of reagents for the same length of time. The 
resin was washed successively with THF, THF/H2O (1:1), THF and CH2CI2 and was 
then dried in vacuo at 40°C over P2O5.
General method fo r  acylation with HOBt activated 9- acridinecarboxylic acid - General 
Procedure F.
The resin (1 g) was mixed with the solution of HOBt activated 9- acridine carboxylic 
acid (1.3 mmol) in DMF (7 mL) then the reactor was flushed with N2, sealed and 
agitated for 16 h. The resin was washed with anhydrous DMF ( 5 x 5  mL) and the 
procedure was repeated with the same quantity of reagent, agitating for 3 h. The resin 
was washed successively with DMF, THF, THF/H2O (1:1), THF then Et2 0  ( 5 x 5  mL 
each solvent) and was then dried in vacuo at 40°C over P2O5.
A;-(f-ButoxycarbonyI)spermine 69
A solution of Boc anhydride (3.6 g, 17 mmol) in THF (30 mL) was added to a stirred 
solution of spermine 1 (10 g, 49 mmol) in THF (40 mL) at 0 °C. The mixture was 
stirred at this temperature for 1 h and then for a further 18 h at 20 °C. The solvent was 
removed in vacuo and then the residue was purified by flash column chromatography on 
silica gel eluting with (TLCL/MeOH/conc. aq. NH3 (10:4:1, 6:4:1 then 4:2:1) to yield 
the title compound 69 as a colourless oil (2.28 g, 15 % with respect to spermine). *H- 
NMR (CDCI3) 6  1.44 (9 H, s, 3 x CH3), 1.51-1.57 (4 H, m, 2 x CH2CH2CH2), 1.60-1.70
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(4 H, m, 2 x CH2CH2CH2), 1.78, (4 H, bs, 2 x NH, NIL), 2.58-2.68 (8  H, m, 2 x 
CH2NHCH2), 2.68-2.94 (2 H, m, CH2NH2), 3.09-3.21 (2 H, m, CH2NHCO), 5.13 (1H, 
bs, NHCO; 13C NMR 5 27.7, 28.3 (3 x CH3), 29.9, 33.7, 39.0, 40.4, 47.5, 47.7, 49.7,
48.8, 78.9 (C(CH3)3), 156.1 (C=0); FAB-MS m/z 303 (MH+), C i s H ^ N ^  requires 302.
A^Butoxycarbonyl-A^^^/V^tribenzyloxycarbonyOspermine 70
Benzyl chloroformate (2.7 mL, 18.8 mmol) was added dropwise (over 30 min) to a 
stirred solution of A'-f-butoxycarbonylspermine 69 (1.725 g, 5.70 mmol) in aq. NaOH 
solution (2 M, 11 mL) at 0 °C. The mixture was stirred for 18 h at 20 °C then CH2CI2 
(20 mL) was added and the mixture stirred for a further 1 h. The organic layer was 
collected and the aq. layer was washed with CH2CI2 (2 x 20 mL). The combined 
organic layers were dried (MgSC>4 ) and evaporated in vacuo to yield the title compound 
70 as a colourless oil (4.24 g, 94 %) which was used without further purification. 'H- 
NMR (CDCI3) 5 1.30-1.57 (13 H, m, 3 x CH3, 2 x CH2CH2CH2), 1.57-1.74 (4 H, m, 
CH2CH2CH2), 2.90-2.30 (12 H, m, 1 x CH2NHZ, 4 x CH2NZ, 1 x CH2NHB0 C), 5.07 ( 6  
H, s, 3 x CH2O), 5.60-5.80 (2H, m, 2 x NHC=0), 7.20-7.40 (15 H, m, 3 x Ph); FAB-MS 
m/z 705 (MH+) C39H52N4Og requires 704.
A/ V^2y/V3-tri(Benzyloxycarbonyl)spermine 71
A/-r-Butoxycarbonyl-A2,Ai,A4-(tribenzyloxycarbonyl)spermine 70 (4.00 g, 5.70 mmol) 
was stirred in trifluoroacetic acid (31 mL) and CH2CI2 (30 mL) at 0 °C for 45 min. The 
solvents were removed in vacuo, as an azeotrope with water and MeOH. The residue 
was purified by flash column chromatography eluting with CH2Cl2/MeOH/conc. aq. 
NH3 (200:10:1) to yield the title compound 71 as a colourless oil (3.38 g, 98 %). *H 
NMR 5 (CDCI3) 1.34-1.76 (10 H, m, 4 x CH2CH2CH2, NH2), 2.56-2.73 (2 H, m,
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CH2NH2), 3.00-3.40 (m, 10 H, 1 x CH^NHZ, 2 x CfHNZCHo), 5.10 ( 6  H, s, 3 x CT^O), 
5.60-5.80 (1 H, m, CH2NHZ), 7.30 (15 H, bs, 3 x Ph); 13C NMR 6  25.2, 31.6, 34.1, 44.0,
46.4, 46.7, 53.3, 66.4 (CH20), 66.3 (CH20), 67.1 (CH20 ), 127.8 (Ph), 127.9 (Ph), 128.4 
(Ph), 136.5 (Ph) 156.1 (C=0), 156.4 (C=0); FAB-MS m/z 605 (MH+), C34H44N4O6, 
requires 604.
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N 1 -(Anthracene-9-carbonyl)- N2, N3, A^-tri(benzyloxycarbonyl)spermine 74
9-Anthracene carboxylic acid 72 (0.10 g, 0.45 mmol), N 'JP JP - 
tri(benzyloxycarbonyl)spermine 71 (0.272 g, 0.45 mmol), DCC (0.139 g, 0.68 mmol), 
HOBt (3 mg, 0.05 equiv.) and CH2C12 (5 mL) were used in general procedure A for 
amide bond formation. The reaction mixture was stirred for 18 h and was purified by 
flash column chromatography on silica gel eluting with 2 % MeOH/CH2Cl2 to yield the 
title compound 74 as a colourless oil (0.276 g, 76 %). 'H NMR (CDCI3 ) 5 1.35-1.70 ( 6  
H, m, 3 x CH2CH2CH2), 1.72-2.04 (2 H, m, CH2CH2CH2), 2.92-3.73 (12 H, m, 1 x 
CH2NHZ, 2 x CU2 NZCH2 , 1 x CFhNHCOAr), 4.91 (2 H, s, Cf^O), 5.01- (4 H, m, 2 x 
CH2O), 7.31 (15 H, m , 3 x Ph), 7.49-7.61 (4 H , m ,C H 2, C H 3, C H 6, C H 7) ,  8.00-8.21 (4 
H, m, C 'H ,  C 4H ,  C 5H , CsH), 8.47-8.52 (1 H ,  m ,  C 10H ) ;  13C-NMR 5 24.8, 25.9, 28.9,
30.3,44.0,46. 6 ,49.1, 67.4 ( C H j O ) ,  68.35 (CTfcO), 124.8, 125.7, 126.6, 127.5, 128.2,
128.4, 131.2, 151.8 (C9), 169.7 (C=0); FAB-MS m/z 809 (MH+), C 49H 51N 4O 7  requires 
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N1 -(Anthracene-9-carbonyl) spermine 67
A solution of 7Vv-(anthracene-9-carbonyl)- N2, N3, A^-tri(benzyloxycarbonyl)spermine 74 
(0.260 g, 0.32 mmol) in MeOH (50 mL) and 10 % palladium on carbon (18 mg) were 
used in general procedure B for hydrogenolysis. The mixture was hydrogenated for 24 h 
and the product was purified by flash column chromatography on silica gel eluting with 
CTLCL/MeOH/conc. aq. NH3 (4:2:1) to yield the title compound 67 as a white, 
hygroscopic foam (0.122 g, 93 %). ‘H NMR (D2 0 ) 8  1.47 (4 H, bs, 2 x CH2CH2CH2),
I.58 (2 H, t, 7=7, CH2CH2CH2), 1.87, (2  H, t, 7=7, CH2CH2CH2), 2.53-2.61 ( 6  H, m, 3 x 
CH2NHCH2), 2.69 ( 2  H, t, 7=7, CH2CH2CH2), 3.20 ( 2  H, bs, CH2NH2), 3.57 ( 2  H, t,
7=7, CH2NHCOAr), 7.40-7.48 (4 H, m, C2H, C3H, C6H, C7H), 7.91 (2 H, d, 7=8, C4H, 
C5H), 7.98 (2 H, d, 7=8 C 'H, C8H), 8.49 (1 H, s, C I0H); l3C-NMR 8  24.6, 26.0, 29.8, 
30.3,43.8,46. 6 ,4 8 .6 , 124.7, 125.7, 126.6, 127.5, 128.2, 131.2, 151.8 (C9), 169.7 
(C=0); UV 7,max = 247 nm, e = 57000; FAB-MS m/z 407 (MH+), C25H35N40  requires 
406; FAB-HRMS calcd. 407.2811 (MH+), found 407.2808; Found C 65.0, H 7.94, N
II.7, requires C 73.86, H 8.43, N 13.78 %.
N1 -(Acridine-9-carbonyl)- N 2, N 3, A4-tri(benzyloxycarbonyl)spermine 75
9-Acridine carboxylic acid hydrate 73 (0.37 g, 1.6 6  mmol), N ^N 2^ 3- 
tri(benzyloxycarbonyl)spermine 71 (1.0 g, 1.66 mmol), DCC (0.680 g, 3.30 mmol), 
HOBt (11 mg, 0.05 equiv.) and DMF (10 mL) were used in general procedure A for 
amide bond formation. The reaction mixture was stirred for 48 h and was purified by 
flash column chromatography on silica gel eluting with 2  % M eO H /C ^C L  to yield the 
title compound 75 as a colourless oil (0.707 g, 53 %). 'H-NMR (CDC13) 8  1.33-1.70 ( 6  
H, m, 3 x CH2CH2CH2), 1.77-2.03 (2  H, m, CH2CH2CH2), 2.93-3.33 (8  H, m, 4 x 
CH2NZCH2 ), 3.40 (2 H, bs, CH2NHZ), 3.62 (2 H, bs, CHsNHCOAr), 4.83-5.14 ( 6  H,
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m, 3 x CH2O), 6.77 and 6.97 (2H, bd, NHCO), 7.32 (15 H, m, 3 x Ph), 7.53 (2 H, t, 7=8, 
C2H, C7H), 7.75 (2 H, t, 7=8, C3H, C6H), 7.80-7.94 (1 H, m, C 'H /C 8H), 8.01 (1 H, d, 
7=9, C 'H/C8® ,  8.19 (2 H, d, 7=9, C4H, C5H); l3C-NMR 5 24.8, 25.5, 33.8,44.0,46.5,
66.4 (CH20), 67.1 (CH20 ), 122.2 (C2, C7), 125.2, 126.7, 127.7 (Ph), 127.8 (Ph), 128.0 
(Ph), 128.4, 129.5 (C4, C5), 130.4 (C3, C6), 140. 2 (CIOa, C4a), 148.4 (C9), 167.0 (C=0); 
FAB-MS m/z 782 (MH+), C47H52N5O6 requires 781.
N1 -(Acridine-9-carbonyl)spermine 6 8
A solution of 7V;-(acridine-9-carbonyl)- N2, N3, iV4-tri(benzyloxycarbonyl)spermine 75 
(0.70 g, 0.87 mmol) in MeOH (50 mL) was added to 10 % palladium on carbon (20 mg) 
and used in general procedure B for hydrogenolysis. The mixture was hydrogenated for 
24 h and the product was purified by flash column chromatography on silica gel eluting 
with CH2Cl2/MeOH/conc. aq. NH3 (4:2:1) to yield the title compound 6 8  as a buff 
coloured hygroscopic foam (0.324 g, 91 %). ‘H NMR (D2 O) 8  1.29-1.99 (8  H, m, 4 x 
CH2CH2CH2), 2.33-2.54 ( 2  H, m, CH2NHCH2), 2.57-2.90 (8  H, m, 3 x Cf^NHCHz, 1 x 
CH2NH2), 3.00-3.17 (2 H, m, C ^N H C O A r), 6.61-6.74 (4 H, m, C2H, C3H, C6H, C7H), 
6.92-7.40 (4 H, m, C'H, C4H, C5H, CsH); i3C-NMR 8  28.2, 30.2, 32.9, 38.2,40.8, 115.7 
(C8a, C!a), 119.3 (C \ C8), 121.4 (C2, C7), 129.6 (C4, C5), 130.0 (C3, C6), 141.4 (C10a, 
C4a), 148.3 (C9), 176. 6  (C=0); UV Xmax = 250 nm, e = 57000; C24H33N5 0 , 407, FAB- 
MS m/z 408 (MH+).
9-Chloroacridine 96 (El-Sherief et al., 1983)
A suspension of 9-(10/7)-acridone 95 (3.0 g, 15.4 mmol) in thionyl chloride (18 mL) 
and DMF (4 drops) was warmed to dissolve all the solid and then the solution was 
heated under reflux for a further 30 min. The solution was evaporated in vacuo and the
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residue was suspended in CH2CI2. This slurry was slowly (5 min) poured into crushed 
ice/conc. aq. NH3 with vigorous swirling. The organic layer was separated and the aq. 
layer was washed with CH2CI2 (2 x 30 mL). The combined organic layer was dried 
(MgSCL) and then evaporated in vacuo to yield the title compound 96, a pale yellow 
solid, MP 119-120 °C (lit. 118-120 °C, Ning e ta l ,  1976) (3.145 g, 96 %). ‘H-NMR 
(CDCI3) 8  7.57 (2 H, t, 7= 5, C2H, C7H), 7.70 (2 H, t, 7=5, C3H, C6H), 8.19 (2 H, d,
7=9), 8.36 (2 H, d, 7=9) (C1, C8 and C4, Cf); ,3C-NMR 8  124.2, 124.5, 126.8, 129.7,
130.4, 148.8, EI-MS m/z 213 (M*) Ci3H8C135N requires 213 and 215 (M+) Ci3H8C137N 
requires 215.
9-Phenoxyacridine 97 (Dupre and Robinson, 1945)
NaOH (0.660 g, 16.5 mmol) was dissolved in phenol (14.41 g), stirred at 80 °C and then 
9-chloroacridine 96 (2.869 g, 13.4 mmol) was added in one portion. The mixture was 
stirred at this temperature for 1.5 h, then poured into aq. NaOH solution (2 M, 20 mL) 
and this mixture was stirred for 18 h. The title compound 97, a yellow precipitate (MP 
124-125 °C, lit. 127-128 °C, Dupre and Robinson, 1945), was filtered off and dried in 
vacuo over phosphorus pentoxide (3.490 g, 99 %). ‘H-NMR (CDCI3 ) 5 6.83 (2 H, d, 
7=8, C2 H, C6 H), 7.01 (1 H, t, 7=7, C4 H), 7.23 (2 H, t, 7=7, C3 H, C5'H), 7.41 (2 H, t, 
7=7, C2H, C7H), 7.74 (2 H, t, 7=8, C3H,C6H), 8.07 (2 H, d, 7=9, C ‘H, C8H), 8.27 (2 H, 
d, 7=9, C4H, CsH); ,3C-NMR 8  115.7 (C2', C6'), 122.8 (C4' or c\ C8), 122.9 (C1, C8 or 
C4'), 126.1 (C2, C7), 129.7 (C4, C5), 130.2 (C3', C5'), 130.8 (C3,C6); FAB-MS m/z 272 
(MH+) C 19H 13NO requires 271.
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A^/-(Acridin-9-yl)-N2, N3, A^-tri(benzyIoxycarbonyl)spermine 99
A mixture of 9-phenoxyacridine 97 (0.9 g; 3.32 mmol) and N^N2^ 3- 
tri(benzyloxycarbonyl)spermine 71 (2.0 g, 3.32 mmol) were mixed with phenol at 80 °C 
and then stirred at this temperature for 18 h. The reaction mixture was poured into 
CH2CI2 (25 mL) and was washed with aq. NaOH (2 M, 3 x 20 mL). The combined aq. 
washes were extracted with CH2CI2 (3 x 2 0  mL) and the combined organic layers were 
dried (MgS0 4 ) and then evaporated in vacuo. The residue was purified by flash column 
chromatography eluting with CTHCh/MeOH/conc. aq. NH3 (200:10:1) to yield the title 
compound 99 as a yellow oil (1.173 g, 44 %) 'H-NMR (CDC13) 5 1.40-1.75 ( 6  H, m, 3 
x CH2CH2CH2), 1.84-2.07 (2  H, m, CH2CH2CH2), 3.05-3.32 (8  H, m, 4 x CH2NZCH2), 
3.43 (2 H, bs, CH2NHZ), 3.72 (2 H, bs, O ^N H A r), 5.08 (4 H, s, 2 x CH2O), 5.21 (2 H, 
s, CH2O), 5.69 (1 H, bs, NHCO), 7.13-7.42 (17 H, m, 3 x Ph, CH2, CH7), 7.64 (2 H, t, 
7=5, CH3, CH6), 8.06 ( 2  H, d, 7=6, CH4, CH5), 8.23 (2 H, d, 7=6, CH 1, CH8); 13C-NMR 
8  25.0,25.6, 27.9,28.7, 29.2, 37.5, 38.1,44.0,46.2,46.4,46.7, 66.4 (CH20), 67.1 
(CH20 ), 67.3 (CH20), 116.9 (C4a, C9a), 122.8, 123.1 (C1, C8 and C2, C7), 127.8 (Ph),
127.9 (Ph), 128.5 (Ph), 129.1, 129.8 (C3, C6 and C4,C5), 136.4 (Ph), 149.1 (C4a, C IOa),
151.9 (C9), 155.9 (C=0), 156.4 (C=0), 157.1 (C=0); FAB-MS m/z 782 (MH+) 
C47H51N5O6 requires 781.
A/-(Acridin-9-yl)spermine 89
A solution of A^;-(acridin-9-yl)-A2, N3, A4-tri(benzyloxycarbonyl)spermine 99 (0.50 g, 
0.64 mmol) in MeOH (50 mL) and 10 % palladium on carbon (20 mg) were used in 
general procedure B for hydrogenolysis. The mixture was hydrogenated for 24 h and the 
product was purified by flash column chromatography on neutral alumina (grade 4) 
eluting with MeOH/CHiCh (20 %, 50 %, 100 %) to yield the title compound 89 as a
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yellow hygroscopic foam (0.214 g, 8 8  %). 'H-NMR (D2O) 8  1.23-1.72 (8  H, m, 4 x 
CH2CH2CH2), 1.90 (2 H, m, CH2NHCH2), 2.38-2.79 (8  H, m, 3 x CH2NHCH2, 1 x 
CH2NH2), 3.15 (2 H, m, CH2NHAcr), 7.28 (2 H, m, CH2, CH7), 7.63 (2 H, m, CH3, 
CH6), 7.80 (2 H, m, CH4, CH5), 8.29 (2 H, m, CH 1, CH8); l3C-NMR 8  25.5, 26.4, 28.6, 
39.3,47.2 ,47.5 ,48.2 ,49.4 ,49.7 ,49.8 , 113.9, 120.6, 126.8, 137.9, 141.0 (C4a, C 10a),
158.9 (C9); FAB-MS m/z 380 (MH+), C23H33N5 requires 379.
5-(£-Butoxycarbonylamino)pentanoic acid 78
A solution of Boc-anhydride (0.82 g, 3.76 mmol) in THF (7 mL) was added in a 
dropwise fashion over 10 min to a stirred suspension of 5-aminopentanoic acid 77 (0.40 
g, 3.41 mmol) in THF (9 mL) at 0 °C. The mixture was stirred at this temperature for 1 
h and then for a further 48 h at 20 °C (with TLC monitoring). The residue was taken up 
in CH2C12 and was washed with water (2 x 30 mL) and saturated aq. NH4 CI (2 x 20 
mL). The organic layer was dried (MgSC>4 ) and then concentrated in vacuo. The 
residue was purified by flash column chromatography eluting with CH2Cl2/MeOH/aq. 
NH3 (15:5:1) to yield the title compound 78, a colourless oil (0.602 g, 82 %). 'H-NMR 
(CDCI3) 8  1.35-1.71 (13 H, m, 3 x CH3, C3H2, C F b), 2.23 (2 H, t, 7=7, C2H2), 3.07 (2 
H, t, 7=6, C5H2), 5.28 (1 H, bs, NH); ,3C-NMR 22.6 (C3), 28.3 (3 x CH3), 29.5 (C4),
35.4 (C2), 40.2 (C5), 79.0 ( C ( C H 3)3) ,  156.3 ( C O N ) ,  179.1 ( C O O H ) ;  FAB-MS m/z 218 
(MH+), C 1 0 H 1 9 N O 4 , requires 217.
A-jS-ir-Iiutoxycarbonylaminopentanoyll-.V3, .V, .V'-trilbenzyloxycarbonyl)-
spermine 79
5-(r-Butoxycarbonylamino)pentanoic acid 78 (0.21 g, 0.97 mmol), N^N2^ 3- 
tri(benzyloxycarbonyl)spermine 71 (0.585 g, 0.97 mmol), DCC (0.296 g, 1.43 mmol),
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HOBt ( 6  mg) and CH2CI2 (5 mL) were used in general procedure A for amide bond 
formation. The reaction mixture was stirred for 48 h and was purified by flash column 
chromatography eluting with CTLCL/MeOH/aq. NH3 (200:10:1) to yield, a colourless 
oil 79 (0.30 g, 38 %). 'H-NMR (CDCI3) 5 1.42-1.89 ( 1 2  H, m, 6  x CH2CH2CH2), 1.53 
(9 H, s, 3 x CH3), 3.12-3.47 (16 H, m, 7 x CH2N, CH2C=0), 4.91 (1H, bs, NHCO), 5.22 
( 6  H, s, 3 x CH2O), 5.80 (1 H, bs, NHCO), 6.77 (1 H, bs, NHCO), 7.33-7.57 (15 H, m, 
Ph); 13C-NMR 5 22.7, 25.2, 27.3, 28.2, 29.1, 33.6, 35.5, 37.1, 39.3, 44.1, 46.4, 53.0, 65.5 
(CH20 ), 6 6 .8  (CH20), 127.8 (Ph), 127.9 (Ph), 128.4 (Ph), 128.4 (Ph), 136.5 (Ph), 155.9 
(C=0), 156.4 (C=0), 156.6 (C=0), 172.7 (C=ON); FAB-MS m/z 804 (MH+), 
C44H61N5O9, requires 803.
A/-[5-Aminopentanoyl]-./V2, N \  AMri(benzyloxycarbonyl) spermine 80
A^y-[5-(r-butoxycarbonylaminopentanoyl]-7/2, N3, 7V*-tri(benzyloxycarbonyl)spermine 79 
(0.30 g, 0.37 mmol) was stirred in trifluoroacetic acid (2 mL) and CH2CI2 (2  mL) at 0  
°C for 45 min. The solvents were removed in vacuo, as an azeotrope with water and 
MeOH. The residue was purified by flash column chromatography eluting with 
CH2Cl2/MeOH/conc. aq. NH3 (100:10:1) to yield the title compound 80 as a colourless 
oil (0.230 g, 8 8  %). 'H-NMR (CDCI3) 5 1.34-1.78 (12 H, m, 6  x CH2CH2CH2), 2.24 (2 
H, bs, CH2NH2), 2.95 (2 H, bs, CH2C=0 ), 3.00-3.32 (12 H, m, 2 x CH2NZCH2, 2 x 
CH2NHC=0 ), 5.09 ( 6  H, s, CH2O), 7.23-7.34 (15 H, m, 3x Ph); l3C-NMR 5 22.65, 24.7,
25.6, 27.0, 27.7, 28.4, 28.8, 32.0, 35.7, 36.1, 37.3, 41.2,43.9, 46.2, 65.9 (CH20 ) , 6 6 .8  
(CH20), 126.7 (Ph), 127.4 (Ph), 136.2 (Ph), 155.9 (C=0), 156.4 (C=0), 157.1 (C=0),
172.9 (C=0); FAB-MS m/z 704 (MH+) C39H53N5O7 requires 703.
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A^ /-(5-(Acridin-9-ylcarbonyl amino)pentanoyl)-A2, N \  AMri(benzyloxycarbonyl)- 
spermine 81
9-Acridine carboxylic acid hydrate 73 (0.145 g, 0.65 mmol), N'-[5- 
aminopentanoylamido]-./V2, N3, Af*-tri(benzyloxycarbonyl)spermine 80 (0.456 g, 0.65 
mmol), DCC (0.20 g,0.97 mmol), HOBt (4 mg, 0.05 equiv.) and DMF (5 mL) were used 
in general procedure A for amide bond formation. The reaction mixture was stirred for 
48 h and was purified by flash column chromatography on silica gel eluting with 2 % 
MeOH/CH2Cl2 to yield the title compound 81 as a pale yellow oil (0.180 g, 31 %). 'H- 
NMR (CDC13) 5 1.29-1.75 (12 H, m, 6  x CH2CH2CH2), 2.98-3.35, (14 H, m, 7 x 
CH2N), 3.65 (2 H, m, CH2C=0 ), 4.95 ( 6  H, m, 3 x CH2O), 7.28 (15 H, m, 3 x Ph), 7.50 
(2 H, t, 7=7, CH2, CH7), 7.73 (2 H, t, 7=7, CH3, CH6), 7.96 (2 H, d, 7=9, CH4, CH5),
8.17 (2 H, d. 7=9, CH1, CH8); l3C-NMR 8  22.3, 25.5, 30.9, 33.7, 35.5,44.0,46.0,46.5,
50.0, 66.3 (CH20 ), 67.4 (CH20 ), 116.4, 122.8, 127.6 (Ph), 127.8 (Ph), 128.5, 136. 5,
148.8 (C9), 156.0 (C=0), 156.5 (C=0), 172.9 (C=ON); FAB-MS m/z 909 (MH+), 
C53H60N6O8 requires 908.
A/-(5-(Acridin-9-ylcarbonylamino)pentanoyl)spermine 76
A solution of A/-(5-(acridin-9-ylcarbonylamino)pentanoyl)-7/2, N3, N4- 
tri(benzyloxycarbonyl)spermine 81 (150 mg, 0.17 mmol) in MeOH (20 mL) was added 
to 10 % palladium on carbon (20 mg) and used in general procedure B for 
hydrogenolysis. The mixture was hydrogenated for 24 h and the product was purified 
by flash column chromatography on neutral alumina (grade 4) eluting with 20 % 
MeOH/CH2Cl2 to yield the title compound 76 as a buff coloured hygroscopic foam 
(0.067 g, 80 %). 'H-NMR (CDC13) 5 1.22-1.69 (12 H, m, 6  x CH2CH2CH2), 2.75-3.02 
(14 H, m, 7 x CH2N), 3.63 (2 H, m, CH2C=0), 6.97 (2 H, t, 7=7, CH2, CH7), 7.10 (2 H,
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t, /=  7, CH3, CH6), 7.58 (2 H, d, 7=9, CH4, CH5), 7.71 (2 H, d. 7=9, CH1, CH8); FAB- 
MS m/z 505 (MH+) C29H42N6O2 requires 506.
A/-(5-(Acridin-9-ylamino)pentanoyl)-A2, iV3,AM ri(benzyloxycarbonyl)sperinine 100
A mixture of 9-phenoxyacridine 97 (0.089 g, 0.33 mmol) and Ay-[5- 
aminopentanoylamido]-^2, N3, A^-tri(benzyloxycarbonyl)spermine 80 (0.23 g, 0.33 
mmol) were mixed with phenol at 80 °C and then stirred at this temperature for 18 h.
The reaction mixture was poured into CH2C12 and was washed with aq. NaOH (2 M, 3 x 
20 mL). The combined aq. washes were extracted with CH2CI2 (3 x20 mL) and the 
combined organic layers were dried (MgS0 4 ) and then evaporated in vacuo. The 
residue was purified by flash column chromatography eluting with C ^C b/M eO H /conc. 
aq. NH3 (200:10:1) to yield the title compound 100 as a yellow oil (0.144 g, 49 %). !H- 
NMR (CDCI3 ) 5 1.40 (4 H, bs, CH2CH2CH2), 1.60 ( 6  H, bs CH2CH2CH2), 1.78 (2 H, 
bs, CH2CH2CH2), 3.00-3.33 (14 H, m, 7 x CH2N), 3.78 (2 H, bs, CH2C=0 ), 5.03 ( 6  H, 
s, 3 x CHjO), 6.01 (1 H, bs, NHCO), 6.90 )1 H, bs, NHCO), 7.11-7.32, (17 H, m, C2H, 
C7H, 3 x Ph), 7.56 (2 H, t, 7=7, C3H, C6H), 7.97 (2 H, d, 7=9, C4H, C5H), 8.14 (2 H, d, 
7=9, C 'H , CSH); l3C-NMR 5 22.0, 22.2, 22.7, 24.9, 25.5, 27.4, 27.9, 28.7, 29.5, 30.2,
32.7, 35.4, 35.6, 36.2, 37.5, 38.0, 41.4,43.9, 46.2, 46.6, 49.7, 66.3 (CH20), 67.0 
(CH20), 115.4, 116.9, 120.8, 120.9, 122.7, 123.3, 126.5, 127.6 (Ph), 127.8 (Ph), 128.2 
(Ph), 128.3 (Ph), 130.6, 132.9, 136.3, 149.8, 152.7 (C9), 155.9 (C=0), 156.4 (C=0), 
156.7 (C=0), 172.7 (NC=0); FAB-MS m/z 881 (MH+), C 52H61N60 7  requires 880; FAB- 
HRMS calcd. 881.4602 (MH+), found 881.4601.
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A^ /-(5-(Acridin-9-yl-amino)pentanoyl)spermine 90
A solution of A^-(5-(acridin-9-ylamino)pentanoyl)-./V2, N \N 4-
tri(benzyloxycarbonyl)spermine 100 (120 mg, 0.14 mmol) in MeOH (20 mL) was added 
to 1 0  % palladium on carbon ( 2 0  mg) and used in the general method for 
hydrogenolysis. The mixture was hydrogenated for 24 h and the product was purified 
by flash column chromatography on neutral alumina (grade 4) eluting with 20 % 
MeOH/CHiC^ to yield the title compound 90 as a hygroscopic yellow foam (53 mg, 79 
%). 'H-NMR (D20 ) 5 1.63-2.09 (12 H, m, 6  x CH2CH2CH2), 2.42-2.51 (2 H, m, 
CH2NH2), 2.88-3.20 ( 1 2  H, m, 3 x CH2NHCH2), 4.08-4.12 (2 H, m, CH2C=0 ), 7.48- 
7.51 (2 H, m, CH2, CH7), 7.67-7.75 (2 H, m, CH3, CH6), 7.88-7.93 (2 H, m, CH4, CH5), 
8.29-8.35 (2 H, m, CH1, CH8); ,3C-NMR 5 25.0, 27.9, 29.2, 29.3, 32.1, 34.8, 40.2,42.4, 
118.1, 119.1, 126.3, 126.4, 127.4, 127.5, 128.2, 129.9, 131.7, 134.4, 141.5, 147.8,
173.1; FAB-MS m/z 479 (MH+) C28H42N6O requires 478; Found C 46.2, H 5.38, N 
8.72, requires C 45.66, H 4.82, N 9.13 %.
Methyl 5-aminopentanoate, HC1 salt 101 (Kukla et a l ,  1990)
Cone. aq. H2SO4 (50 mL, 96 %) was dropped onto solid NaCl (50 g) and the resulting 
HC1 gas was bubbled through MeOH (60 mL) until gas production ceased. 5- 
Aminopentanoic acid 77 (6.50 g, 55.5 mmol) was added to the acidic MeOH and the 
solution was heated under reflux for 3 h. The reaction mixture was evaporated in vacuo 
and the residue was recrystallised (MeOH) to yield the title compound 101 as a white 
solid MP 140-141 °C (Lit. 145-146 °C, Oelofsen and Li, 1968) (8.42 g, 91 %). 'H-NMR 
(CDCI3) 6  1.67-1.90 (4 H, m, CH2CH2CH2CH2), 2.20 ( 2  H, t, J=l, CH2NH3+), 3.06 (2  
H, bs, CH2C=0 ), 3.68 (s, 3 H, CH3).
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Methyl 5-(5-(f-butoxycarbonylamino)pentanoylamino)pentanoate 102
5-(r-Butoxycarbonylamino)pentanoic acid 78 (0.30 g, 1.38 mmol), methyl 5- 
aminopentanoate 101 (0.181 g, 1.38 mmol), DCC (0.433 g, 2.10 mmol), HOBt (9 mg, 
0.05 equiv.) and CH2CI2 (5 mL) were used in general procedure A for amide bond 
formation. The reaction mixture was stirred for 48 h and was purified by flash column 
chromatography on silica gel eluting with 2  % MeOH/CTLCL to yield the title 
compound 102 as a colourless oil (0.206 g, 45 %). 'H-NMR (CDCI3 ) 5 1.38-1.55 (17 H, 
m, 3 x CH3, 4 x CH2CH2CH2), 2.25-2.34 (2  H, m), 3.05-3.35 ( 6  H, m), 4.10 (3 H, s, 
COCH3); 13C-NMR 5 ; FAB-MS m/z 331 (MH+), C16H3oN2C>5 requires 330.
5-(5-(f-Butoxycarbonylamino)pentanoyIamino)pentanoic acid 103
Methyl 5-(5-(r-butoxycarbonylamino)pentanoylamino)pentanoate 102 (0.2 g, 0.61 
mmol) was stirred in dioxane (5 mL) and aq. potassium hydroxide solution (2 M, 5 mL) 
for 2 h. The reaction mixture was neutralised (aq. 2 M HC1) and dioxane removed in 
vacuo. The remaining aq. suspension was extracted with CH2CI2 (3 x 20 mL) and the 
combined organic layers were dried (MgSC>4 ) and evaporated in vacuo. The residue was 
purified by flash column chromatography eluting with C^CL/M eO H /conc. aq. NH3 
(200:10:1) to yield the title compound 103 as a colourless oil (0.174 g, 90 %). 'H-NMR 
(CDCI3) 5 1.35-1.50 (17 H, m, 3 x CH3, 4 x CH2CH2CH2), 2.21 ( 2  H, m), 3.01-3.41 ( 6  
H, m, 2 x CH2N, CH2CO); FAB-MS m/z 317 (MH+), C 15H28N2O5 requires 316.
A/-5-(5-(^-Butoxycarbonylamino)pentanoylamino)pentanoyl-A2, N 3, N 4- 
tri(benzyloxycarbonyI)spermine 104
5-(5-(r-Butoxycarbonylamino)pentanoylamino)pentanoic acid 103 (0.30 g, 0.95 mmol), 
A^A^A^-trKbenzyloxycarbonyOspermine 71 (0.574 g, 0.95 mmol), DCC (0.293 g, 1.42
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mmol), HOBt (9 mg, 0.05 equiv.) and CH2CI2 (15 mL) were used in general procedure 
A for amide bond formation. The reaction mixture was stirred for 48 h and was purified 
by flash column chromatography on silica gel eluting with 2  % MeOH/CTLCL to yield 
the title compound 104 as a colourless oil (0.311 g, 36 %). ‘H-NMR (CDCI3) 5 1.33- 
1.90 (27 H, m ,), 3.06-3.51 (18 H, m), 5.26 (6  H, s, 3 x OCH2), 7.35-7.41 (15 H, m, 3 x 
Ph); 13C-NMR 5 22.65, 25.2, 27.3, 28.0 (3 x CH3), 34.0, 35.4, 37.0, 39. 6 , 44.1, 46.4,
52.9, 65.4 (OCH2), 6 6 .8  (OCH2), 78.8 (C(CH3)3), 127.6 (Ph), 127.6 (Ph), 128.3 (Ph),
128.4 (Ph), 136.4 (Ph), 156.2 (C=0), 172.7 (C=0), 173.0 (C=0); FAB-MS m/z 903 
(MH+), C49H70N6O 10 requires 902.
A/-5-(5-Aminopentanoylamino)pentanoyl-A2, N \  AMri(benzyloxycarbonyl)- 
spermine 105
A/-5-(5-(r-Butoxycarbonylamino)pentanoylamino)pentanoyl-A^2, N3, N4- 
tri(benzyloxycarbonyl)spermine 104 (0.30 g, 0.33 mmol) was stirred in trifluoroacetic 
acid ( 2  mL) and CH2CI2 ( 2  mL) at 0 °C for 45 min. The solvents were removed in 
vacuo, as an azeotrope with water and MeOH. The residue was purified by flash 
column chromatography eluting with CTLCL/MeOH/conc. aq. NH3 (200:10:1) to yield 
the title compound 105 as a colourless oil (0.263 g, 99 %). ‘H-NMR (CDCI3) 5 1.29- 
1.72 (16 H, m, 8  x CH2CH2CH2), 2.54 ( 2  H, m, CH2NH2), 2.65-2.68 (4 H, m, 2  x 
CH2C=0 ), 3.04-3.36 (14 H, m, 2 x CH2NZCH2, 2 x CH2NHC=0 , CH2NZ), 5.20 ( 6  H, 
s), 7.30 (15 H, m); ,3C-NMR 8  22.5, 24.6, 25.7, 27.1, 27.7, 28.3, 29.9, 23. 6 , 35.7, 36.6,
37.3.42.18.43.9, 44.0,46.2, 65.9, 67.1, 112.8, 113.0, 139.3, 156. 9, 157.0, 157.2, 172. 
9, 173.0;FAB-MS m/z 803 (MH+), C44H62N6O8 requires 802.
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Ar/-5-(5-(Acridin-9-ylamino)pentanoylamino)pentanoyl-N2, N 3, N4- 
tri(benzy loxy carbony l)spermine 106
A/-5-(5-Aminopentanoylamino)pentanoyl-./V2, N3, A'-trKbenzyloxycarbonyOspermine 
105 (0.25 g, 0.31 mmol) and 9-phenoxyacridine 97 (0.084 g; 0.31 mmol) were mixed 
with phenol (1.0 g) at 80 °C and were stirred for 18 h. The reaction mixture was poured 
into CH2C12 and was washed with aq. NaOH (2 M, 3 x 20 mL). The combined aq. 
washes were extracted with CH2CI2 and the combined organic layers were dried 
(MgS0 4 ) and then evaporated in vacuo. The residue was purified by flash column 
chromatography eluting with CT^C^/MeOH/conc. aq. NH3 (200:10:1) to yield the title 
compound 106 as a yellow oil (0.127 g, 45 %). 'H-NMR (CDCI3) 8  1.39-1.80 (16 H, m, 
8 x CH2CH2CH2), 2.98-3.39, (16 H, m, 8  x CH2N), 3.80 (4 H, m, 2 x CH2C=0 ), 5.10 ( 6  
H, s, 3 x CH2O), 7.30 (17 H, m), 7.54 (2 H, t, 7=7), 7.95 (2 H, d, 7=9), 8.14 (2 H, d, 
7=9); FAB-MS m/z 980, C57H69N7O8 requires 979.
Ar/-5-(5-(Acridin-9-ylamino)pentanoyIamino)pentanoylspermine 91
A solution of A7-5-(5-(acridine-9-ylamino)pentanoylamino)pentanoyl-A^, N3, N4~ 
tri(benzyloxycarbonyl)spermine 106 (0.10 g, 0.10 mmol) in MeOH (20 mL) was added 
to 10 % palladium on carbon (20 mg) and used in general procedure B for 
hydrogenolysis. The mixture was hydrogenated for 24 h and the product was purified 
by flash column chromatography on neutral alumina (grade 4) eluting with 
MeOH/GHLCL (20%, 50%, 100%) to yield the title compound 91 as a yellow 
hygroscopic foam (0.048 g, 81 %). 'H-NMR (CDCI3) 5 1.35-1.78 (16 H, m), 2.75-3.05 
(16 H, m), 3.89 (4 H, m), 7.39 (2 H, m), 7.62 (2 H, m), 7.83 (2 H, m) 8.19, (2 H, m); 
l3C-NMR 6  24.9, 27.9, 27.9, 29.2, 29.3, 29.4, 32. 6 , 35.7, 42. 6 , 42.6, 116.7, 120.5,
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122.6, 130.6, 131.1, 142.5, 148.1, 172.7, 172.8; FAB-MS m/z 578 (MH+), C33H5 ,N70 2
requires 577.
Methyl 4-aminobenzoate 111 (Hosangadi and Dave, 1996)
Thionyl chloride (1.3 mL, 17.8 mmol) was added in a dropwise fashion (15 min) to 
MeOH (32.5 mL) being stirred at 0 °C. 4-Aminobenzoic acid 109 (0.50 g, 3.56 mmol) 
was added to the solution and the mixture was stirred for 18 h at 20 °C. The reaction 
mixture was neutralised with aq. NaOH (1 M) and the MeOH was removed in vacuo. 
The remaining aq. suspension was extracted with CH2CI2 (3 x 30 mL) and the combined 
organic extracts were dried (Na2 S0 4 ) and evaporated in vacuo. The residue was 
recrystallised (MeOH) to yield the title compound 111 as a white solid (0.447 g, 82 %). 
MP 108-109 °C (Lit. 108-110 °C, Carr, 1972); !H-NMR (CDCI3 ) 8  3.86 (3 H, s, OCH3),
4.15 (2 H, bs, NH2) 6.63 (2 H, d, 7=5, C3H, C5H), 7.83 (2 H, d, 7=5, C2H, C6H); 13c- 
NMR 8  51.8 (OCH3), 113.6 (C3,C 5), 119.1 (C1), 131.6 (C2, C6), 150.1 (C4), 167.3 
(C=0); EI-MS m/z 151 (M+), C8H9N 0 2 requires 151.
Methyl 4-(acridin-9-ylamino)benzoate 113
9-Chloroacridine 96 (0.555 g, 2.60 mmol) and methyl 4-aminobenzoate 111 (0.393 g,
2.60 mmol) were stirred in anhydrous MeOH (10 mL) until all the solid had dissolved. 
Methanesulfonic acid (0.3 mL) was added and the reaction mixture was stirred for 18 h. 
The mixture was neutralised with aq. NaOH solution (2 M) and was evaporated in 
vacuo. The residue was partitioned between CH2CI2 and water and the aq. layer was 
washed with CH2CI2 ( 2  x 40 mL). The combined organic layers were dried (Na2 S0 4 ) 
and then evaporated in vacuo. The residue was purified by flash column
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chromatography eluting with 5 % ethyl acetate-hexane to yield the title compound 113 
as an orange solid (0.769 g, 85 %). MP 169-170 °C; 1 H-NMR (CDCI3) 8  3.87 (3 H, s, 
OCH3), 6.80 (2 H, t, 7=9, CH3', CH5 ), 7.15-7.28 (2 H, m, CH2, CH7), 7.59 (2 H, t, 7=7, 
CH3, CH6), 7.82 (2 H, bs, CH2', CH6'), 7.93 (2H, d, 7=9, CH4, CH5), 7.98 (2H, d, 7=9, 
CH1, CH8); 13C-NM R851.8 (OCH3), 116.1, 120.1, 122.1, 123.8, 125.3, 130.8, 131.5,
167.1 (C=0); FAB-MS mJz. 329 (MH+) C2 iH16N20 2 requires 328.
4-(Acridin-9-ylamino)benzoic acid 115
Methyl 4-(acridin-9-ylamino)benzoate 113 (0.70 g, 2.13 mmol) was stirred in dioxane 
(20 mL) and aq. KOH solution (2 M, 20 mL) for 6  h. The reaction mixture was 
neutralised (aq. 2 M HC1) and dioxane removed in vacuo. The remaining aq. 
suspension was filtered and the filter cake was purified by flash column chromatography 
eluting with 10 % ethyl acetate-hexane to yield the title compound 115 as an orange 
solid (0.570 g, 85 %). MP 285-287 °C; 1 H-NMR (CD3 OD) 5 7.03 (2H, d, 7=9, CH3', 
CH5'), 7.16 (2 H, t, 7=7, CH2, CH7), 7.63-7.70 (4 H, m, CH2', CH6', CH3, CH6), 7.91 (2 
H, d, 7=9, CH4, CH5), 7.98 (2 H, d, 7=9, CH1, CH8); 13C-NMR 8 117.2, 119.4, 119. 7,
122.4, 124.7, 126.5, 131.3, 132.9, 141.5, 151.2, 167.2 (C=0); C20H 14N2O2 FAB-MS m/z 
315 (MH+) C20H 14N2O2 requires 314.
N1 -[4 -(Acridin-9-yIamino)benzoyl]-iV2 ,iV3 ,A^-tri(benzyIoxycarbonyl) spermine 117
4 -(Acridin-9-ylamino)benzoic acid 115 (0.325 g, 1.03 mmol), N ^N 2^ 3- 
tri(benzyloxycarbonyl)spermine 71 (0.625 g, 1.03 mmol), DCC (0.320 g, 1.55 mmol) 
and HOBt (7 mg) were combined in THF (7 mL) according to general procedure A for 
amide bond formation. After stirring for 48 h the mixture was filtered and the filtrate
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was evaporated in vacuo. The residue was purified by flash column chromatography 
eluting with 10 % MeOH-CH2Cl2 to yield an orange oil 117 (0.282 g, 31 %). 1 H-NMR 
(CDC13) 5 1.35-1.85 (8  H, m, 4 x CH2CH2CH2), 2.98-3.40 (12 H, m, 6  x CILN), 5.10 ( 6
H, s, 3 x CH20 ), 7.19 (2 H. t, 7=7, CH2, CH7), 7.22-7.49 (17 H, m), 7.61 (2 H, t, 7=7, 
CH3, CH6), (7.95, 6  H, m): 13C-NMR 8 25.6, 27.9, 32.2, 33.8,43.8,46.1, 66.0, 67.4,
116.7, 121.0, 124.2, 125.20,125.6, 127.4, 128.3, 133.8, 136.5, 141.1,152.1,156.2, 
157.1; FAB-MS m/z 901 (MH+), C54H56N6O7 requires 900.
1VC[ 4  -(Acridin-9-ylamino)benzoyI]spermine 107
A solution of A,A[4-(acridm-9-ylamino)benzoyl]-iV3 ,jV3 ,Af‘,-tri(benzyloxycarbonyl) 
spermine 117 (0.50 g, 0.55 mmol) in MeOH (50 mL) and 10 % palladium on carbon (20 
mg) were used in general procedure B for hydrogenolysis. The mixture was 
hydrogenated for 24 h and the product was purified by flash column chromatography on 
neutral alumina (grade 4) eluting with MeOH-CTLCh (2 0 %, 50%, 1 0 0 %) to yield the 
title compound 107 as an orange hygroscopic foam (0.172 g, 61 %). lH-NMR (D2 O) 6
I.25-2.01 (8  H, m, 4 x CH;CH2CH2), 2.35 (2 H, m, CH2NH2), 2.51-2.85 (8  H, m, 2 x 
CH2NHCH2), 3.15 (2 H, m. ClfcCONAr), 7.21 (2 H, t, 7=7, C2H, C7H), 7.34 (2 H, d, 
7=8), 7.42 (2 H, d, 7=8), 7.55 (2 H, t, 7=7), 7.89-7.94 (4 H, m); 13C-NMR 8  28.5,29.1, 
30.2, 23.9, 38.2,41.1,42.7,116.8, 119.3, 120.1, 122.3, 125.4, 137.0, 132.5, 133.8,
139.8, 141.1, 122.3, 157.2 (C=0); FAB-MS m/z 499 (MH+), C3oH38N60  requires 498.
Methyl 4-amino-3-methoxybenzoate 112
Thionyl chloride (0.8 mL, 11.0 mmol) was added in a dropwise fashion (15 min) to 
MeOH (20 mL) stirred at 0 °C. 4-Amino-3-methoxybenzoic acid 110 (0.40 g, 0.60
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mmol) was added to the solution and the mixture was stirred for 18 h at 25 *C. The 
reaction mixture was neutralised with aq. NaOH solution (1 M) and MeOH was 
removed in vacuo. The remaining aq. suspension was extracted with CH2CI2 (3 x 20 
mL) and the combined organic extracts were dried (Na2 SC>4 ) and evaporated in vacuo. 
The residue was recrystallised (MeOH) to yield the title compound 112 (0.337 g, 78 %) 
as a white solid, MP 125-127 °C (Lit. 127-128 °C, Rizzacasa and Sargent, 1988). *H 
NMR (CDCI3 ) 5 3.85 (3 H, s, CH3), 3.88, (3 H, s, CH3), 4.28 (2 H, s, NFL), 6.65 (1 H,
d, 7=8, C5H), 7.45 (1 H, s, C2H), 7.54 (1 H, d, 7=8, C6H); 13C-NMR 6  51.7 (OCH3, 55.4 
(OCH3), 111.0, 113.0 (C3 and C6), 119.3 (C2), 124.0 (C1), 141.1 (C4), 146.0 (C5), 167.3 
(0 = 0 ); FAB-MS m/z 182 (MH+), C9H ,iN 03 requires 181.
M ethyl 4-(acridin-9-ylamino)-3-methoxybenzoate 114
9-Chloroacridine 96 (0.396 g, 1.85 mmol) and methyl 4-amino-3-methoxybenzoate 112 
(0.337 g, 1.85 mmol) were stirred in anhydrous MeOH (40 mL) until all the solid had 
dissolved. Methane sulfonic acid (0.2 mL) was added and the reaction mixture was 
stirred for 18 h. The mixture was neutralised (aq. 2 M NaOH) and was evaporated in 
vacuo. The residue was partitioned between CH2CI2 and water and the aq. layer was 
washed with CH2CI2 (2 x 40 mL). The combined organic layers were dried over sodium 
sulphate and evaporated in vacuo. The residue was purified by flash column 
chromatography eluting with 5 % ethyl acetate-hexane to yield an orange solid 114 
(0.630 g, 95 %). ‘H-NMR (CDCI3) 5 3.93 (3 H, s, OCH3), 3.98 (3 H, s, OCH3), 
6.31(1H, d, 7=8, CyH), 7.23, (1H, bs, C6'H), 7.44 (2H, bs, C*H, CH8), 7.64 (1H, s,
C2 H), 7.74 (2H, bs, C3H, C6H), 8.03 (2 H, d, 7=9, C4H, C5H), 8.20 (2H, bs, C2H, C7H ): 
l3C-NMR 8 51.8 (OCH3), 55.9 (OCH3), 110.9 (C2), 112.4(C5'), 121.1, 121.9, 123.6 (C1.
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C8), 123.7 (C4,C 5), 125.2, 130.3 ( C \C 6), 146.41, 166.9 (C=0); FAB-MS m/z 359
(MH+), C22H 18N2O3 requires 358.
4-(Acridin-9-yIamino)-3-methoxybenzoic acid 116
Methyl 4-(acridin-9-ylamino)-3-methoxybenzoate 114 (0.63 g, 1.76 mmol) was stirred 
in dioxane (20 mL) and aq. KOH solution (2 M, 20 mL) for 6  h. The reaction mixture 
was neutralised (aq. 2 M HC1) and dioxane removed in vacuo. The remaining aq. 
suspension was filtered and the filter cake was purified by flash column chromatography 
eluting with 10 % ethyl acetate-hexane to yield the title compound 116 (0.570 g, 85 %), 
an orange solid. 1H-NMR ((CD3)2 SO) 8  4.03 (3 H, s, OCH3), 6.50 (1 H, d, 7= 8 , CH5’),
7.18-7.33 (2 H, m), 7.44 (1 H, d, 7=8, CH6'), 7.76-7.83 (7 H, m); 13C-NMR 5 55. 9 
(OCH3), 111.0, 121.6, 122.1, 124.7, 125.4, 131.2, 149.2, 165.4; FAB-MS m/z 345 
(MH+), C21H 16N2O3 requires 344.
^-[4-(Acridin-9-ylamino)-3-methoxybenzoyl]-Ar2 7^A^"tri(benzyloxycarbonyl) 
sperm ine 118
4-(Acridin-9-ylamino)-3-methoxybenzoic acid 116 (0.340 g, 0.98 mmol), 
tri(benzyloxycarbonyl)spermine 71 (0.597 g, 0.98 mmol), DCC (0.303 g, 1.47 mmol), 
HOBt (7 mg, 0.05 equiv.) and THF (15 mL) were used in general procedure A for amide 
bond formation. The reaction mixture was stirred for 48 h and was purified by flash 
column chromatography on silica gel eluting with 1 0  % M eO H -C ^C L to yield the title 
compound 118 as an orange oil (0.345 g, 38 %). ^ -N M R  (CDCI3) 8  1.38-1.80 (8  H, 
m, 4 x CH2CH2CH2), 3.00-3.41 ( 1 2  H, m 6  x CILN), 4.05 (3 H, s, OCH3), 5.06 ( 6  H, s,
3 x CH2O), 6.42 (1 H, d, 7=8, CH5 ), 7.19-7.47 (18 H, m, 3 x Ph, C'H, C8H, C6 H), 7.60
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(1 H, bs, CH2’), 7.75 (2 H, t, 7=7, C3H, C6H), 8.07 (2 H, d, 7=9, C4H, CSH), 8.17 (2 H, d, 
7=9, C 2H, C7H); l3C-NMR 5 24.7,25.7, 30.8, 32.0, 33.6,35.5, 37.4,43.5,46.3, 53.7,
56.1 (CH3), 66.1 (O O F,),67.1 (OCH2), 110.0 (C2'), 113.1 (C5), 119.6, 121.0, 123.8 (C 1, 
C6), 125.0, 127.6, (Ph), 128.0 (Ph), 128.3 (Ph), 130.7 (C3, C6), 136.5 (Ph), 146.7, 148.1,
156.5, (C=0), 157.2 (C=0), 166.8 (NC=0; FAB-MS m/z 931 (MH+), CssHjgNsOs 
requires 930.
A^-[4-(Acridin-9-ylamino)-3-hydroxybenzoyl]spermine 119
^-[4-(Acridin-9-ylamino)-3-methoxybenzoyl]-iV2 ,A^v/V4 -tri(benzyloxycarbonyl) 
spermine 118 (0.15 g, 0.16 mmol) was dissolved in dry CH2CI2 (2 mL) and TMSI (0.08 
mL, 0.53 mmol) was added in a dropwise fashion over 5 min. The reaction mixture was 
stirred for 48 h and was then neutralised (aq. 2 M NaOH). The solution was evaporated 
in vacuo and the residue was purified by flash column chromatography on neutral 
alumina (grade 4) eluting with 2 0  % MeOH-CTLCL to yield the title compound 119 as 
an orange hygroscopic foam (0.077 g, 91 %)7H NMR (D2O) 5 1.03-1.35 (10 H, m), 
1.43-1.72 ( 6  H, m), 1.78 (2 H, m), 2.06 (2 H, m), 6 .6 8  (2 H, t, 7=7), 6.89 (1 H, t, 7=7), 
7.11 (m, 2 H), 7.38, (1 H, m), 7.83, (1 H, m), 8.05 (2 H, d, 7=9), 8.18 (2 H, d,7=9); 
FAB-MS m/z 515 (MH+), C30H38N6O2 requires 514.
A / -[4-(Acridin-9-yIamino)-3-methoxybenzoyl]-iV^-(^-butoxycarbonyl) spermine 120
4-(Acridin-9-ylamino)-3-methoxybenzoic acid 116 (0.228 g, 0.66 mmol), NL(r- 
butoxycarbonyl)spermine 69 (0.20 g, 0.66 mmol), DCC (0.205 g, 0.99 mmol), HOBt (4 
mg, 0.05 equiv.) and DMF (1 mL) were used in general procedure A for amide bond 
formation. The reaction mixture was stirred for 24 h and was purified by flash column
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chromatography on silica gel eluting with QLCL-MeOH-concentrated aq. NH3 
(100:10:1, 50:10:lthen 10:5:1) to yield the title compound 120 as an orange foam (0.153 
g, 37 %). 1H-NMR (CDCI3 ) 8  1.40 (9 H, s, 3 x CH,), 1.49 (4 H, m), 1 .6 6  (2 H, m), 1.76 
(2 H, m), 2.51-2.71 (8  H, m), 2.90-3.12 (4 H, m), 4.07 (3 H, s, OCH3), 6.38 (1 H, d, 7=8, 
CH5'), 7.25 (2 H, bs), 7.64 (1 H, bs, CH2'), 7.75 (2 H, t, 7=7, C3H, C6H), 8 .11 (2 H, d, 
7=9, C*H, C5H), 8.15 (2 H, d, 7=9, C2H, C7H); FAB-MS m/z 629 (MH+), C36H48N60 4  
requires 628.
A^ i -[4-(Acridin-9-ylamino)-3-methoxybenzoyl]-spermine tri-trifluoroacetate salt 
108
N ]-[4-(Acridin-9-ylamino)-3-methoxybenzoyl]-A^-(f-butoxycarbonyl) spermine 120 
(0.09 g, 0.14 mmol) was stirred in trifluoroacetic acid (2 mL) and CH2CI2 (2 mL) at 0 
°C for 45 min. The solvents were removed in vacuo, as an azeotrope with water and 
MeOH and the residue was lyophilised to yield the title compound as an orange 
hygroscopic foam (0.121 g, 99 %). 'H NMR (D20 ) 8  1.04-1.34 (10 H, m), 1.37-1.68(4 
H, m), 1.80 (2 H, m), 2.10 (2 H, m), 4.05 (3 H, s, OCH3), 6.70 (2 H, t, 7=7), 6.89 (1 H, t, 
7=7), 7.13 (m, 2 H), 7.34, (1 H, m), 7.86, (1 H. m), 8.10 (2 H, d, 7=9), 8.19 (2 H, d,
7=9); RP-HPLC 90 % MeCN: 10 % aq. TFA (0.1 %), X = 224 nm, 8  min; FAB-MS m/z 
529 (MH+), C31H40N6O2 requires 528.
Activation of Resin
p-Alkoxybenzylalcohol resin (5 g, 3.25 mmol) was suspended in anhydrous CH2CI2 (10 
mL) and A-methylmorpholine in CH2CI2 was added (5 mL of a 1.3 M solution). 4- 
Nitrophenyl chloroformate (6.55g; 32.5 mmol) was dissolved in CH2CI2 (30 mL) and
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added to the reactor which was flushed with N3 and was agitated for 16 h. The resin 
was repeatedly washed with anhydrous CH2CI2 (10 x 40 mL), under N2, until the washes 
showed no trace of reagent (spotted on TLC plate and visualised by UV light). The 
resin was suspended in CH2CI2 (10 mL) and was agitated for a further 3 h with half 
quantities of reagents. The resin was washed, under N2, with anhydrous CH2CI2 (10 x 
40 mL) until the washes showed no traces of reagent. The resin was dried in vacuo at 
40 °C over P20 5. IR 3030, 2700, 1770.
Resin 127
The activated resin was suspended in anhydrous CH2CI2 (25 mL) and a solution of Af- t-  
butoxycarbonyl-Ny-(3-aminopropyl)-l,3-diaminopropane (5.0 g , 21.6 mmol) in 
anhydrous CH2CI2 (10 mL) was added to the suspended resin then the reactor was 
sealed under N2 and was agitated for 16 h. The resin was washed with CH2CI2, THF, 
THF/H2O (1:1) using 5 x 40 mL of each solvent and was then suspended in THF/H2O 
(1:1) and was agitated for 48 h. The resin was washed with THF/H2O (1:1) then THF 
(both 5 x 40 mL) then CH2CI2 and then Et2 0  (both 3 x 40 mL). The resin was dried in 
vacuo at 40 °C over P2O5. 13C NMR (gel phase in CDCI3): 28.40 (3 x CH), 31.6, 32.40 
( 2  x CH2CH2CH2), 39.4 (CNCO2), 40.5 (CNH2), 43.9 (CNBocC), 79.8 (C(CH3)3), 155.9 
(C=0); IR 3030, 2900, 1940, 1870, 1800.
Acridine-9-acyl chloride hydrochloride 128
9-Acridinecarboxylic acid hydrate 73 (320 mg, 1.3 mmol) was suspended in toluene (2 
mL). DMF (2 drops) and thionyl chloride (0.49 mL, mmol) were added to the 
suspension and the reaction mixture was heated to 80 °C for 45 min after which time all 
the reactants were in solution. The reaction mixture was evaporated in vacuo and the
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yellow residue was washed with anhydrous Et2 0  (70 mL). The filter cake was dried in 
vacuo at 40 °C over P2O5 and was used without further purification. IR 2230, 1950, 
1780.
Acylation with 128
Resin 127 (400 mg) was swollen in DMF (4 mL) for 15 min. Acridine-9-acy! chloride 
(160 mg, 0.58 mmol) was dissolved in DMF (2 mL) and //-methylmorpholine in CH2CI2 
(0.9 mL of a 1.3 M solution) was added. This solution was added to the resin and the 
reactor was sealed, with an atmosphere of N2, and was agitated for 16 h. The resin was 
washed with CH2CI2 ( 5 x 5  mL) and was dried in vacuo at 40 °C over P2O5. The resin 
was reacted again with the same quantities of reagents for the same length of time and 
was washed and dried in the same way. (IR 2890, 1940, 1870, 1800). The product was 
cleaved from the resin using general procedure C. TLC of the residue showed only 
uncoupled polyamine.
Acylation with 128
Resin 127 (400 mg) was swollen in DMF (4 mL) for 15 min. Acridine-9-acyl chloride 
128 (160 mg, 0.58 mmol) was dissolved in DMF (2 mL) and TEA (0.4 mL) was added. 
This solution was added to the resin and the reactor was sealed, with an atmosphere of 
N 2, and was agitated for 16 h. The resin was washed with CH2CI2 ( 5 x 5  mL) and was 
dried in vacuo at 40 °C over P2O5. The resin was reacted again with the same quantities 
of reagents for the same length of time and was washed and dried in the same way. The 
product was cleaved from the resin using general procedure C. TLC of the residue 
showed only uncoupled polyamine.
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Acylation with 2-mercaptothiazoIine activated acridine-9-carboxlic acid 129
Acridine-9-acylchloride hydrochloride 128 (290 mg, 1.04 mmol) was suspended in 
anhydrous CH2CI2 ( 6  mL) and TEA (0.3 mL, 2.08 mmol) was added. 2- 
Mercaptothiazoline (157 mg, 1.32 mmol) and DMAP (1 mg) were added and the 
solution was stirred for 1.5 h. Resin 127 (400 mg) was swollen with anhydrous CH2CI2 
(2 mL) and a portion of the solution of activated acridine (3 mL) was added. The 
reactor was sealed under N 2 and was agitated for 16 h. The resin was washed with 
anhydrous CH2CI2 ( 5 x 5  mL) and was reacted with a further portion of the solution of 
activated acridine (3 mL) as before. The resin was washed with CH2CI2, MeOH, 
CH2CI2 ( 5 x 5  mL) of each solvent and was dried in vacuo at 40 °C over P2O5. (IR 
3020,2890, 1940, 1870, 1800). The product was cleaved from the resin using general 
procedure C. TLC of the residue showed only uncoupled polyamine.
HOBt activated acridine-9-carboxylic acid 130
Acridine-9-carboxylic acid hydrate 73 (1.1 g, 5.6 mmol) was suspended in anhydrous 
DMF (20 mL) then DCC (1.43 g, 6 .8 6  mmol) in anhydrous DMF (5 mL) and HOBt 
(680 mg, 5.03 mmol) in anhydrous DMF (5 mL) were added to the suspension. The 
reaction was stirred for 18 h at 60 °C and was then cooled and filtered. The filtrate was 
used without further treatment in acylation reactions.
Acylation with 130
Resin 127 (400 mg) was mixed with the solution of HOBt activated 9- acridine 
carboxylic acid 130 (0.6 mmol) in DMF (3.5 mL) then the reactor was flushed with N2, 
sealed and agitated for 16 h. The resin was washed with anhydrous DMF (5 x 5 mL) 
and the procedure was repeated with the same quantity of reagent, agitating for 3 h. The
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resin 131 was washed successively with DMF, THF, THF/H2O (1:1), THF then Et2 0  (5 
x 5 mL each solvent) and was then dried in vacuo at 40°C over P2O5. (IR 3310, 3020, 
1940, 1870, 1800). The product was cleaved from the resin 131 using general procedure 
D. The residue was purified by flash column chromatography on silica gel eluting with 
CH2Cl2/MeOH/conc. aq. NH3 (8:5:1) to yield the product 132 as a pale yellow gum (80 
mg). lH-NMR (D2 0 )  5 2.18 (2 H, m, CH2CH2CH2), 2.27 (2 H, m, CH2CH2CH2), 3.15 
(2 H, m, CILN), 3.27 (2 H, m, CTLN), 3.31 (2H, m, CFLN), 3.80 (2 H, m,
CH2NHC=0), 7.82 (2 H, t, 7=7,), 8.09 (2 H, t, 7=7), 8.14 (2 H, d, 7=8), 8.26 (2 H, d, 
7=8); FAB-MS m/z 337 (MH+), C20H24N4O requires 336; TLC Rf 0.60 (4:2:1, 
CH2Cl2/MeOH/NH4OH); IR 3250, 1640, 1470.
Resin 137
The resin 127 (2.0 g) was swollen in anhydrous DMF/EtOH (3:1) (12 mL) and 4- 
azidobutanal 134 (1.2 g, 10.6 mmol) was dissolved in anhydrous DMF (2 mL) and was 
added to the suspended resin. BAP (8  M in CH2CI2, 1.3 mL) was added to the reaction 
mixture. The reactor was flushed with Ar before being sealed and agitated for 48 h.
The resin 137 was washed with DMF, THF, THF/H20  (1:1), THF, Et2 0  ( 5 x 5  mL each 
solvent). The resin was dried in vacuo at 40 °C over P2O5. ER 3330, 2030, 2090, 1940, 
1880, 1800.
Resin 136
The resin 127 (2.0 g) was swollen in anhydrous DMF/EtOH (3:1) (12 mL) and 5- 
azidopentan-2-one 133 (960 mg, 7.6 mmol) was dissolved in anhydrous DMF (2 mL) 
and was added to the suspended resin. BAP (8  M BH3, 1.3 mL) was added to the 
reaction mixture then the reactor was flushed with Ar before being sealed and agitated
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for 48 h. The resin was washed with DMF, THF, THF/HoO (1:1), THF, EtiO ( 5 x 5  mL 
each solvent). The resin 136 was dried in vacuo at 40 °C over P2O5. IR 3030, 2090, 
1940, 1880, 1800.
Resin 138
The resin 127 (2.0 g) was swollen in anhydrous DMF/EtOH (3:1) (12 mL) and the 3- 
(Pnt-amino)propanal 135 (1.2 g, 7.73 mmol) was dissolved in anhydrous DMF (2 mL) 
and was added to the suspended resin. BAP (8  M in CH2CI2, 1.3 mL) was added to the 
reaction mixture then the reactor was flushed with Ar before being sealed and agitated 
for 48 h. The resin 138 was washed with DMF, THF, THF/H2O (1:1), THF, Et2 0  ( 5 x 5  
mL each solvent). The resin was dried in vacuo at 40 °C over P2O5. IR 3330, 3030,
1940.1870, 1800.
Resin 139
Resin 136 (1.0 g) was swollen in CH2CI2 (5 mL) and Boc anhydride (725 mg, 3.32 
mmol) was added. The reactor was flushed with N2 and sealed and was then agitated for 
15 h. The resin was washed with CH2CI2 ( 5x5  mL) and was reacted a second time 
with the same quantity of Boc anhydride. The resin 139 was washed with CH2CI2, THF, 
THF/H 2O (1:1) and THF ( 5 x 5  mL each solvent) and was dried in vacuo at 40 °C over 
P2O5. IR 3330, 3030, 2090, 1940, 1880, 1800.
Resin 142




Resin 142 was used in the general procedure F for HOBt activated 9-acridinecarboxylic 
acid acylation. IR 3310, 3020, 1940, 1870, 1800.
Af-(3-(4-(Acridine-9-ylcarbonylamino)-l-methylbutylamino)propyl)-l, 3-diamine 
123
Resin 145 was used in general procedure D for resin cleavage. The residue was purified 
by flash column chromatography on silica gel eluting with CH2Cl2/MeOFI/conc. aq.
NH3 (8:5:1) to yield the product 123 as a pale yellow gum (9 mg). !H-NMR (D2O) 8  
1.42 (3 H, s, CH3), 2.15-2.21 (8  H, m, 4 x CH2CH2CH2), 3.04-3.32 (8  H, 4 x CH2N), 
3.42-3.53 (1 H, m, CHCH3), 3.79 (2  H, t, CH2NHC=0), 7.98 (2 H, t, 7=7), 8.31 (4 H, 
m), 8.48 (2 H, d, 7=8); FAB-MS m/z 422 (MH+), C25H35N5O requires 421.
Resin 148
Resin 136 (1.0 g) was used in general procedure F for acridine acylation. IR 3330,
2850, 2090, 1950, 1880, 1800.
Resin 151
Resin 148 was used in general procedure E for azido reduction. IR 3340, 3030, 1940, 
1870, 1800.
Cleavage of Resin 151
Resin 151 was used in general procedure D for resin cleavage. TLC of the crude product 
showed only uncoupled polyamines.
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Resin 140
Resin 137 (1.0 g) was swollen in CH2CI2 (7 mL) and Boc anhydride (725 mg, 3.32 
mmol) was added. The reactor was flushed with N2 and sealed and was then agitated for 
15 h. The resin was washed with CFLCL ( 5 x 5  mL) and was reacted a second time 
with the same quantity of Boc anhydride. The resin 140 was washed with CH2CL, THF, 
THF/H2O (1:1) and THF ( 5 x 5  mL each solvent) and was dried in vacuo at 40 °C over 
P2O5 . IR 3330, 3030, 2090, 1940, 1880, 1800.
Resin 143
Resin 140 was used in general procedure E for azide reduction. IR 3360, 2950, 1940, 
1870, 1800.
Resin 146
Resin 143 was used in general procedure F for HOBt activated acridine-9-carboxylic 
acid acylation. IR 3310, 3020, 1940, 1870, 1800.
A^ i -(4-(Acridine-9-ylcarbonyIamino)but\l)-iV2 -(3-aminopropyl)propan-l,3-diamine 
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Resin 146 was used in the general procedure for resin cleavage. The residue was 
purified by flash column chromatography on silica gel eluting with CT^CL/MeOH/conc. 
aq. NH 3 (8:5:1) to yield the product as a pale yellow gum. ^ -N M R  (D2 O) 5 2.08-2.20 
( 8  H, m, 4 x CH2CH2CH2), 3.05-3.30 (8  H, 4 x CH2N), 3.42-3.53 (2 H, m, CH2NH2),
3.60 (2 H, m, C th N H C ^ ), 7.87 (2 H, t, 7=7), 8.27 (4 H, m), 8.46 (2 H, d, 7=8); FAB- 
MS m/z 408 (MH+), C24H33N5O requires 407; IR 3260, 1640, 1480.
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Resin 149
Resin 137 (1.0 g) was used in general procedure F for acridine acylation. IR 3330,
2850, 2090, 1950, 1880, 1800.
Resin 152
Resin 149 was used in general procedure E for azido reduction. IR 3340, 3030, 1940, 
1870, 1800.
Cleavage of Resin 152
Resin 152 was used in general procedure D for resin cleavage. TLC of the crude product 
showed only uncoupled polyamines.
Resin 141
Resin 138 was swollen in CILCL (5 mL) and Boc anhydride (725 m g , ) was added. The 
reactor was flushed with N 2 and sealed and was then agitated for 15 h. The resin was 
washed with CH2CI2 ( 5 x 5  mL) and was reacted a second time with the same quantity 
of Boc anhydride. The resin 141 was washed with CH2CI2, THF, THF/H2O (1:1) and 
THF ( 5 x 5  mL) and was dried in vacuo at 40 °C over P2O5. IR 3330, 3030, 1940, 1880, 
1800.
Resin 144
Iodine (3.3g, 13mmol) was dissolved in THF/H2O (1:1) (7 mL) and the resin 141 was 
swollen in the solution. The reactor was sealed and was agitated for 18 h then the resin 
was successively washed with THF, THF/H2O (1:1), THF/sat. aq. Na2S2C>3, THF,
153
CH2CI2 then Et2 0  ( 5 x 5  mL each solvent). The resin 144 was dried in vacuo, over 
P2O5 . IR 3330, 3030, 1940, 1880, 1800.
Resin 147
Resin 144 was used in general procedure F for HOBt activated 9-acridinecarboxylic acid 
acylation. IR 3310, 3020, 1940, 1870, 1800.
iV7-(3 -(Acridine-9-ylcarbonyIamino)propyl)-iV2-(3-aininopropyI)propan-l,3- 
diamine 1 2 1
Resin 146 was used in the general procedure for resin cleavage. The residue was 
purified by flash column chromatography on silica gel eluting with CH2Cl2/MeOH/conc. 
aq. NH3 (8:5:1) to yield the product 121 as a pale yellow gum. 'H-NM R (D2 O) 6  2.10- 
2.18 ( 6  H, m, 3 x CH2CH2CH2), 3.05-3.25 (8  H, 4 x ClfcN), 3.37-3.45 (2 H, m,
CHNH2), 3.55 (2 H, m, C H zN H C ^), 7.82 (2 H, t, 7=7), 8.35 (4 H, m), 8.48 (2 H, d, 
7=8); FAB-MS m/z 394 (MH+), C23H31N5O requires 393; IR 3260, 1640, 1480.
Resin 150
Resin 138 (1.0 g) was used in general procedure F for acridine acylation. IR 3330,
3030,1940, 1880, 1800.
Resin 153
Iodine (3.3 g, 13 mmol) was dissolved in THF/H2O (1:1) (7 mL) and the resin 150 was 
swollen in the solution. The reactor was sealed and was agitated for 18 h then the resin 
was successively washed with THF, THF/H20  (1:1), THF/sat. aq. Na2S20 3, THF,
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CH2CI2 then Et2 0  ( 5 x 5  mL each solvent). The resin 153 was dried in vacuo, over 
P20 5. IR 3330, 3030, 1940, 1880, 1800.
Cleavage of Resin 153
Resin 153 was used in general procedure D for resin cleavage. TLC of the crude product 
showed only uncoupled polyamines.
Isoferulic acid 173 (Blase and Banerjee, 1995)
3-Hydroxy-4-methoxybenzaldehyde 172 (5.00 g, 32.9 mmol) and malonic acid (7.75 g,
74.4 mmol) were dissolved in piperidine (0.5 mL) and pyridine (30 mL). The solution 
was heated to 80 °C for 1 h and was allowed to cool before being poured into water (200 
mL). This solution was acidified with 2 N aq. HC1 and the precipitate was collected by 
filtration. This product (6.02 g, 94 %) was dried in vacuo over P2O5 (MP 236-238 °C; 
lit. 238-240 °C Stoll and Seebeck, 1957). 'H-NMR (D6-DMSO) 5 3.77 (3H, s, OCH3),
6.24 (1H, d, 7=16, C2 H), 6.92 (1H, d, 7=8, C6H), 7.5-7.10 (2 H, m, C5H, C2H), 7.45 
(1H, d, 7=16, CrH); l3C-NMR 8  55.7 (OCH3), 111.9 (C5), 114.0 (C2), 116.3 (C6), 121.1 
(C2'), 127.1 (C1), 144.0 (C1'), 146.8 (C3), 149.5 (C4), 177.1 (C=0); EI-MS m/z 194 (M+), 
C 10H 10O4 requires 194; Found C 61.70, H 5.20, N 0.00, requires C 61.85, H 5.19, N 
0.00 % .
4-FIuorocinnamic acid 177 (Luo et a l, 1990)
4-Fluorobenzaldehyde 174 (17.3 mL, 160 mmol) and malonic acid (21.4 g, 480 mmol) 
were dissolved in a mixture of piperidine (3 mL) and pyridine (200 mL). The solution 
was heated to 80 °C for 4.5 h and was then cooled to room temperature. The solution 
was poured onto crushed ice (500 g) and the mixture was acidified with conc. aq. HC1.
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Once the ice melted the mixture was filtered and the filtrate, a purple solid, was 
recrystallised from EtOH to yield white needles MP BERGGMAN(23.6 g, 89 %). H- 
NMR (d6 DMSO) 8  6.54 (1H, d, 7=16, C2 H), 7.27 (2H, t, 7=9, C2H, C6H), 7.64 ( 1H, d, 
7=16, C ' H), 7.79 (2H, dd, 7HH=9, 7hf= H , C3H, C5H); bC-NMR 8  116.2 (d, 7=22, C3, 
C5), 119.3 (C2), 130.7 (d, 7=8, C2, C6), 131.1 (d, 7=2, C1), 143.0 (C1), 163.4 (d, 7=220, 
C4), 167.9 (C=0); FAB-MS m/z 167 (MH4), C9H7F 0 2 requires 166; Found C 65.00, H 
4.34, N 0.00, requires C 65.06, H 4.25, N 0.00 %.
4-Fluoro-3-nitrocinnamic acid 176
4-Fluorocinnamic acid 177 (3.7 g, 22.3 mmol) was added to conc. HNO3 over 5 min and 
the mixture was stirred for a further 1 h. The reaction mixture was the poured over 
crushed ice ( 2 0 0  g) and the precipitate formed was collected by filtration once the ice 
had melted. The filtrate was washed well with water and was dried in vacuo over P2O5. 
The product was a white solid (4.0 g, 85 %). ‘H-NMR (d6 DMSO) 5 6.53 (1 H, d, 7=16, 
C2 H), 7.68 (1  H, td, 7 =8 , 7=2, C5H), 7.79 ( 1H, d, 7=16, C ‘H), 7.97-8.08 (2 H, m, C2H, 
C6H); l3C-NMR 8  112.6 (d, 7=27, C3), 121.5 (d, 7=22, C5), 124.2 (C2), 126.2 (d, 7=4, 
C 1), 131.7 (d, 7=9, C2/6), 138.1 (C1), 149.1 (d, 7=9, C276), 162.1 (d, 7=252, C4), 167.1 
(C=0); EI-MS m/z 2 1 1 (M+), C9H6FN 04 requires 2 1 1 ; Found: C 49.80, H 2.42, N 8.31 
requires C 49.72, H 2.38, N 8.28 %.
N'-t -Butoxycarbonyl-Ni -(3-aminopropyl)-l,3-diaminopropane 181
/7-(3-Aminopropyl)-1,3-diamine 178 (5.00 g, 38.2 mmol) was dissolved in THF (15 
mL) then ethyl trifluoroacetate (9.1 mL, 76.3 mmol) was added over 5 min. The 
reaction mixture was stirred for 1 h then Boc anhydride (12.5 g, 57.3 mmol) was added. 
The reaction mixture was stirred for a further 18 h then conc. aq. NH3 was added to the
156
reaction mixture until the pH was >11. The reaction mixture was stirred for 24 h until 
TLC showed the reaction was complete. The reaction mixture was evaporated in vacuo 
and the residue was purified by flash column chromatography on silica gel eluting with 
CH2Cl2/MeOH/conc. aq. NH3 (15:10:1) to yield the title compound 181 as a colourless 
oil (5.47 g, 62 %). ’H-NMR (CDC13) 5 1.47 (9H, s, C(CH3)3), 1 -6 6  (4H, quin., 7=6, 2  x 
CH2CH2CH2), 2.68 (8 H, t, 7=7, 2 x CILNH^, 3.27 (4 H, bs, CILNBocCH^; ,3C-NMR 
5 28.5 (3 x CH3), 30.8 (CH2CH2CH2), 31.8 (CH2CH2CH2), 38.5 (CH2NH2), 39.1 
(CH2NH2), 43.6 (CH2NBoc), 44.3 (CH2NBoc), 79.3 (C(CH3)3), 155.6 (C=0); FAB-MS 
m/z 232 (MH+) C nH 25N30 2 requires 231.
Ai -^-Butoxycarbonyl-Ai -(3-(3-hydroxy-4-methoxycinnamoylamino)propyl)-l,3- 
diaminopropane 182
3 -Hydroxy-4 -methoxycinnamic acid 173 (140 mg, 0.72 mmol) was dissolved in THF (5 
mL). DCC (164 mg, 0.80 mmol), 2-mercaptothiazolidine (95 mg, 0.80 mmol) and 
DMAP (1 mg) were added and the reaction mixture was stirred for 1 h. The white 
precipitate was removed from the yellow solution by filtration. N;-f-Butoxycarbonyl-iVy- 
(3-aminopropyl)-l,3-diaminopropane 181 (333 mg, 1.44 mmol) was dissolved in THF 
(30 mL) and the yellow filtrate was added in one portion. The reaction mixture was 
stirred for 10 h and was then evaporated in vacuo. The residue was purified by flash 
column chromatography on silica gel eluting with CH2Cl2/MeOH/conc. aq. NH3 
(50:10:1) to yield the title compound 182 as a white wax (61 mg, 75 %). lH-NMR 
(CDCI3) 5 1.39 (9 H, s, C(CH3)3), 1.56-1.72 (4 H, m, CH2CH2CH2), 2.88-3.03 (4 H, m, 
CKhNBocCHz), 3.10-3.33 (4 H, m, CTLNH^ CH2NHC=0), 3.81 (3 H, s, OCH3), 6.26 
(1 H, d, 7=16, C2 H), 6.73 (1 H, d, 7=8, C6H), 6.83-6.94 (1 H, m, C5H), 7.06 (1H, s, 
C2H), 7.42 (1 H, d, 7=16, C' H); FAB-MS m/z 167 (MH+), C9H7F 0 2 requires 166.
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FN'-t -Butoxycarbonyl-A^i -(3-(3-hydroxy-4-methoxycinnamoylamino)propyl)-A^2 -(4- 
fluoro-3-nitrocinnamoyl)-l,3-diaminopropane 183
4-Fluoro-3-nitrocinnamic acid 176 (97 mg, 0.46 mmol) was dissolved in THF (5 mL). 
DCC (113 mg, 0.65 mmol), 2-mercaptothiazolidine (60 mg, 0.50 mmol) and DMAP (1 
mg) were added and the reaction mixture was stirred for 1 h. The white precipitate was 
removed from the yellow solution by filtration. Ny-r-butoxycarbonyl-Af7-(3-(3-hydroxy-
4-methoxycinnamoylamino)propyl)-l,3-diaminopropane 182 (160 mg, 0.46 mmol) was 
dissolved in THF (5 mL) and was added to the yellow filtrate. The reaction mixture was 
stirred for 10 h and was then evaporated in vacuo. The residue was purified by flash 
column chromatography on silica gel eluting with 5 % MeOH/CH2Cl2 to yield the title 
compound 183 as a white wax (190 mg, 69 %). 'H-NMR (CDCI3) 8  1.41 (9H, s, 3 x 
CH3), 1.61-1.85 (4 H, m, 2 x CH2CH2CH2), 3.08-3.43 (8  H, 4 x CH2N), 3.85 (3 H, s, 
OCH3), 6.29 (1  H, d, J=16, C2'H), 6.38 (1  H, d, J=16, C4'H), 6.79 (1 H, d, J=8 , C3H), 
6.93 (1 H, dd, J=8 , J= l, C l2H), 7.08 (1 H, d, j=2, CSH), 7.27 (1 H, s, C6H), 7.48 (1 H, d, 
7=16, C3 H), 7.57 (1 H, bs, C2H), 7.71 (1 H, dd, J=8 , J=2, CUH), 7.95 (1H, d, j=16,
C 1 H); l?C-NMR 5; 28.3 (CH3), 36.3 (b), 37.1 (b), 44.7 (b), 55.8 (C(CH3)3), 80.0 
(OCH3). 1 10.8 (C5), 112.9 (C2), 118.8 (C6), 120.8 (d, 7=20, C1'), 121.3 (C2'), 126.4 
(C4), 127.3 (d, 7=3, C 7), 128.0 (C1), 130.7 (d, 7=9, C 12), 132.6 (C9), 134.7 (C3), 140.5
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(Cr), 146.0 (C3), 148.5 (C4). 158.2 (d, 7=258, C 10), 163.8(C=0), 165.0(C=O), 166.7 
(C=0); FAB-MS m/z 601 (MH+), C30H37FN4O8 requires 600; FAB-HRMS calcd. 
601.2474 (MH+), found 601.2686.
A-Boc-0-methyI-2'-nitronorcadabicine 170
A7-r-Butoxycarbonyl-iV7-(3-<3-hydroxy-4-methoxycinnamoylamino)propyl)-iV2-(4- 
fluoro-3-nitrocinnamoyl)-1.3-diaminopropane 183 (90 mg, 0.16 mmol) and CsF (121 
mg, 0.80 mmol) were combined in anhydrous DMF (16 mL) and were stirred for 18 h. 
H2O (30 mL) was added to the reaction mixture and this solution was washed with 
EtOAc (3 x 30 mL). The combined organic washes were dried (MgS0 4 ) and evaporated 
in vacuo. The residue was purified by RP-HPLC (1:4 aq. TFA (0.1 %)/MeOH, X=250 
nm) to yield the product 170 as a buff foam (73 mg, 79 %). ‘H-NMR (CDCI3) 5 1.48 (9 
H, s, C(CH3)3), 1.67-1.90 (4 H, m, CH2CH2CH2), 3.12-3.47 (8  H, m, CH2N), 3.90 (3 H, 
s, OCH3), 6.31 (1H, d, 7=16), 6.42 (1H, d, 7=16), 6.78 (1H, d, 7=8), 6.92 (1H, d, 7=8),
7.09 (1 H, s), 7.48 (1 H, d, 7=16), 7.53-7.64 (2 H, m), 7.71 (1H, d, 7=8), 7.94 (1H, d, 
7=16); ,3C-NMR 5; 28.4 (CH3), 36.2, 37.0,44.6, 55.9 (C(CH3)3), 89.8 (OCH3), 110.7, 
112.1, 112.6, 118.8, 120.6, 120.9, 121.5, 126.7, 127.6, 128.2, 131.3, 132.9, 135.0,
140.6, 145.9, 148.5, 160.1 (C=0), 164.3 (C=0), 165.0 (C=0); FAB-MS m/z 581 (MH+), 
C30H3N4O8 requires 580.
4-(Tetrahydropyrimidin-l-yl)butylamine 184 (Almedia et a l , 1988)
Spermidine 2 (2.0 g, 13.8 mmol) was dissolved in H20  (50 mL) and the solution was 
cooled to 5 °C. 36 % aq. formaldehyde solution (1.0 mL, 12.4 mmol) was added over 5 
min then the reaction mixture was allowed to warm to 20°C and was stirred for 1 h.
NaCl was added until the solution was saturated and it was then extracted with CHC13
159
(4 x 40 mL). The combined organic extracts were dried (MgSC^) and evaporated in 
vacuo to give a colourless viscous oil (1.93 g, 89 %) which was used without further 
purification. 'H-NMR (CDC13) 5 1.41-1.71 (6 H, m, 3 x CH2CH2CH2), 2.18-2.30 (2H, 
m, CH2N), 2.46-2.63 (2H, m, CH2N), 2.68-2.85 (4H, NCH2CH2CH2N), 3.30-3.50 (5H, 
NCH2N, 3 x NH); 13C-NMR 5 24.0 (CH2CH2CH2CH2), 26.6 (CH2CH2CH2CH2), 30.4 
(CH2CH2CH2), 41.1 (CH2N), 44.5 (CH2N), 52.7 (NCH2CH2CH2N), 55.0 
(NCH2CH2CH2N), 69.5 (NCH2N); FAB-MS m/z 158 (MH+) C8Hi9N3 requires 157.
Af-(3-Hydroxy-4-methoxycinnamoyl)-4-(tetrahydropyrimidin-l-yl)butylamine 185
3-Hydroxy-4-methoxycinnamic acid 176 (435 mg, 2.24 mmol) was suspended in a 
mixture of CHCI3 (10 mL) and CH2C12 (10 mL). DCC (690 mg, 3.36 mmol), 2- 
mercaptothiazolidine (294 mg, 2.46 mmol) and DMAP (1 mg) were added and the 
reaction mixture was stirred for 1 h. The white precipitate was removed from the 
yellow solution by filtration. 4-(Tetrahydropyrimidin-l-yl)butylamine 184 (700 mg, 
4.48 mmol) was dissolved in a mixture of CHCI3 (20 mL) and CH2C12 (20 mL) and this 
solution was cooled to -78 °C. The yellow filtrate was added and the solution was 
allowed to warm to 20 °C and was stirred for 5 h. The reaction mixture was evaporated 
in vacuo and the residue was purified by flash column chromatography on silica gel 
eluting with CH2Cl2/MeOH/conc. aq. NH3 (200:10:1, 100:10:1 then 50:10:1) to yield 
the title compound 185 as a white foam (410 mg, 55 %). 'H-NMR (CDCI3) 8  137-1.73 
(6 H, m, 3 x CH2CH2CH2), 2.08-2.30 (2H, m, CH2N), 2.50 (2H, bs, CFLN), 2.74 (2H, 
bs, CH2N), 3.08-3.42 (4 H, m, NCFLN, CH2NHOO), 3.79 (3 H, s, OCH3), 6.36 (1 H, 
d, 7=16,), 6.71 (1 H, d, 7=8,), 6 .8 6  (1 H, d, 7=8), 7.08 (1 H, s , ), 7.46 (1 H, d, 7=16); 
13C-NMR 5:23.7 (CH2CH2CH2CH2), 25.2 (CH2CH2CH2CH2), 27.2 (CH;>CH2CH2), 39.2,
44.5 (CH2N), 52.5 (CH2N), 54.6 (CH2NHC=0), 55.6 (OCH3), 68.7 (NCH2N), 111.0
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(C5), 113.3 (C2), 118.3 (C6), 121.1 (Cr ), 127.6 (C1), 140.3 (Cr), 146.8 (C3), 149.4 (C4),
166.8 (C=0); FAB-MS m/z 334 (MH+) C 18H27N1O3 requires 333.
A^-3-Hydroxy-4-methoxycinnamoylspermidine 186
jy-Q-Hydroxy^-methoxycinnamoylM-Oetrahydropyrimidin-1 -yl)butylamine 185 (200 
mg, 0.60 mmol), pyridine and malonic acid (225 mg, 2.16 mmol) were dissolved in 
anhydrous MeOH (5 mL). The reaction mixture was heated to reflux for 2 h and was 
then evaporated in vacuo. The residue was purified by flash column chromatography on 
silica gel eluting with (T^CH/MeOH/conc. aq. NH3 (8:5:1) to yield the title compound 
186 as a colourless glass (152 mg, 79 %). 'H-NMR (CD3OD) 5 1.21-1.57 (6 H, m, 3 x 
CH2CH2CH2), 2.37-2.92 (6 H, m, 2 x CfLNH, CFLN), 3.05 (2 H, m, CH2NC=0 ), 3.60 
(3 H, s, OCH3), 6.17 (1 H, d, 7=16, C2'), 6.61 (1 H, d, 7=8,), 6 .6 8  (1 H, d, 7=8), 6.78 (1 
H, s, C2), 7.14 (1  H, d, 7=16, C 1); 13C-NM R8 ; 26.3, 27.5, 28.6, 29.1, 30.1, 32.3, 40.2, 
41.1,56.9 (OCH3), 112.8 (Cs), 115.1 (C2), 119.3 (C6), 122.0 (C2), 125.7 (C1), 142.2 
(C1), 146.8 (C3), 149.3 (C4), 169.2 (C=0); FAB-MS m/z 322 (MH+), C 17H27N3O3 
requires 321.
N l -3 -Hydroxy-4-methoxycinnamoyl-iV3-4-fluoro-3-nitrocinnamoyIspermidine
4-Fluoro-3-nitrocinnamic acid 176 (73 mg, 0.34 mmol) was suspended in CH2CI2 (10 
mL) and DCC (106 mg, 0.51 mmol), 2-mercaptothiazolidine (45 mg, 0.38 mol) and 
DMAP (1 mg) were added. The reaction mixture was stirred for 1 h and was then 
filtered to remove the white precipitate from the yellow solution. Ny-3-Hydroxy-4- 
methoxycinnamoylspermidine 186 (110 mg, 0.34 mmol) was dissolved in MeOH (20 
mL) and the solution was cooled to -78 °C. The yellow filtrate was added to this 
solution and the reaction mixture was allowed to warm to 20 °C and then stirred at this
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temperature for 3 h. The reaction mixture was evaporated in vacuo and the residue was 
purified by flash column chromatography on silica gel eluting with CH2Cl2/MeOH/conc. 
aq. NH3 (50:10:1) to yield the title compound as a pale brown glass (107 mg, 61 %). 
'H-NMR (CD3OD) 5 1.48 (4H, bs, 2 x CH2CH2CH2), 1.63-1.81 (2H, m, CH2CH2CH2), 
2.57-2.73 (4H, m, 2 x CTLNH), 3.23 (4 H, t, 7=9, 2 x C IL N C ^ ) , 374 (3 H, s, OCH3),
6.24 (1 H, d, 7=16), 6.38 (1 H, d, 7=16), 6.70-6.89 (3 H, m), 7.23 (1 H, d, 7=16), 7.32 (1 
H, td, 7=8, 7=2), 7.57 (2 H, m), 7.70 (1 H, d, 7=16); FAB-MS m/z 515 (MH+), 
C26H3 iFN40 6  requires 514.
N 2 -1 -Butoxycarbonyl-iVM-fluoro-S-nitrocmnamoyl-A^-S-hydroxy^- 
methoxycinnamoylspermidine 187
A3-4-Fluoro-3-nitrocinnamoyl_/V7-3-hydroxy-4-methoxycinnamoyIspermidine ( \ 0 0  mg,
0.19 mmol) and Boc anhydride (85 mg, 0.39 mmol) were mixed in MeOH (5 mL). The 
reaction mixture was stirred for 18 h and then water (5 mL) was added. After a further 4 
h the reaction mixture was evaporated in vacuo and the residue was purified by flash 
column chromatography on silica gel eluting with 5 % CH2Cl2/MeOH to yield the title 
compound 187 as a pale brown glass (96 mg, 82 %). 'H-NMR (CDCI3) 5 1.43 (9 H, 
C(CH3)3), 1.43-1.56 (6 H, m, 3 x CH2CH2CH2), 1.56-1.96 (8 H, m, 4 x CjHbN), 3.89 (3 H, 
s, OCH3), 6.32 (1 H, d, 7=16), 6.42 (1 H, d, 7=16), 6.92 (1 H, dd, 7=8,7=2), 7.08 (1 H, 
d, 7=2), 7.24 (1 H, d, 7=8), 7.48 (1H, d, 7=16), 7.48-7.63 (2H, m), 7.70 (1H, dd, 7=8, 
7=3), 7.94 (1H, d, 7=16); 8 ; FAB-MS m/z 615 (MH+), C31H39FN4O8 requires 614; FAB- 




methoxycinnamoylspermidine 187 (49 mg, 0.081 mmol) and CsF (37 mg, 0.024 
mmol)were combined in anhydrous DMF (14 mL) and were stirred for 18 h. H2O (30 
mL) was added to the reaction mixture and this solution was washed with EtOAc (3 x 
30 mL). The combined organic washes were dried (MgSCU) and evaporated in vacuo. 
The residue was purified by RP-HPLC (1:4 aq. TFA (0.1 %)/MeOH, A.=250 nm) to yield 
the product 188 as a buff foam (34 mg, 71 %). ‘H-NMR (CDCI3) 5 1.43 (9 H, s, 
C(CH3)3), 1.55 (4 H, bs, 2  x CH2CH2CH2), 1.73 (2  H, bs, CH2CH2CH2), 3.1-3.48 (8  H,
4 x CFLN), 3.90 (3 H, s, OCH3), 6.30 (1 H, d, 7=16), 6.42 (1 H, d, 7=16), 6.78 (1 H, d, 
7=8), 6.85-6.97 (1 H, bm), 7.08 (1 H, bs), 7.49 (1 H, bd, 7=16), 7.53-7.64 (2 H, bm), 
7.70 (1 H, bd, 7=8), 7.94 (1 H, d, 7=16); FAB-MS m/z 595 (MH+), C31H38N4O8 requires 
594; FAB-HRMS calcd. 595.2768 (MH+), found 595.2793.
2 ’-N itrocadabicine 189
0-M ethyl-2’-nitrocadabicine (20 mg; 0.040 mmol) was dissolved in anhyd. CH2CI2 (1 
mL) and the solution was cooled to -78 °C. BBr3 (11 mg; 0.044 mmol) was added and 
the solution was stirred for 3 h. The reaction mixture was diluted with CH2CI2 (20 mL) 
and was then extracted with aq. 1 M NaOH (3 x 20 mL). The organic layer was dried 
(MgS0 4 ) and evaporated in vacuo. The residue was purified by flash column 
chromatography on silica gel eluting with 10 % MeOH/CT^CH to yield the title 
compound 189 as a buff coloured gum (11 mg; 60 %).'H-NMR (CDCI3) 8  1.49 (4 H, bs, 
2  x CH2CH2CH2), 1 .6 8  (2  H, bs, CH2CH2CH2), 2.85-2.97 (4 H, 2 x CH2N), 3.09-3.33 (4 
H, 2 x CH2N), 6.28 (1 H, d, 7=16), 6.40 (1 H, d, 7=16), 6.76 (1 H, d, 7=8), 6.80-6.95 (1 
H, m), 7.08 (1 H, bs), 7.47 (1 H, d, 7=16), 7.52-7.67 (2 H, bm), 7.70 (1 H, bd, 7=8), 7.96
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(1 H, d, 7=16); FAB-MS m/z 481 (MH+), C ^ g N ^  requires 480; FAB-HRMS calcd. 
481.2087 (MH+), found 481.2099.
N 2, AfJ-di-(f-Butoxycarbonyl)spermine 192 (O’Sullivan et cil, 1997)
Spermine 1 (2.00 g, 9.88 mmol) was dissolved in THF (10 mL) then ethyl trifluoro- 
acetate (2.4 mL, 19.7 mmol) was added over 5 min. The reaction mixture was stirred 
for 1 h then Boc anhydride (3.23 g, 14.8 mmol) was added. The reaction mixture was 
stirred for a further 18 h then conc. aq. NH3 was added to the reaction mixture until the 
pH was >11. The reaction mixture was stirred for 24 h until TLC showed the reaction 
was complete. The reaction mixture was evaporated in vacuo and the residue was 
purified by flash column chromatography on silica gel eluting with QLCL/M eOH/ 
conc. aq. NH3 (15:10:1) to yield the title compound 192 as a colourless oil (3.14 g, 55 
%). ‘H-NMR (CD3CI) 8  1.43 (18H, s, 2 x 0 1 3 )3), 1.44-1.52 (4H, m, 2 x CH2CH2CH2), 
1.65-1.70 (4H, m, 2  x CH2CH2CH2), 2.65-2.79 (4 H, m, 2 x CH2NH2), 3.13-3.30 (8  H, 
m, 4 x CH2N); l3C-NMR 8 ; 25.2, 28.0 (CH3), 28.5, 37.5, 43.4, 46.0, 79.9 (C(CH3)3),
161.8 (C=0); FAB-MS m/z 403 (MFC) C20H42N4O4 requires 402.
N 1- 3 -Hydroxy-4-methoxycinnamoyl-A2^V3-di f-butoxycarbonylspermine (used to 
prepare 193)
3-Hydroxy-4-methoxycinnamic acid (241 mg, 1.24 mmol) was dissolved in THF (7 
mL). DCC (384 mg, 1.87 mmol), 2-mercaptothiazolidine (163 mg, 1.37 mmol) and 
DMAP (1 mg) were added and the reaction mixture was stirred for 1 h. The white 
precipitate was removed from the yellow solution by filtration. A2, A^-Di-(r- 
butoxycarbonyl)spermine (1.0 g, 2.49 mmol) was dissolved in THF (30 mL) and the 
yellow filtrate was added in one portion. The reaction mixture was stirred for 10 h and
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was then evaporated in vacuo. The residue was purified by flash column 
chromatography on silica gel eluting with CH2Cl2/MeOH/conc. aq. NH3 (50:10:1) to 
yield the title compound as a white wax (424 mg, 59 %). 'H-NMR (CDCI3) 5 1.33-1.57 
(2H, m, 3 x C(CH3)3, 2 x CH2CH2CH2), 1.63-1.82 (4H, m, 2 x CH2CH2CH2), 2.77 (2H, 
bt, 7=7, CH2NH2), 3.05-3.42 (10 H, m, 2 x Q ^ N B o c Q i,, C H ^ O O ) ,  3.87 (3 H, s, 
OCH,), 6.35 ( 1H, d, 7=16, C2'H), 6.80 (1 H, d, 7=8, C6H), 6.95 (1  H, bd, 7=8, C5H),
7.10 (1 H, bs, C2H), 7.50 (1 H, d, 7=16, C' H); "C-NMR 8 ; FAB-MS m/z 579 (MH+) 
C30H 50N4O7 requires 578.
3 1 2 3N  -4-Fluoro-3-nitrocinnamoyl-./V -3-hydroxy-4-methoxycinnamoyI-A ,N  -di-f- 
butoxycarbonylsperm ine 193
4-Fluoro-3-nitrocinnamic acid 176 (42 mg, 0.20 mmol) was dissolved in THF (5 mL). 
DCC (61 mg, 0.30 mmol), 2-mercaptothiazolidine (26 mg, 0.22 mmol) and DMAP (1 
mg) were added and the reaction mixture was stirred for 1 h. The white precipitate was 
removed from the yellow solution by filtration. A;-3-hydroxy-4-methoxycinnamoyl- 
N2,N3-di r-butoxycarbonylspermine (114 mg, 0.20 mmol) was dissolved in THF (5 mL) 
and was added to the yellow filtrate. The reaction mixture was stirred for 10 h and was 
then evaporated in vacuo. The residue was purified by flash column chromatography on 
silica gel eluting with 5 % MeOH /CH2C12 to yield the title compound 193 as a buff 
coloured foam (111 mg, 73 %). 'H-NMR (CDCI3) 8  1.50 (18 H, s, 2 x C(CH3)3), 1.60- 
2.00 ( 8  H, m, 4 x CH2CH2CH2), 3.03-3.43 (12 H, 6  x CHsN), 3.87 (3 H, s, OCH3), 6.31 
(1 H, d, 7=16), 6.47 (1 H, d, 7=16), 6.80 (1 H, d, 7=8), 6.87-6.99 (1 H, m), 7.10 (1 H, 
bs), 7.46 (1 H, d, 7=16), 7.55-7.78 (3 H, m), 7.93 (1 H, d, 7=16); 13C-NMR 5 FAB-MS 
m/z 772 (MH+), C39H54FN5O 10 requires 771; FAB-HRMS calcd. 772.3933 (MH+), 
found 772.3930.
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Boc-protected 28-membered macrocycle 194
A^-Fluoro-S-nitrocinnamoyl-A^-S-hydroxy^-methoxycinnamoyl-A^A^-di-r- 
butoxycarbonylspermine ( 61 mg, 0.079 mmol), 18-crown-6 (208 mg, 0.79 mmol) and 
anhydrous K2CO3 (33 mg, 0.24 mmol)were combined in anhydrous DMSO (14 mL) and 
were stirred for 5 h at 50 °C. H2O (30 mL) was added to the reaction mixture and this 
solution was washed with EtOAc (3 x 30 mL). The combined organic washes were 
dried (M gSO^ and evaporated in vacuo. The residue was purified by RP-HPLC (1:4 aq. 
TFA (0.1 %)/MeOH, \=25Q nm) to yield the product as a buff foam (39 mg, 6 6  %). ‘H- 
NMR (CDCI3) 8  1.40 (9 H, s, C(CH3)3), 1.53-1.80 (8  H, bs, 4 x CH2CH2CH2), 2.98-3.34 
(12 H, 6  x CH2N), 3.83 (3 H, s, OCH3), 6.23 (1 H, d, 7=16), 6.32 (1 H, d, 7=16), 6.73 (1 
H, d, 7=8), 6.91 (1 H, bd, 7=9), 7.03 (1 H, bs), 7.20-7.33 (1 H, bm), 7.43 (1 H, bd,
7=16), 7.48-7.60 (1 H, bm), 7.67 (1 H, bd, 7=8), 7.85 (1 H, d, 7=16); FAB-MS m/z 752 
(MH+), C39H53N5O10 requires 751; FAB-HRMS calcd. 752.3871 (MH+), found 
752.3895.
28-Membered macrocycle 195
Compound 194 (20 mg, 0.067 mmol) was stirred in trifluoroacetic acid (1 mL) and 
CH2CI2 (1 mL) at 0 °C for 45 min. The solvents were removed in vacuo, as an 
azeotrope with water and MeOH. The residue was purified by flash column 
chromatography eluting with C^CL/MeOH/conc. aq. NH3 (100:10:1) to yield 
compound 195 as a colourless glass (12 mg, 80 %). ‘H-NMR (CDCI3) 8  1.57-1.75 (8  H, 
bs, 4 x CH2CH2CH2), 2.98-3.34 (12 H, 6  x CH2N), 3.81 (3 H, s, OCH3), 6.22 (1 H, d, 
7=16), 6.32 (1 H, d, 7=16), 6.75 (1 H, d, 7=8), 6.91 (1 H, bd, 7=9), 7.03 (1 H, bs), 7.20- 
7.33 (1 H, bm), 7.43 (1 H, bd, 7=16), 7.48-7.57 (1 H, bm), 7.66 (1 H, bd, 7=8), 7.80 (1 
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A b str a c t
T o  d e v e lo p  n ew  c y to to x in s , w h ich  co u ld  find use as a n ti-can cer  a gen ts, p o ly a m in e  co n ju g a te s  w ere  
sy n th e siz e d  co n ta in in g  sp erm in e an d  an  an th racen e or acridine u n it . S p erm ine is k n o w n  to  g r o o v e -b in d  to  
D N A ;  a n th ra cen e  an d  acrid in e  are k n ow n  to  in tercalate. It w as h o p e d  th a t th ese  p o ly a m in e -p o ly a r o m a tic  
c o n ju g a te s  w o u ld  u se  b o th  m o d e s o f  b inding.
S tu d ies  o f  g ro w th  in h ib it io n  o f  B 16 m urine m elan om a cells sh o w e d  the co n ju a te s  to  b e m o re  effective  
th a n  eith er  sp erm in e , a n th racen e-9 -carb oxy lic  acid  or a crid in e-9 -carb oxy lic  a c id , a n d  o f  th e  co n ju g a tes , 
th e  a cr id in e  d eriv a tiv e  sh o w e d  greatest activity.
P o ly a m in e s , su c h  as sp erm in e (1 ) a n d  sperm id ine (2) (F ig . 
1), o ccu r  n a tu ra lly  in  c e lls  in  a t lea st pM co n cen tra tion s  
(T a b o r  &  T a b o r  1984). A lth o u g h  the ir  precise fu n ctio n s are 
n o t fu lly  u n d e r sto o d , th ey  are k n o w n  to  be in vo lv ed  w ith  
ce ll g r o w th  a n d  rep lica tio n  an d  are th o u g h t to  p lay  a  role  
in  th e  s ta b ility  o f  ch ro m a tin  stru ctu re (H eb y  & Persson  
1990; B a su  e t  a l 1992). P o ly a m in e s  are k n ow n  to  have  
a n ti-tu m o u r  a c t iv ity  w h ich  is a ttr ib u ted  to  either general 
d e p le t io n  o f  p o ly a m in e  p o o ls ,  d o w n -r eg u la tio n  o f  en zym es  
su ch  a s  o r n ith in e  d eca rb o x y la se  a n d  sperm ine/sperm id ine- 
N' -a cety ltra n sfera se  (B e m a c k i e t  al 1992) or D N A  b in d in g  
a n d  in terferen ce  w ith  D N A  tran scrip tion . A t  p h y sio log ica l 
p H , m o st n a tu ra lly  occu rr in g  p o ly a m in es  are fu lly  pro- 
to n a te d , th e  p K , v a lu es  fo r  sp erm in e are 11-50, 10-95, 9-79  
a n d  8-90 (T a k ed a  et a l 1983; U sh e r w o o d  & Blagbrough 
1989). T h e se  p o sit iv e  ch a rges in teract w ith  the n egative  
ch a rg es o n  th e  su g a r-p h o sp h a te  b a ck b o n e  o f  D N A  cau sin g  





F ig. 1. Structures o f  spermine (1), spermidine (2) and amsacrine 
(3).
Correspondence: I. S. Blagbrough, School o f  Pharmacy and 
Pharmacology, University o f  Bath, Bath BA2 7AY, UK .
et al 1995). T h is  e lec tro sta tic  b o n d in g  c a n  b e  further su p ­
p lem en ted  b y  h y d r o p h o b ic  v a n  d er W a a ls’ in te ra ctio n s b e­
tw een m eth y len e  g ro u p s in  th e  p o ly a m in e  ch a in  an d  m eth y l 
groups o n  th y m in e  b a ses in  th y m id in e .
D N A  in terca la tors in c o r p o r a te  p la n a r  a ro m a tic  ring sy s­
tem s w h ich  in terca la te  b e tw e e n  th e  h e tero cy c lic  b a se  pairs, 
perpendicu lar to  the  a x is  o f  th e  d o u b le  h e lix  (W ilso n  1990). 
In terca lators b in d  b y  in te r a c tio n  b e tw een  their  7i-orbitals 
and th o se  in  th e  D N A  b a se s . T h e  9 -a m in o a cr id in e  d eriva tive  
am sacrine (3 , F ig . 1) is  a n  in te rca la to r  w h ich  h a s b een  
sh ow n  t o  have an ti-ca n cer  a c tiv ity , cu rren tly  fin d in g  u se  in  
the c lin ic  to  treat acu te  le u k e m ia  (B a g u le y  1991). S tr u c tu r e -  
activ ity  re la tio n sh ip  s tu d ie s  o f  a  ser ies  o f  a n a lo g u e s  h ave  
show n th a t th e  stren gth  o f  in te r c a la tio n  c lo se ly  corre la tes  
ta  the a ctiv ity  a s  an  a n ti- tu m o u r  a g en t (F erg u so n  &  B a g u ley  
1981).
To o b ta in  c o m p o u n d s  w ith  en h a n ced  cy to to x ic ity , w e  
d esigned  the syn th esis  o f  c o n ju g a te s  w ith  b ifu n ctio n a l m o d e s  
o f  b in d in g  to  D N A . S tu d ies o f  a m sa cr in e  a n d  o th e r  lig a n d s  
w ith su b stitu en ts o n  th e  a r o m a tic  r in g  sy stem  h a v e  sh o w n  
that th e y  can  p ro tru d e  in to  o n e  o f  th e  D N A  g ro o v es . I f  
this su b stitu en t is  a  k n o w n  g ro o v e-b in d e r , su ch  as sp erm in e  
(1), then sp ec tro sco p y  a n d  c o m p u te r  m o d e llin g  h a v e  sh o w n  
that it is  p o ss ib le  to  o b ta in  m o le c u le s  s im u lta n e o u s ly  d is­
playing b o th  m o d e s o f  b in d in g  (A d la m  e t a l 1994; R o d g e r  
et al 1994 , 1995). T h is  d u a l in te r a c tio n  sh o u ld  stren gth en  
the a sso c ia tio n  b etw een  lig a n d  a n d  D N A , a n d  therefore  
increase the cy to to x ic ity  c o m p a r e d  to  th a t sh o w n  b y  e ith er  
the g ro o v e-b in d er  o r  th e  in te rca la to r  a lo n e . O ur target 
co m p o u n d s (F ig . 2) c o n s is te d  o f  e ith er  an  a n th ra cen e  (4 ) 
or an acrid in e (5 ) u n it lin k ed  to  sp erm in e  v ia  an  a m id e  
bond at p o sit io n  9. T h e se  co n ju g a te s  w ere sy n th esized , 
purified a n d  then  screen ed  a g a in st  B 1 6  m u rin e m e la n o m a  
cells for cy to to x ic ty . F o r  c o m p a r iso n , sp erm in e (1 ), an -  
th racen e-9 -carb oxy lic  a c id  a n d  th e  p yrid in e  a n a lo g u e  ac-  
r id in e-9-carb oxylic  a c id , a n d  m ix tu res  o f  sp erm in e w ith  
these a cid s (1:1 , w /w ) w ere  a lso  screen ed .
Materials and Methods
Chemistry
T he syn th etic  co n ju g a tes  w ere  p rep ared  b y  co u p lin g  
sperm ine w ith  either a n th ra c en e  o r  a cr id in e -9 -ca rb o x y lic
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Fig. 3. Activity o f  spermine (1) ( □ )  and the two synthetic conjugates 
4 (O ) and 5 ( ■ )  in the M TT assay.
a cid s. In itia lly , th e  a c id  w a s co u p led  using  
d icy c lo h ex y lca rb o d iim id e  (D C C )  a n d  a  ca ta ly tic  am ount 
(0  05  eq u iv a len ts )  o f  h y d ro x y b en zo tr ia zo le  (H O B t) to  
sp erm in e w ith  o n e  p rim ary  a m in e  p rotected  w ith  a I» 
b u to x y ca r b o n y l (B O C ) g ro u p . T h e se  co u p lin g s gave poor  
y ie ld s w h ich  w ere fo u n d  to  b e  d u e  to  side reaction s w ith  
th e  se co n d a r y  a m in e  g ro u p s. T h is  p ro b lem  w as overcom e  
by  u sin g  sp erm in e w h ich  h a d  b een  p rotected  w ith  
b en zy lo x y ca rb o n y l (Z ) g ro u p s o n  b o th  secon dary  am ines 
an d  o n e  o f  the  prim ary  a m in es.
T h er e fo re , sp erm in e w a s first reacted  w ith  B O C  anhydride  
in  d ich lo ro m e th a n e  in  the  r a tio  th ree  eq u iv a len ts o f  sperm ine  
to  o n e  o f  an h yd rid e . T h e  / / ' -m o n o -B O C  p rotected  sperm ine  
w a s iso la te d  in  27%  y ie ld  b y  fla sh  c o lu m n  ch rom atograph y  
o n  silica  g e l (e lu a n t 10:4:1 C H 2C l2-m e th a n o l-c o n c . N H 4O H , 
v /v /v ). R e a c t io n  w ith  b en zy l ch lo ro fo rm a te  in  aq u eou s  
so d iu m  h y d ro x id e  so lu t io n  g a v e  94%  tri-Z -m on o-B O C  
sp erm in e a fter  w o rk -u p . S tirring  w ith  tr iflu oroacetic  acid at 
0 °C  fo r  4 5 m in  c lea v ed  th e  B O C  g ro u p  y ie ld in g  tri-Z  
sp erm in e in  94%  y ie ld . T h is  w a s c o u p le d  to  anthracene-9- 
ca rb o x y lic  acid  an d  a cr id in e -9 -ca rb o x y lic  acid  u sin g  D C C
an d  a  ca ta ly tic  a m o u n t  o f  H O B t (0  05  eq u iv a le n ts )  m  
d ich lo ro m e th a n e  a n d  d im e th y lfo rm a m id e , resp ective ly . T h e  
p ro tected  in te rm ed ia tes  w ere  reco v ered  in  y ie ld s  o f  7 0  an d  
60% , resp ectiv e ly , a fter  ch ro m a to g ra p h y . T h e  target  
c o m p o u n d s  w ere  o b ta in e d  in  90%  y ie ld  a fter  ca ta ly tic  
h y d ro g en o ly sis  o v e r  10% p a lla d iu m  o n  carb on .
M TT assay
T h e tria l c o m p o u n d s  w ere  screen ed  in  th e  3 -(4 ,5 -  
d im e th y lth ia z o l-2 -y l)-2 ,5 -d ip h e n y l tetra zo liu m  b rom id e  
(M T T ) a ssa y  a s  rep o rted  b y  M o sm a n n  (19 8 3 ).
B 16  m u r in e  m e la n o m a  c e lls  w ere  in cu b a ted  in  R P M I  
m ed ium  c o n ta in in g  te st  c o m p o u n d s  a t 37°C  fo r  4 8  h  (4 0 0 0  
cells /w ell in  a  9 6 -w e ll p la te ). T h e  p la te  w a s w a sh e d  an d  
then  in cu b a ted  w ith  1 r a g m L ' 1 M T T  in  seru m -free  R P M I  
m ed iu m  fo r  3 h . T h e  b lu e  fo rm a z a n  crysta ls p ro d u ced  b y  
v iab le  ce lls  w ere  d isso lv e d  in  d im e th y lsu lp h o x id e  to  a llo w  
assay  u sin g  a  m ic r o p la te  sp e c tr o p h o to m e te r  a t 54 0  n m  (test)  
an d  6 9 0  n m  (b a c k g r o u n d ). F o r m a z a n  g en era tio n  w a s a  
linear fu n c tio n  o f  th e  n u m b er  o f  v ia b le  ce lls  p resen t, a llo w in g  
th e  e s tim a tio n  o f  th e  E C 5 0  fo r  g ro w th  in h ib it io n .
Results and Discussion
T h e resu lts fro m  th e  a ssa y s  are sh o w n  in  T ab le  1 an d  
F ig . 3. T h e  a n th r a c e n e -9 -c a r b o x y lic  acid  a n d  a crid in e-9 -  
ca rb o x y lic  a c id  b o th  h ad  n e g lig ib le  effects. S p erm in e  (1 )  
in h ib ited  cell g r o w th  w ith  a n  E C 5 0  o f  3 x  1 0 -4 m a n d  sim p ly  
m ix in g  sp erm in e  w ith  th e  a r o m a tic  a c id s sh o w e d  n o  in crease  
in  p o te n c y  o v e r  sp erm in e  a lo n e . T h e co n ju g a te  (4) 
c o n ta in in g  th e  a n th ra c en e  u n it sh o w e d  in h ib it io n  w ith  an  
E C 50  o f  2  x  1 0 -5 m, a n  in crea se  in  p o te n c y  o f  a n  o rd er o f  
m a g n itu d e  o v er  sp er m in e , w h ils t  th e  acrid in e  a n a lo g u e  (5 )  
had  an  E C 5 0  o f  6 x  10 ~ 6 m , a lm o st  a  f ifty fo ld  in crease  in  
p o te n c y  o v er  sp er m in e . T h e se  resu lts  sh o w  th a t th e  sy n th etic  
co n ju g a tes c o m b in in g  b o th  a n  in terca la to r  a n d  g r o o v e-  
binder sh o w  g rea ter  c y to to x ic ity  th a n  c o m p o u n d s  w h ich  
exh ib it ju s t  o n e  o f  th e se  m o d e s  o f  b in d in g . C o ­
ad m in istra tio n  o f  a  p o ly a m in e  w ith  an  in te rca la to r  sh o w e d  
n o  en h a n cem en t o f  p o te n c y , d em o n stra tin g  th e  n ecessity  to  
link  p h y sica lly  th e  tw o  m o ie tie s  in  ord er  to  g iv e  b ifu n ctio n a l  
binders. S u ch  b ifu n c tio n a l D N A -lig a n d s  in h ib it the  gro w th  
o f  B 16  m u r in e  m e la n o m a  c e lls  a n d  are therefo re  n o v e l  
sp erm in e a n a lo g u e s  w h ich  o ffer  a  n ew  lead  in  the  d esig n  o f  
c y to to x ic  p o ly a m in e s  w ith  a n ti-ca n cer  activ ity .
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Table 1. Growth inhibition o f B16 murine melanoma cells as determined by the M TT assay.
EC50 (M)







Spermine (1) 2-9 ( +  1 -5) x 10-4 3-5
Anthracene-9-carboxylic acid >  10“3 < 3
Acridine-9-carboxylic acid >  10-3 < 3
Anthracene-9-carboxylic acid and spermine (1:1, w/w) 2-2 ( ±  0-6) x 10-4 3-7
4 1-8 ( ±  0-3) x 1 0 -5 4-8
5 6-2 ( ±  2-3) x 1 0 -6 5-2
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Polyamines and Polyamine Amides as Potent Selective Receptor 
Probes, Novel Therapeutic Lead Compounds and Synthetic 
Vectors in Gene Therapy
IA N  S . B L A G B R O U G H , S IM O N  C A R R I N G T O N  A N D  A N D R E W  J. G E A L L  
School o f  Pharmacy and Pharm acology, University o f  Bath, Bath BA2 7AY, UK
A b s t r a c t
The family of polyamines and polyamine amides, especially unsymmetrical synthetic 
members, is critically assessed with respect to chemical structure and pharmacological 
activity. Naturally occurring polyamines (and diamines) and mono- (and di-) acylated 
polyamines (polyamine amides) are blockers of cation channels that are receptor- or 
voltage-gated. Such compounds are leads for the design of novel therapeutic agents. 
Furthermore, polyamines and polyamine amides are templates for the design of synthetic 
vectors with potential application in gene therapy.
Natural di- and polyamines, spider and wasp venom polyamine amide toxins and their 
analogues, and totally synthetic polyamines, are potent cation-channel blockers with uses 
as selective receptor probes for nicotinic acetylcholine and glutamate (NMDA and non- 
NMDA) receptors, sodium and calcium channels. Therefore, as receptor probes, they may 
help us to understand the molecular mechanisms of neurodegeneration, and ultimately to 
design drugs for the treatment o f neurodegenerative diseases, especially stroke. Polyamine 
conjugates are also novel therapeutic lead compounds for possible treatments of cancer, 
diarrhoea, malaria and haemochromatosis (/Tthalassaemia). The metal chelating properties 
of (poly-) ethylenediamines have led to their incorporation in ion chelators which are 
synthetic RNase and DNase enzymes. Synthetic polyamines and polyamine amides have 
potential as novel vectors in gene delivery. Such compounds can condense DNA to form 
toroidal particles which may be incorporated in a non-viral gene delivery system. The 
applications of polylysine, polyethylenimine, Starburst polyamidoamine dendrimers, 
Transfectam (DOGS), cholic acid, and cholesterol conjugates to gene therapy are 
compared as a function of structure and pKa.
This assessment of polyamines and polyamine amides stresses the basicity of the amine 
functional groups. The pKa’s of these functionalities are a major determinant in their 
binding to biological macromolecules. Selectivity of pharmacological action also encom­
passes contributions from solution conformation and lipophilicity as well as amine pKa. 
The use of these compounds as leads for the design of novel therapeutics or gene medicines 
is demonstrated to be practical as well as theoretically possible.
Naturally occurring polyamines, such as the tetra- 
amine spermine (1) and the triamine spermidine (2) 
(Figure 1) occur in cells at micromolar concentra­
tions, and may even rise to millimolar levels in 
certain cancer cells (Tabor & Tabor 1984). The 
biosynthetic building blocks for these and closely 
related polyamines are the a-amino acids ornithine 
and lysine, affording the diamines putrescine (3) 
(1 ,4-diaminobutane) and cadaverine (4) (1,5-di-
Correspondence: I. S. B lagbrough. School o f  Pharmacy and 
Pharm acology, U niversity o f  Bath, Bath B A 2 7A Y , UK.
aminopentane), respectively (Figure 1). In recent 
years, we have established that polyamines, and the 
new class of cation-channel blocking agents poly­
amine amides, derived from analogy with the low 
molecular weight fraction of the venoms of certain 
spiders and a parasitic wasp, have potential as 
potent, selective receptor probes and even as novel 
therapeutic lead compounds in the design of anti­
tumour agents. Other workers, especially and 
Bergeron et al (1987, 1989), have addressed the 
usefulness of polyamines in cancer chemotherapy. 
In more recent studies, polyamines have been
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1 Spermine 2 Spermidine
3 Putrescine 4  Cadaverine
Figure l. Structures o f  p h ysio log ica l polyam ines and di­
am ines.
identified as novel leads for the design o f anti- 
diarrhoeal agents and antimalarials, and as ion 
chelators. Furthermore, the possibility o f using 
poly-amines (especially the dimers to hexamers of 
ethyl-enediam ine) for the design o f  specific syn­
thetic RNase or D Nase enzym es has been addres­
sed in elegant studies by Yoshinari et al (1991).
W e also considet the potential for polyamines, in 
an extension o f  one o f  their possible in-vivo roles, 
in maintaining D N A  condensation working with or 
without histones to stabilize the three-dimensional 
structure o f  polynucleic acids. Thus, polyamines 
and polyamine amides display many o f the ideal 
properties o f  synthetic vectors for polynucleotide 
delivery in gene therapy. Recent improvements in 
the use o f polylysine in D NA condensation and cell 
transfection have com e with the design of unsym- 
metrical polyam ine amides and the application of 
synthetic polyamines. Polyethylenim ine and Star- 
burst polyamidoamine dendrimers are two such 
polyamine based gene-delivery systems. Transfec- 
tam (DOGS) is an unsymmetrical glycine-sper- 
mine conjugate, designed and prepared by Behr et 
al (1989). It incorporates two long lipid chains for 
bilayer formation. DOGS is the parent member of  
lipopolyamine gene-delivery vectors, forming 
compact particles which are not cationic liposomes. 
By analogy, cholesterol and cholic acid conjugated 
unsymmetrical polyamine amides have recently 
been reported as synthetic vectors for gene therapy.
channel blockers is not surprising when one con­
siders their structures (Figure 2), essentially fully  
protonated at physiological pH. By comparison, the 
pKa’s o f spermine (1) and spermidine (2) are 11 -50, 
10-95, 9-79, 8-90 and 11-56, 10-80, 9-52, respec­
tively (Takeda et al 1983). The corresponding data 
for PhTX-3.4.3 (6) are 11-4, 10-4, 9-5 and 8-5, 
although the measured pKa o f 9-5 also accounts for 
the phenolic functional group, and therefore an 
increase in acidity from pH 10-4 to 9-5 finds both 
the secondary amine nearer to the tyrosine residue, 
and the phenoxide o f  tyrosine gaining protons 
(Jaroszewski et al 1996). The pKa o f phenol is 
10 0, and the pK a’s o f tyrosine are 10 07 and 9 1 1  
(and 2-20).
Many polyam ine amides have now been isolated  
from the venom  o f  certain spiders, (reviews by 
Blagbrough & Usherwood 1992; Schafer et al
1994) and characterized pharmacologically 
(reviews by U sherwood & Blagbrough 1991; Car­
ter 1995; M ueller et al 1995). These low molecular 
weight toxins (argiotoxins) (7 -12 , Figure 3) are 
potent selective non-com petitive antagonists o f 
glutamate receptors, blocking the cation-selective  
channels associated with this excitatory a-amino 
acid (both N M D A  and non-NM DA glutamate 
receptors). Therefore, they have potential as phar­
m acological probes and as lead compounds for the 
design o f drugs to treat neurodegeneration, espe­
cially stroke (Parks et al 1991; Blagbrough & 
Usherwood 1992; Carter 1995). However, unsym ­
metrical polyam ine amides require complete 
syntheses for sufficient material to be available for 
detailed pharm acological characterization.
The novel polyam ine FTX-3.3 (13) (Blagbrough 
& Moya 1994) and the polyamine amide sFTX-3-3 
(14) (M oya & Blagbrough 1994) are important 
pharmacological tools (Figure 4) for modulation of  
voltage-sensitive calcium  channels (VSCC). These 
polyamines block VSCC with differential inhibi-
Ion-channel blockers
Spermine (1) is found in the venom of certain 
spiders where it accompanies a range of small- 
m olecule phenols (Fischer & Bohn 1957; Gilbo & 
Coles 1964). The venom o f a solitary parasitic 
wasp (Philanthus triangulum) contains thermo­
spermine (a regioisom er o f spermine) conjugated to 
L-tyrosine in PhTX-4.3.3 (5) (Figure 2). This 
unsymmetrical polyamine amide is essentially 
equipotent with synthetic spermine-containing 
analogue PhTX-3.4.3 (6). These polyamine amides 
(philanthotoxins) are potent blockers of the cation 
channels gated exogenously by nicotine and endo­
genously by acetylcholine. That they are cation-
PhTX -4 .3 .
P h T X -3 .4 .3
Figure 2. Structures o f  polyam ine am ide w asp toxin PhTX- 
4.3 .3  (5) and its essen tia lly  equipotent analogue PhT X -3.4.3  
(6).
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Figure 3. Structures o f  polyam ine am ide spider toxins.
tion in mature rat cerebellar Purkinje cells (Dupere 
et al 1996) and antagonize P-, N- and L-type VSCC 
in a voltage-dependent manner (Norris et al 1996). 
Other pharmacological evidence for cation-channel 
blockage com es from one endogenous role of 
cytosolic spermine (1) and spermidine (2) as gating 
molecules for inward rectifying potassium channels 
(Ficker et al 1994; Lopatin et al 1994).
Cancer
There is ever increasing realization o f the biologi­
cal effects o f polyamines, particularly in cellular 
processes, including growth and replication (Heby 
& Persson 1990). Thus, it is not surprising that 
polyamine conjugates continue to be the focus of  
significant attention as potential anticancer agents.
There is a polyamine transporter which specifically  
mediates the uptake o f extracellular polyam ines 
into cells (Seiler & Dezeure 1990), and rapidly 
dividing tumour cells require large quantities o f  
polyamines. Consequently, this polyamine trans­
porter is up-regulated in tumour cells moreso than 
in normal cells (Seiler et al 1990). Polyamines 
groove-bind to D N A  from either the major or the 
minor groove (Rodger et al 1994, 1995) and it is 
thought that endogenous polyam ines also affect 
chromatin stability and structure (Basu et al 1992). 
The biosynthetic pathway o f  the common physio­
logical di- and polyam ines, putrescine (3), cada- 
verine (4), spermidine (2) and spermine (1) is w ell 
characterized (reviews by Tabor & Tabor 1984; 
Marton & Pegg 1995). Indeed, inhibitors have been 
synthesized for som e o f the key enzym es (Guo et al 
1995; Pegg et al 1995). Taking these three aspects 
into account when designing polyamine based 
anticancer agents, there exists a potential uptake 
mechanism with selectivity for cancer cells (Cohen  
& Smith 1990) and two possible modes o f  cyto­
toxicity. This toxicity may be mediated either by 
DN A  binding and hence disruption o f transcription 
(Feuerstein et al 1990), or by interference with 
polyamine biosynthetic pathways thereby mod­
ulating the cellular concentrations o f endogenous 
polyamines.
To date, som e o f  the sim plest and most effective  
synthetic polyam ines to show anticancer activity 
have been developed by Porter, Bergeron and their 
co-workers. They initially found activity with 
spermidine and spermine analogues which are N- 
alkylated (Porter et al 1982, 1985). Further studies 
showed the best analogues to be tetra-amines which  
have been b/s-ethylated on the terminal, primary 
amines (e.g. 15, 16 and 17) (Bergeron et al 1987, 
Porter et al 1987) (Figure 5). These compounds are
15  DENSPM
1 3  FTX-3.3




Figure 4. Structures o f  synthetic polyam ines which modulate 
voltage-sensitive calcium  channels.
Figure 5. Structures o f  synthetic antiproliferative polyam ines  
D E N SPM  (15), D E SP M  (16) and D EH SPM  (17).
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recognized and taken into cells by the polyamine 
transporter. Once inside the cells, they deplete 
intracellular polyamine pools by down-regulating 
the enzym e ornithine decarboxylase (ODC), the 
first enzym e in the polyamine synthesis pathway, 
and up-regulating the sperm ine-sperm idine N ]- 
acetyltransferase (SSAT) enzym e which works in 
the back conversion pathway (Bergeron et al 1989). 
The synthetic analogues were found to replace the 
physiological polyam ines and, over a 24-h period 
in-vitro, it was found that the total amount o f  
polyam ine normalized and the nitrogen content o f  
each m olecule (i.e. 3 in spermidine, 4 in spermine) 
remained constant. The cytotoxic effects o f the 
analogues DENSPM  (15), DESPM (16) and 
DEHSPM (17) in in-vitro cultures o f L1210 cells, 
over 96 h, were 1-3 fXM, 0-2 fiM and 0-06 /tM 
respectively. Investigation into their mode o f action 
showed a significant variation in their ability to 
compete with native polyam ines for cellular 
uptake, but in time it was found that they reached 
comparable concentrations in the cells and had 
similar depleting effects on endogenous polyamine 
pools. As the analogues show different cytotoxic 
effects, the displayed cytotoxicity might be partly 
due to som e site-specific interactions not involved  
in polyamine biosynthesis. Investigations are on­
going both into the mechanism o f action o f  these 
compounds and into their clinical use.
Another approach to the development o f anti­
tumour compounds is the covalent linking o f  
cytotoxic agents, whose activity is mediated 
through direct interaction with DNA, to a poly­
amine. The resulting conjugate will be transported 
into the cell through the polyamine transport 
mechanism (if recognized) and the polyamine 
should further aid D NA binding o f the cytotoxic 
component at its DNA target site. We have been 
linking polyaromatic anthracene and acridine m oi­
eties to spermine (Carrington et al 1996). Acridine 
derivatives, especially 9-aminoacridines, show  
pronounced antitumour activity. Extensive research 
into structure-activity relationships culminated in 
the antileukaemic drug amsacrine (Denny et al 
1983). The activity of these compounds is due to 
their ability to bind to D NA through intercalation, 
resulting in disruption o f  D N A  transcription. Initi­
ally, the N ] position o f spermine was bound to the 9 
position o f anthracene through an amide bond. The 
interaction o f the resulting conjugate with DNA  
was then investigated by linear and circular 
dichroism, and normal absorption techniques 
(Adlam et al 1994; Rodger et al 1994). These data 
were supported by dynamic computer modelling 
simulations o f the conjugate in the presence of a 
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Figure 6. Structures o f  cytotox ic synthetic conjugates o f  
polyam ines with tricyclic arom atics.
1995). One o f the outcom es o f  these experiments 
was the conclusion that this conjugate can bind in a 
bifunctional manner with the polyam ine in the 
groove, and the anthracene intercalating between  
the base pairs. In-vitro structure-activity studies on 
a series o f  analogues (18-22) (Figure 6), on B16  
murine melanoma cells, have shown that the best 
activity is achieved by attaching spermine to acri­
dine via an aniline (Qarawi et al 1997). The most 
potent cytotoxin in this series, synthesized to date, 
also has a 5-carbon spacer derived from 5-amino- 
valeric acid between the acridine and spermine 
m oieties (21) which may confer a region o f flex­
ibility between the two bonding regions.
Chlorambucil is a nitrogen mustard containing 
compound which is used to treat a number o f  
cancers. Its mechanism o f action is DNA alkylation 
and hence cross-linking o f  D NA strands. Chlor­
ambucil has been conjugated to both spermidine (2) 
and spermine (1), resulting in D NA cross-linkers 
with the potential to carry up to 3 (23) or 4 (24) 
positive charges at physiological pH (Cohen et al 
1992, Cullis et al 1995) (Figure 7). In-vitro 
experiments have established that these polyamine 
conjugates are recognized by cellular uptake sys­
tems— the spermidine conjugate displayed ~ 3 5  
times more cytotoxicity than chlorambucil alone. 
These conjugates alkylate DN A  in the same posi­
tions as chlorambucil indicating that the polyamine 
moiety does not affect the mechanism o f alkylation. 
However, in-vivo studies did not display the high 
level o f activity predicted by in-vitro assays (Cullis 
et al 1995). A more promising approach to the 
design and synthesis o f polyam ines containing a 
reactive functional group capable o f DNA alkyla­
tion has recently been described (Li et al 1996). 
Spermidine and spermine analogues (e.g. 25) were 
prepared with the primary amines replaced by 
aziridine functional groups (Figure 7) to give a bis- 
alkylating agent bound to a polyam ine backbone. 
Studies showed these compounds to be transported 
into cells and to cross-link D N A . The in-vivo
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Figure 7. Structures o f  polyam ine-containing com pounds 
which cross-link  D N A .
activity o f spermine analogue 25 was comparable 
with that shown by other 6/s-alkylating agents in 
the same assay, making it a lead compound with the 
potential for further development.
Diarrhoea
Tabor & Tabor (1964) reported that relatively high 
concentrations o f spermine (1) and spermidine (2) 
are found in the gastrointestinal tract. The physio­
logical activity o f polyam ines in the gut was sub­
sequently characterized with initial investigations 
carried out with polymers derived from ethyleni- 
mine, com m only available polyamine-containing 
compounds with a variety o f industrial uses (M el­
amed et al 1977). Branched-chain polymers were 
shown to inhibit gastric emptying in rats, while 
linear structures had negligible physiological 
activity. It was thought that polyamines might find 
use as appetite suppressants or in prolonging the 
action o f orally administered drugs. However, fur­
ther experimentation involving oral administration 
to dogs resulted in a severe retching response 
(Tansy et al 1977). Investigations were also carried 
out with sm all-m olecule polyamines, for example, 
spermine (1), spermidine (2) and synthetic close 
analogues (Belair et al 1981). The naturally 
occurring polyam ines were found to have a pro­
found effect on gastric emptying, while synthetic 
analogues had significantly lower activities.
In HIV-related infections, there is a frequent 
occurrence o f  serious diarrhoea, either as a result o f 
infection or as a side effect from certain drugs. So 
far this has been difficult to treat, existing drugs 
giving only a partial response and a high relapse 
rate. A new approach to treatment, developed by 
Bergeron et al (1996), has been the use of synthetic 
polyam ines to slow  gut motility. After initial 
structure-activity assessment, DEHSPM (17) was 
found to show antidiarrhoeal activity in a castor-oil
induced diarrhoea model in rats, and has now been 
used to treat patients in the clinic. The drawback 
with this compound is chronic toxicity associated  
with the accumulation o f metabolites. In-vivo stu­
dies have shown that DEHSPM (17) is first meta­
bolized by V-de-ethylation. Normally, the next 
stage in polyamine metabolism would be removal 
of the 3-aminopropyl m oieties through the action 
of SSAT and polyam ine oxidase. However, the 
remaining homospermine contains only 4-am ino- 
butyl fragments which are not m etabolized and 
therefore accumulate in the patient’s tissues. This 
problem has been resolved by synthesizing com ­
pounds substituted with hydroxyl groups (on tet­
rahedral carbon atoms o f  ^-configuration) (26) on 
methylenes located y to the ethylated amines 
(Figure 8). These alcohol functional groups offer 
potential sites for enzym atic conjugation or oxida­
tion leading to further metabolism  and elimination. 
Studies showed that tetra-amine 26 retains its gas­
trointestinal activity and has significantly reduced 
chronic toxicity, although the exact mechanism of  
degradation is not known (Bergeron et al 1996). 
These results illustrate the way in which toxicity  
associated with polyam ines can be reduced without 
the loss o f therapeutic effect.
Malaria
Malaria continues to be a major health problem in 
the world today despite the progress which has 
been made in its treatment. Major problems are 
now related to strains o f the malaria parasite which 
are resistant to chloroquine and other antimalarial 
drugs. This has led to a continuing search for drugs 
of different chem ical classes and with new modes 
of action (Fairlamb & Cerami 1992). Much work 
has been carried out on the biosynthesis and func­
tion of diamines putrescine (3) and cadaverine (4), 
and polyamines spermidine (2) and spermine (1) in 
a number o f human infective parasites (reviews by 
Tabor & Tabor 1984; Marton & Pegg 1995). x- 
Difluoromethylomithine (DFM O) (27) was identi­
fied as a potential therapeutic agent as it is known 
to be an inhibitor o f  ornithine decarboxylase, the 
enzyme which transforms ornithine to putrescine in 
the first stage in polyam ine biosynthesis (M etcalf et 
al 1978; Bacchi et al 1987). In-vivo trials showed 




Figure 8. A substituted polyam ine (26) for the treatment o f  
diarrhoea.
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som e cases it fails to bring about a com plete cure. 
A further approach involves synthetic polyamines 
which have previously found use in treating cancer 
(Bitonti et al 1989). Terminally 6/s-benzylated  
tetra-amines were initially identified as inhibiting 
the growth o f the parasites Plasm odium  falciparum  
and Plasmodium berghi. Further studies were car­
ried out to investigate the optimum number of 
methylene groups required in the polyamine chain, 
as well as the effect o f changing the benzyl sub­
stituents to m oieties o f similar size (e.g. cyclo- 
hexylmethyl and ring substituted benzyls) 
(Edwards et al 1991. As a result o f testing both in- 
vitro and in-vivo (using a P. berghi infection in 
m ice) a lead compound was chosen with terminal 
N-benzyl groups and a sequence o f 3 then 7 then 3 
m ethylene groups separating the four amines (28) 
(Figure 9). This tetra-amine is less potent than 
chloroquine yet more active than tetracycline, an 
antibiotic used to treat resistant strains o f  infection. 
On co-administration of tetra-amine 28 with 
DFMO (27), a com plete cure was effected in the in- 
vivo mouse model. The mechanism o f action of 
these compounds has not yet been fully investi­
gated, but it is thought that they interfere with 
polyamine biosynthesis as well as possibly occu­
pying key binding sites on DNA.
Iron chelation
In all forms o f life, except for a few  species of 
bacteria, iron plays an important role, principally in 
metabolic processes where the interconversion 
between the +  2 and -I- 3 oxidation states is used in 
a variety o f redox proteins. In the environment, iron 
generally occurs at the ferric oxidation level which 
is largely insoluble and hence presents a problem to 
microorganisms. Microbes have solved this by 
generating iron chelator systems called sidero- 
phores which com plex (sequester) ferric iron, 
allowing it to be accessed (Bergeron 1984). Many 
siderophores contain polyamine or polyamide 
moieties, for exam ple, parabactin (29), agrobactin 
(30) and desferrioxamine B (31) (Figure 10). Phy- 
tosiderophores are low molecular weight ion-che­
lating compounds endogenous to plants. They
facilitate iron solublization and transport in a 
manner analogous to the microbial siderophores. 
The phytosiderophore nicotianamine (32) (Scholz  
et al 1992; Matsuura et al 1994) is a triamine which  
contains a primary, a secondary and a tertiary 
amine functional groups. These polyamine based 
compounds are important as probes for the inves­
tigation o f iron transport into various cells, the 
roles o f  iron in infection and, in their own right, 
as potential treatments for haemochromatosis 
(/?-thalassaemia).
RNase and DNase
The design and synthesis o f  synthetic catalysts 
which hydrolyse RNA with the aim o f developing  
systems which mediate site-selective scission has 
recently been reported (Yoshiriari et al 1991). 
Originally, the catalysts were based around transi­
tion metal chemistry, but recent developments have 
incorporated oligoam ines, such as ethylenediamine, 
which will efficiently hydrolyse RNAs. In this 
cleavage, the mechanism o f  action involves an 
intramolecular acid-base co-operation between an 
ammonium cation and an uncharged amine. To 
make a site-selective RNA cleaving agent, ethyle­
nediamine has been linked to a 19-mer piece o f  
synthetic DNA (33) (Figure 11), designed so that 
the DNA sequence is complementary with the RNA  
sequence adjacent to the desired site for scission. 
Ethylenediamine is used here for its acidity, rather 
than as a metal-ion chelator. The pKa’s o f ethyle­
nediamine are 9-2 and 6-5 (Yoshinari et al 1991), 
or 9-92 and 6-86 (Albert & Serjeant 1984). How-
HO R
v-o W
° v A 'H 2 >
N OH
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2 9  R = H, Parabactin
3 0  R = OH, Agrobactin
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2 7  DFMO
Figure 9. Structures o f  D FM O  (27) and a tetra-amine (28) for 
the treatment o f  malaria.
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Figure 10. Structures o f  siderophores parabactin (29), agro­
bactin (30), desferrioxam ine B (31 ) and nicotianam ine (32).
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ever, “that intramolecular co-operation between 
two amino residues plays a dominant role is 
strongly evidenced” with “remarkable acceleration 
o f RNA hydrolysis by simple oligoam ines as highly 
potent catalytic m oieties for artificial 
ribonucleases” (Yoshinari et al 1991). DNA inter­
calators (anthraquinones) substituted with metal 
chelating m oieties (ethylenediamines), and com- 
plexed to cupric ions, induce the chain cleavage of 
double stranded DNA (Ihara et al 1994). Other 
artificial ribonucleases have been designed on a 
polyamine or am ine-im idazole template (Breslow
1995), with acridine used to effect RNA intercala­
tion (Shinozuka et al 1994).
DNA condensation for polynucleotide delivery 
in gene therapy
Polylysine condenses D NA and effects cell trans­
fection (Marquet & Houssier 1991; Behr 1993; 
Perales et al 1994). However, poly lysine has 
becom e the subject o f more recent interest when 
covalently attached to a protein, such as transferrin 
(Cotten et al 1990), as a targeting moiety. This 
protein then enables target cell penetration by 
receptor-mediated endocytosis. However, in order 
to avoid enzym atic lysosom al degradation, the 
inclusion o f free chloroquine (Cotten et al 1990) or 
the attachment o f replication-deficient adenoviruses 
(Wagner et al 1992) is required to ensure better 
survival and more efficient transfer o f the foreign 
D NA into the cytosol o f  the target cell. Other 
polyamine based gene-delivery system s include 
polyethylenim ine, an organic macromolecule with 
a high cationic charge density potential which 
should facilitate D N A  condensation and pH buf­
fering (Boussif et al 1995). These applications of 
polyamines m imic the natural effects o f histones 
interacting with D N A  (Ong et al 1976). Starburst 
polyamidoamine dendrimers are a new class of 
highly branched spherical polymers that are soluble 
in aqueous solution and have a unique surface of 
primary amino functional groups (Tomalia et al 
1990; Wu et al 1994; Kukowska-Latallo et al
1996). At physiological pH, these amino groups 
w ill be positively charged and should interact with 
polyanions (phosphates along nucleic acid poly­
mers). Recent studies have shown that certain 
polyamidoamine dendrimers form stable com-
HI
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Figure 11. D N A -eth y len ed ia m in e  conjugate (33) as a syn­
thetic R N ase.
plexes (aggregates) with D N A  under most physio­
logical conditions, som e o f  which are capable o f  
mediating non-specific in-vitro transfection. H ow ­
ever, these starburst polyam ine dendrimers may not 
condense D NA into toroidal particles without the 
use o f an additional polycation (DEAE-dextran) 
(Kukowska-Latallo et al 1996).
The binding o f polyam ines has a profound effect 
on DNA structure, causing transitions from B to 
both A and Z forms o f DN A . At higher con­
centrations, polyam ines mediate conformational 
changes such as D N A  aggregation and condensa­
tion. Condensation is caused by alleviation o f  the 
charge repulsion between neighbouring phosphates 
on the D NA helix allow ing collapse into a more 
compact structure. D N A  condensation is dependent 
upon three characteristic properties o f the natural or 
synthetic polyam ines— the number o f positive 
charges which therefore influence the local ionic 
strength (Stewart & Gray 1992), the regiochem ical 
distribution o f  these charges whose pKa’s are 
intimately dependent upon their co-operativity, and 
the local salt concentration. The prerequisites for 
delivery o f D N A  across an intact cytoplasm ic 
membrane are condensation and masking o f  the 
negative charges o f  the phosphate backbone. 
Spermine (1) and spermidine (2) are two o f  the 
smallest natural polycations capable o f effecting  
both charge neutralization and condensation o f  the 
polynucleic acid. These interactions are, however, 
readily reversible under physiological conditions 
(Behr 1993). Indeed, many studies (Allison et al 
1981; Feuerstein et al 1990; Plum et al 1990; 
Rowatt & W illiam s 1992; Stewart & Gray 1992) 
have shown structure-activity relationships for the 
binding and condensation o f DNA with poly­
amines, indicating that appropriately modified 
polyamines are ideally suited for use as gene 
delivery systems. In order to reinforce these effects, 
it is apparently beneficial if  a lipid is covalently  
bound to the polyam ine (Behr 1986).
At present, most gene therapy protocols involve  
the use o f  highly efficient recombinant viral vec­
tors. These gene vectors, however, have a limited 
carrier capacity and are associated with immuno-
v  v  ^  ^  O  Ms 
Me
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Figure 12. Structures o f  L ipofectin  com ponents D O TM A  
(34) and D O PE (35).
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logical problems as a function o f high dose or 
repeated use (Temin 1990). Synthetic vectors 
could, in principle, solve these problems, and the 
design o f such systems has recently becom e an area 
o f considerable research interest. Lipofectin  
(Feigner et al 1987) (Figure 12), was the first 
cationic lipid formulation to receive widespread 
attention as a gene delivery agent. Lipofectin con­
sists o f a 1:1 mixture o f (m ono-)cationic lipid 
bw-ether (2,3-dioleyloxy)propyl-V , N, V-trimethyl- 
ammonium chloride (DOTM A, 34) and fusogenic  
lipid diester dioleoylphosphatidylethanolamine 
(DOPE, 35, Figure 12). As the cationic lipid 
requires the presence o f  a phosphatidylethanola- 
mine (e.g. DOPE) capable o f  destabilizing bilayer 
membranes and promoting membrane fusion, it has 
been postulated (Walker et al 1996) that the 
encapsulated D N A  must gain entry to the cyto­
plasm by fusion or destabilization o f the plasma or 
endosomal membrane.
D ioctadecylam idoglycylsperm ine (DOGS, Trans- 
fectam, 36), and dipalmitoylphosphatidyl-ethano- 
lamine spermine (DPPES, 37) were the first poly­
amine based lipid (lipopolyam ine) gene delivery  
vectors (Behr et al 1989).These m olecules contain 
spermine (1) covalently bound to two hydrophobic 
chains (Figure 13). When m ixed with D N A , these 
polyamine-incorporating vectors cause condensa­
tion and formation o f self-organized compact 
nuclear particles with an excess coat o f cationic 
lipid. These compact particles are not cationic 
liposomes. The fact that DOGS (36) does not 
require the presence o f a fusogenic lipid or a d if­
fusing weak base such as chloroquine (which acts
N— N N - H
by buffering the acidic lysosom al interior), has two  
possible explanations— either the particles gain 
access to the cells via direct membrane fusion, or 
the D N A  escapes from the degradative lysosom al 
enzym es because o f the unique buffering capacity 
o f spermine (Remy et al 1994). This interpretation 
is supported by an analysis o f  the pKa’s o f DOGS 
(36) which are 10-5, 9-5, 8-4 and 5-5. It may indeed  
be significant that the fourth (lowest) o f  these pKa 
values corresponds to the internal pH o f  the (acidic) 
lysosom e (Remy et al 1994).
Cationic facial amphiphiles (m olecules w hose  
hydrophilic and hydrophobic regions are segre­
gated along the long axis) are another polyam ine- 
based system showing promise for gene delivery  
(W alker et al 1996). Various polyam ines— sper­
mine (1), tetraethylenepentamine (38), and pen- 
taethylenehexam ine(39)— have been conjugated to 
bile acid based amphiphiles and then m ixed with  
DOPE (35) (1:1) to facilitate transfection. To date, 
bis-glycosylated c/s-AB-steroid (40), a 3a, 7a, 12a- 
cholic acid amide linked to pentaethylenehexamine 
(Figure 14) has shown the greatest ability to pro­
mote /Tgalactosidase plasmid uptake in COS-7 
cells (W alker et al 1996).
The pKa values o f tetraethylenepentamine (38) 
are reported as 10 0, 9-2, 8-2, 4 1  and 2-6 (Paoletti 
et al 1973). This is an exquisite example o f the co- 
operativity o f  pKa’s along a polym ethylene chain, 
as the fourth pKa is comparable with acetic acid 
(pKa 4-76), and the fifth with chloro- (pKa 2-87) 
and fluoroacetic acids (pKa 2-59) (Albert & Ser­
jeant 1984). Therefore, at pH 7 0, a + 3  charge for 
the bile acid monoacylated conjugate o f pen­
taethylenehexamine is assumed (Walker et al
1996). W hile it is also assumed that the polyam ine 
moiety o f  this cholic acid conjugate w ill bind to 
DNA and cause condensation, the com plete
HjN.
3 8  T e t ra th y len ep e n ta m in e
3 6  DOGS
H - N
3 7  DPPES
3 9  P en ta e th y le n e h e x a m in e
4 0  Ri = R2 + ix-glucoside
Figure 13. Structures o f  lipopolyam ines D O G S (36 ) and 
DPPES (37).
Figure 14. Polyam ines and a g lycosy lated  cholic  acid  
conjugate (4 0 ).
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mechanism of DNA uptake, mediated by this syn­
thetic vector, is unclear. One possible theory is that 
the destabilizing properties of facial amphiphiles 
(i.e. molecules which possess a nonpolar steroid 
nucleus with a polar side chain) might increase the 
fusogenic potential of the transfecting particle.
Spermidine- (41) and spermine-cholesterol (42) 
(Figure 15), with spermidine carbamoylated at Nl or 
N3, and used as an unknown mixture of these two 
+  2  charged regioisomers, are novel transfection 
agents (Guy-Caffey et al 1995). The mechanism by 
which these compounds promote DNA delivery is 
unknown, but it is possible that the cationic portion 
interacts with the nucleic acid, while the hydro- 
phobic cholesteryl moiety associates with the 
membrane lipid bilayer, resulting in fusion with, or 
transient disruption of the cell membrane effecting 
direct delivery of DNA to the cytosol (Guy-Caffey et 
al 1995). Another cationic cholesterol transfection 
agent is cholesteryl-spermidine (43) (alkylated at 
N , therefore potentially a 4 - 3 charged species) 
(Moradpour et al 1996) (Figure 15), similar to 
DOGS (36) and (like DOGS) not dependent on the 
presence of a fusogenic lipid for DNA delivery to the 
cell. A detailed analysis of the structure and for­
mulation of cationic lipids which are efficient in 
achieving gene delivery to the lung, with particular 
respect to cystic fibrosis, has established that catio­
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Figure 15. Structures o f  polyam ine-containing cholesterol 
transfection agents.
vectors (Lee et al 1996). Possibly more significant is 
the conclusion that the activity of cationic lipids for 
in-vivo gene delivery could not be predicted from 
the in-vitro analysis, and therefore this has to be 
tested directly (Lee et al 1996).
Conclusions
Polyamines and polyamine amides continue to 
demonstrate significant potential in the pharmaceu­
tical sciences both as lead compounds for a variety 
of therapeutic targets, and as synthetic vectors in 
gene therapy for efficiently effecting gene delivery.
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Optimization of the MTT Assay for B 16 Murine Melanoma Cells 
and its Application in Assessing Growth Inhibition by 
Polyamines and Novel Polyamine Conjugates
M O U S A  A . Q A R A W I , S IM O N  C A R R I N G T O N , I A N  S . B L A G B R O U G H , S T E P H E N  H . M O S S
A N D  C O L IN  W . P O U T O N
School o f  Pharm acy and Pharmacology, U niversity o f  Bath, Bath BA2 7AY, UK
Abstract
As part o f our continuing development of new cytotoxins with potential anticancer activity, 
w e have synthesized polyamine conjugates containing both the linear tetra-amine spermine 
and an acridine unit.
Studies o f growth inhibition by these novel conjugates and spermine were carried out 
using B16 murine melanoma cells. The 3-(4,5-dim ethylthiazol-2-yl)-2,5-diphenyltetrazo- 
lium bromide (MTT) bioassay has been optimized for this cell line with respect to 
incubation time for MTT metabolism, inoculum density and incubation period.
A linear relationship has been established between the amount o f formazan produced and 
the number o f  viable B16 murine melanoma cells. Furthermore, the optimal incubation 
time o f  cells with MTT is 3 h. Beyond this time no further significant amount o f  formazan 
was generated. The optimal seeding density was determined (4000 ce lls /w e ll for 2- or 3- 
day experiments), and we estimate that the doubling time for B16 cells is approximately 
24 h. In 48-h assays, spermine (1) inhibits cell growth with an EC50 o f  450 ^M, acylated 
analogue (5) has an EC50 o f 5 yM, almost a hundred-fold increase in potency over 
spermine, and the aniline analogue (6) has an EC50 o f  1 /^M, a five-fold increase in potency 
over amide analogue (5). The EC50 for spermine (1) and aniline (6) changed little over 3 
and 6 days compared with the EC50 over 2 days.
We conclude that there is little significant metabolic influence (with time) on the 
observed toxicity data. We have also shown that the synthetic conjugates combining 
both an intercalator and groove binder show greater cytotoxicity than compounds that 
exhibit just one o f these modes o f binding. These analogues therefore offer a new lead in 
the design o f  cytotoxic polyamines with potential anticancer activity.
Many biological assays require the measurement of 
surviving and proliferating cells. This can be 
achieved by several methods, including counting 
cells that include or exclude dye as an indicator of  
cell membrane integrity (Hoskins et al 1956), 
chromium release in which radioactive chromate 
bound to cellular protein is released as a function of 
cell lysis (Fass & Fefer 1972), measuring incor­
poration o f radioactive DNA precursors such as 
[3H]thymidine or [ 125I]iodo-deoxyuridine during 
cell proliferation as an index correlating inhibition 
o f DNA synthesis with cell death (Brereton et al 
1975), and measuring the metabolism o f tetra- 
zolium  bromide by the dehydrogenase enzymes in
Correspondence: I. S. B lagbrough, School o f  Pharmacy and 
Pharm acology, U niversity o f  Bath, Bath B A 2 7A Y , UK.
the mitochondria o f living cells, as in the 3-(4,5- 
dim ethylthiazol-2-yl)-2,5-diphenyltetrazolium  bro­
mide (M TT) bioassay (Mosmann 1983).
As part o f  our continuing research into novel 
polyam ine-based compounds with anticancer 
activity, we have synthesized small m olecules 
based on the naturally occurring polyam ine sper­
mine (1, Figure 1), so that these synthetic analogues 
will bind to D N A  with potential cytotoxic results. 
Polyam ines are structurally simple aliphatic com ­
pounds consisting o f two or three flexible carbon 
chains connected by basic nitrogen atoms that are 
protonated at physiological pH (Takeda et al 1983; 
Usherwood & Blagbrough 1989). They are recog­
nized as playing an important role in many cellular 
processes including cell growth and replication 
(Heby & Persson 1990). Polyam ines have also
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demonstrated anticancer activity which is attributed 
to DNA binding and interference with DNA tran­
scription (Feuerstein et al 1990), general depletion 
of poly amine pools and down-regulation of 
enzymes such as ornithine decarboxylase and 
spermine-spermidine-iV1 -acetyltransferase (Porter 
et al 1991). Notable examples of these synthetic 
polyamines are diethylnorspermine (DENSPM) (2), 
diethylspermine (DESPM) (3) and diethylhomos- 
permine (DEHSPM) (4) (Bergeron et al 1989, 
Figure 1). Our novel analogues are composed of a 
polyamine conjugated to the 9 position of acridine, 
either through an amide bond (5) or directly as the 
aniline (6 ) (Figure 1). Polyaromatics such as acri­
dine are known to bind to DNA through inter­
calation (Wilson 1996 and acridine analogues have 
been shown to have anticancer activity (Denny et al 
1983). We anticipated that our conjugates will 
show bifunctional modes of DNA binding (Adlam 




Figure 1. Structures o f  sperm ine (1), diethylnorsperm ine (2), 
diethylsperm ine (3 ), diethylhom osperm ine (4) and the two  
synthetic sperm ine conjugates am ide (5) and aniline (6).
enhanced cytotoxicity over either the polyamine or 
polyaromatic moiety alone (Carrington et al 1996).
To make an initial assessment of the growth 
inhibitory activity of our synthetic conjugates, we 
carried out in-vitro studies using B16 murine mel­
anoma cells to obtain EC50 values. We chose the 
MTT assay with continuous drug exposure as it 
involves no washing or cell transference steps and 
leads to rapid, sensitive and reliable indices of 
growth. Furthermore, there is reproducible drug 
sensitivity in an individual cell line over the course 
of multiple passages and over several months of 
cultivation (Alley et al 1988).
In this assay, the tetrazolium ring in MTT is 
cleaved by dehydrogenase enzymes in the active 
mitochondria of living cells, converting the water- 
soluble yellow tetrazolium salt to the insoluble blue 
formazan crystals. Dissolving these crystals in 
dimethylsulphoxide allows determination of the 
number of viable cells present at the time of MTT 
addition by colorimetric assessment. This approach 
to in-vitro testing has been successfully used for 
large scale screening of potential new anti­
neoplastic drugs by the National Cancer Institute in 
the USA.
As a literature search failed to reveal any record 
of the MTT assay being applied to cultures of the 
B16 murine melanoma cell line, it was necessary to 
optimize the inoculum density and incubation per­
iod to estimate the cell growth rate and ensure that 
drug assays were conducted in the logarithmic 
phase of cell growth. It was also necessary to 
determine the optimum time for the viable cells to 
metabolize the available MTT, and to prove that 
the relationship between cell number and absor­
bance of the formazan metabolite is linear. We 
address these issues as part of our optimization of 
the MTT assay for B16 murine melanoma cells, 
and apply this assay to assess the growth inhibition 




The synthetic conjugates were prepared by acyla- 
tion or alkylation of acridine species with spermine 
bearing three amine protecting groups, leaving one 
nucleophilic primary amine functional group free 
to react. Acridine-9-carbonyl-Af1 -spermine was 
prepared as previously reported (Carrington et al
1996) from acridine-9-carboxylic acid and Nl, N2, 
N3 -tribenzyloxycarbonyl-spermine. Acridine-9-
(Nl -spermine) was prepared by first reacting 
9(10H)-acridone with thionyl chloride (DMF 2 
drops, heated under reflux, 0-5 h) to yield 9-chlor-
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oacridine (96%). This was then stirred with solid 
NaOH in molten phenol (18 h) to afford 9-phe- 
noxyacridine (99%). Displacement o f phenoxide 
by N ], N2, /V3-tribenzyloxycarbonyl-spermine was 
achieved by stirring the reactants in molten phenol 
(18 h) to yield, after silica gel chromatography, the 
protected intermediate (44%). The target com ­
pound was obtained in 90% yield after catalytic 
hydrogenolysis over 10% palladium on carbon.
C ell culture
B 16 murine melanoma cells were cultured in RPMI 
1640 media (Gibco) containing 10% heat-inacti­
vated foetal bovine serum (ICN), 2 mM L-gluta- 
mine, 1% non-essential amino acids, 50 int. units 
m L -1  penicillin, and 50 fig m L " 1 streptomycin in 
a humidified atmosphere o f  95% air and 5% C 0 2.
M TT assay
All MTT assays were carried out in 8 x 12-well 
culture plates (Nunc) using a standard configuration 
o f w ells containing B16 murine melanoma cells in 
RPMI media containing a test compound, cells in 
media, or test compound in media. The wells 
lacking drug served as a control for cell growth. 
The w ells without cells were blank controls during 
spectrophotometric detection o f  MTT, allowing for 
chem ical reduction o f MTT, and for contributions 
to absorbance by chrom ogenic drug solutions. The 
96-w ell plates were incubated at 37°C for the 
required time periods, washed with serum-free 
RPMI 1640 media, and then incubated with 
1 mg m L -1  MTT in serum-free RPMI media for 
the predetermined optimal period. The blue for­
mazan crystals produced by viable cells were dis­
solved in dim ethylsulphoxide to allow assay using 
a microplate spectrophotometer (Perkin-Elmer) at 
540 nm (test) and 690 nm (background). The 
measured absorbances were used to estimate EC50 
values for the test compounds.
Results and Discussion
Before using the MTT assay to assess the cyto­
toxicity o f antineoplastic agents on B16 cells, 
control experiments were performed to ascertain 
the relationship between B 16 cell number and the 
amount o f tetrazolium metabolized to formazan. 
The optimal time required for the metabolism of 
tetrazolium was also determined (Figure 2). This 
confirms the linear relationship between the amount 
of formazan produced and the number o f viable 
B16 murine m elanoma cells. It also shows the 
optimal incubation time o f  cells with MTT to be 
3 h, as beyond this time no further significant 
amount o f  formazan was generated.
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Figure 2. Correlation o f  v iab le B 1 6  murine m elanom a cell 
number against the absorbance o f  m etabolized  M T T (at 
540 nm test w avelength  less 6 9 0  nm  background) after incu­
bation o f  c e lls  w ith M TT for ♦  1 h; O  2  h; +  3 h and ■  4  h. 
Each point represents the mean va lu e for eight independent 
determ inations perform ed in one experim ent.
The optimal seeding density was determined over 
several time periods (Figure 3) allowing us to 
estimate the doubling time for B 16 cells to be 
approximately 24 h. From this we determined that 
for experiments o f  48 or 72-h duration the optimal 
seeding density is 4000 cells/w ell. For 6-day 
experiments, the optimal density was 1000 
cells /w ell (data not shown). These initial seeding 
densities gave enough cell growth to allow  con­
veniently large amounts o f  formazan metabolite to 
be generated on addition o f  MTT, without limiting 
the growth o f the cells as they becom e confluent.
The results from the assays over 48 h are shown in 
Figure 4. Spermine (1) inhibits cell growth with an
1 - 8 -
0  2 0 0 0  4 0 0 0  6 0 0 0  8 0 0 0  1 0 0 0 0
Inoculation density (cells/well)
Figure 3. Correlation o f  absorbance o f  m etabolized  M TT by 
B16 cells  w ith their inoculation  density  after incubation in 
RPMI m edia for O  0  h; ♦  24  h; -P 4 8  h or ■  72 h. Each point 
represents the m ean value for eigh t independent determ inations 
performed in one experim ent.
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Figure 4. Dose-dependent growth inhibitory effect of O  
spermine (1) and synthetic conjugates ■  5 and -I- 6, following 
incubation with B16 cells for 48 h as estimated by the MTT 
assay. Each curve represents the average of three independent 
assays with six replicate samples for each data point. Error bars 
have been omitted for clarity (s.e. of all values < 20%).
EC50 of 450 /iM, the acylated analogue (5) has an 
EC50 o f 5 /iM, almost a hundred-fold increase in 
potency over spermine, and the alkylated (aniline) 
analogue (6) has an EC50 of 1 /tM, approximately a 
five-fold increase in potency over amide analogue (5). 
The EC50 for spermine (1) and aniline (6) changed 
little over 72 h and 6 days compared with the EC50 
over 48 h (Figures 4, 5). Spermine (1) was incubated 
for 48 h and 72 h (Figure 6). Synthetic conjugates (5) 
and (6) were tested for 48 h, and up to 6 days with 
continuous drug exposure throughout these periods. 
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Figure 5. Dose-dependent growth inhibitory effect o f ------
spermine (1) a n d  synthetic conjugate 6 following expo­
sure to B16 cells for ■  48 h; O  72 h or +  6 days as estimated 
by the MTT assay. Each curve represents the average of three 
independent assays with six replicate samples for each data 




72 h 48 h 48 h 6 days 72 h 48 h 
Time
Figure 6. Mean EC50 values for ■  spermine (1) and syn­
thetic conjugates 5 and S3 6 as determined using the MTT 
assay aher incubation with B16 murine melanoma cells for 
various time periods. Each value represents the average of 
three independent assays with six replicate samples for each 
data point.
due to limited solubility in culture medium and modes 
of action requiring extended contact with cells were 
detected (Figure 6).
A comparison o f the antiproliferative activity of 
DENSPM (2-3) and DEHSPM (4) against L1210 
cells in culture, showed average 48 h EC50 values 
of > 1 0 0  fiM, 36 /tM and 0-4 /iM  and 96-h EC50 
values of 1-3 /iM , 0-2 /iM and 0 06 /iM , respec­
tively, (Bergeron et al 1989). The reason for this 
increase in cytotoxicity with time was attributed to 
interference with enzymes in polyamine biosyn­
thetic pathways and hence depletion o f polyamine 
pools. From the results obtained with our con­
jugates (Figure 6), we conclude that there is little 
significant metabolic influence (with time) on the 
observed toxicity data. We have also shown that the 
synthetic conjugates combining both an intercalator 
and groove binder show greater cytotoxicity than 
compounds that exhibit just one o f these modes of 
binding (Carrington et al 1996). These are therefore 
analogues that offer a new lead in the design of cy ­
totoxic polyamines with potential anticancer 
activity.
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N o v e l 2 3 - , 2 4 -  a n d  2 8 -m e m b e r e d  c y c l ic  p o ly a m in e  a m id e s  
( c in n a m a m id e s )  h a v e  b e e n  p r e p a r e d  b y  c lo su r e  o f  d ip h e n y l  
eth ers; fu n c t io n a liz e d  c o n ju g a te s  o f  sp e r m id in e  an d  sp er ­
m in e  u n d e r w e n t  in tr a m o le c u la r  a r o m a t ic  n u c le o p h ilic  su b ­
s t itu t io n  to  a ffo r d  n itr o -s u b s t itu te d  a n a lo g u e s  o f  ca d a b ic in e  
c la s s  (2 4 -m e m b e r e d  p o ly a m in e  la c ta m )  a lk a lo id s .
P o ly a m in es su ch  as triam ine sp erm id in e  1 and tetraam ine 
sp erm in e 2  are w id e ly  d istributed  in nature and d isp lay  a variety  
o f  b io lo g ica l a c t iv it ie s .1 C in n am ic acid  (3 -p h en y lp rop en o ic  
acid ) con ju g a tes are co m m o n ly  iso la ted  as the corresponding N- 
substitu ted  a m id es from  plant so u r c e s .2 F eru lic  acid (4-  
h y d ro x y -3 -m eth o x y c in n a m ic  ac id ) 3  is  found as feru loyl-  
putrescine, a co n ju g a te  o f  1 ,4 -d iam in ob u tan e.3 Arl,Ar}-D i- (£ >  
feru loy lsp erm id in e 4  h as b een  iso la ted  from  Corylus avellana 
L .3-4 S p erm id in e co n ju g a tes  h av e  a lso  b een  found  asym m et­
rically  su b stitu ted  w ith  b oth  feru lic  and c a ffe ic  (3 ,4 -d ih yd rox-  
y c in n a m ic) a c id s 5 .3 M a y ten in e ,5 from  Maytenus chuchuhua- 
sha, is  the u n su b stitu ted  d ic in n a m a m id e  o f  sperm id ine 1. 
D icin n a m a m id es o f  sp erm in e 2  in c lu d e  kukoam ine A , a 
b io lo g ica lly  a c tiv e  b is (d ih y d r o c a ffe o y l)  co n ju g a te .6-7 
C y c lic  p o ly a m in e  a m id e  co n ta in in g  c in n am am id es are less  
com m on  natural p rod u cts w h o se  b io lo g ic a l a c tiv itie s  are largely  
un k n ow n .2-8 S p erm in e  2  co n ta in in g  m a cro cy c lic  polyam ine  
lactam s in c lu d e  inter alia ch a en orh in e and ephedradine A .8 
S p erm id in e 1 co n ta in in g  p o ly a m in e  lactam s in clu d e cod on o-  
carpine 6 , from  Codonocarpus australis,9 and capparisin ine 7 .10 
C ad ab icin e 8  is a d ip h en y l eth er  2 4 -m em b ered  ring containing
sperm idine 1, from  Cadaba farinosa Forsk. T h e  reg ioch em ica l 
substitution o f  the d ip h e n y l ether m o iety  is  reversed  with  
respect to the u n sym m etrica l sp erm id in e m o iety  in  6  and 7 . 11 
W e are unaw are o f  a sy n th e s is2-8 o f  a  ca d a b ic in e  8  class  
alkaloid, a lthough  a  reg io co n tro lled  sy n th esis  o f  the Lunaria 
diphenyl eth er a lk a lo id  co d o n ocarp in e 6  h as b een  rep orted .12
M a crocycles co n ta in in g  d ip h en y l ethers are o f  ch em ica l and 
b io log ica l in terest a s th ey  o ccu r  in v a n co m y c in  and ristocetin  
antibiotic fa m ilie s .13-15 A lso , th ese  su b stitu tion  patterns are 
found in an ti-can cer  p ep tid e  con jugate  R A -V II  and A C E  
inhibitor K -1 3 .15-16 M a c r o c y c lic  p o ly a m in e  lactam s incorporat­
ing a d ip h en y l ether h a v e  b een  prepared u sin g  in term olecu lar  
U llm ann d iaryl eth er  sy n th e sis  fo llo w ed  b y  lactam  form a­
tion.8-12 H erein  w e  report the  first d esig n  and sy n th e s is  o f  23 -, 
24 - and 28 -m em b ered  ring p o ly a m in e  lactam  con ju g a tes that 
are nitro-substituted a n a lo g u es  o f  ca d ab ic in e  8  c la s s  a lka lo ids.
The required su b stitu ted  c in n a m ic  a cid s w ere  prepared from  
the corresponding b en za ld eh y d es  by K n o ev en a g e l co n d en sa ­
tio n .17-18 Isoferu lic  a c id  (3 -h y d ro x y -4 -m eth o x y c in n a m ic  acid ) 9 
w as prepared in g o o d  y ie ld  (92% ) under standard con d ition s  
starting w ith  m a lo n ic  acid  (E tO H , p ip erid ine , pyrid in e, 3 h, 
reflu x ).17 4 -F lu o ro b en za ld eh y d e  w as sim ila r ly  con verted  into  
4-flu orocin n am ic a c id  10  (85% ). N itration ortho to fluorine, in 
order to activate the fin a l in tram olecu lar n u c leo p h ilic  substitu ­
tion (SN/A r) reaction , a c h ie v e d  w ith  c o n c . n itr ic acid , afforded  
4-f]uQ ro-3-n itrocinnam ic acid  11 (1 h, 0  °C , 72% ).
For the 2 3 -m em b ered  ring 1 2 , N -(3 -a m in o p r o p y l)- l ,3 -d i-  
am inopropane w as p rotected  w ith  triflu oroacety l grou p s on the
H,N' H,N'
y r * i
4 R1 = OH. R2 = OMe
5 R1 = OH. R2 = OH
OH
6 R1 = H. R2 = OMe
7 R1 = OMe. R2 = H
8 n= 1. R’ =OH. R2 = H
12 n = 0. R1 =OMe, R2 = N02
13 n= 1. R1 = OMe, R2 = N02
14 /?= 1. R1 =OH, R2 = N02
3 R* = OH. R2 = OMe 
9 R1 = OMe. R2 = OH
10 R1 = F, R2 = H
11 R1= F ,R 2 = N 02
OMe n o 2
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prim ary am ino  groups (2  equ iv . C F 3C 0 2Et, TH F, 10 min, 
25 ° C ) .lv-2i T h is  w as fo llo w ed  by im m ediate B oc protection o f  
the central, secon dary  am ine (B 0 C2 O , TH F, 18 h, 25  C). C one, 
aq. am m on ia  w as added to the so lu tion  o f  tri-protected triaminc 
until the pH w as greater than 11 to rem ove the trifluoroacetyl 
protecting groups (2 4  h). M on o -B o c  protected am ine was 
iso la ted  and purified  by flash colum n chrom atography ( 1 5 : 5 :  I , 
C H 2C I2-M e O H -c o n c .  aq. N H 3, v /v /v , /?, 0 .1 3 ). The cinnam ic  
acid  m o ie t ie s1 7 18 w ere cou p led  sequentia lly  (first the iso- 
feru loyl 9  then the 4 -flu oro-3 -n itro  11) to the primary am ines by 
p re-activation  w ith  2-m ercap toth iazo lin c (2 -th iazo line-2-th io l, 
th ia z o lid in e -2 -th io n e)5 (D C C , 0 .01 equiv. D M A P , C H 2CI2, 1 h, 
25 °C , fo llo w e d  by filtration to rem ove the urea). M on o-B oc  
protected  triam ine w as added to the y e llo w  C H 2C12 solu tion  o f  
the /V -acylated 2 -m ercap to th iazo lin e  and the coupling was 
ty p ic a lly  c o m p le te  after 3 h (ca . 50%  each acylation). C yclisa-  
tion  w a s brought about by stirring w ith  5 equiv. C sF  in 
anhydrous D M F  (1 8  h) to g iv e  23-m em bered  ring polyam ine  
lactam  1 2  (79%  iso la ted  y ie ld ). O -A rylation  has occurred by 
in tram olecu lar arom atic n u c leop h ilic  substitution (S N/Ar) reac­
tion  o f  o -n itro -a ctiv a ted  fluoride by the rem ote phenol.
For the 2 4 -m em b ered  ring 14 , sperm idine 1 w as reacted w ith  
form alin  to  g iv e  a hexahydropyrim id ine adduct (0 .9 5  equiv. 
37%  w /w  aq. form ald eh yd e, H 20 ,  1 h, 91% ) as d evelop ed  
in d ep en d en tly  by G an em  and H esse  and their co-w ork ers.22-23 
Iso feru lic  acid  9 ' 718 w as co u p led  to the primary am ine o f  this 
r e g io se le c t iv e ly  protected  sperm id ine through the 2-m ercapto- 
th ia zo lin e  activa ted  in term ediate ( —78 to 25  °C, 55% ). A fter  
ch rom atograph y, this hexahydropyrim id ine w as deprotected by 
heating w ith  m alon ic  acid  and pyridine (EtO H , reflux, 2 h, 
79% ).22 4 -F lu o ro -3 -n itro c in n a m ic  acid 11 w as coupled  to the 
u n covered  prim ary am ine and then the secondary am ine w as 
protected  by a B o c  group (1.1 equ iv . B o c20 ,  M eO H , 18 h, 
25 °C , 89% ) to afford  a linear precursor o f  cadabicine analogue  
13. C y c lisa tio n  w as carried out by stirring with 3 equiv. C sF  in 
anhydrous D M F  (1 8  h, 71 % iso lated  y ie ld ), final purification by 
R P -H P L C  (5 pm  C 8 inertpak co lu m n  elu ting with 1:4 aq. TFA  
(0 . l% )-M e O H , v /v , A = 2 5 0  nm). T F A  catalysed  deprotection  
(1:1 T F A -C H 2C12, v /v , 45  m in, 0  °C , 90% ) o f  the B oc group in 
diaryl eth er  15 w as fo llo w ed  by O -dem ethylation  with B B r3 
(1 .2  eq u iv ., C H 2C12, 3 h, —78 °C ) to g iv e  2 /-nitrocadabicine 14 
in 60%  iso la ted  y ie ld .
For the 2 8 -m em b ered  ring 15, sperm ine 2 w as protected in a 
sim ilar fa sh ion  to A /-(3 -am in op rop yl)-l,3 -d iam in op rop an e vide 
supra. T r iflu oroacety l groups w ere used to b lock the two  
prim ary a m in es then tw o  B oc groups w ere introduced at the 
secon dary  am in es. C on e. aq. am m onia  w as used to rem ove the 
tr iflu oroacety l protectin g  groups and the /VAA^-diBoc sperm ine  
w as then purified  by chrom atography. The tw o cinnam ic acid  
m o ie t ie s17-18 w ere introduced  in a step w ise  fashion using  
2-m erca p to th ia zo lin e  activation  to y ield  the cyclisation  pre­
cursor. C y c lisa tio n  w as carried out in anhydrous D M SO  with 3 
equ iv . K 2C 0 3 and 10 eq u iv . 18-crow n-6. the oxygen  nucleophi- 
lic ity  w a s found to be too  low  w ithout the crow n ether. The  
cy c lisa tio n  reaction  did not proceed  to com pletion  at 25 °C 
(starting m aterial still present after 24  h). H ow ever, heating the 
m ixture to 5 0  °C , in the presence o f  18-crow n-6. led to com plete  
reaction after 5 h, y ie ld in g  the desired m acrocycle  15 (66% ).
T h e  p rev io u sly  prop osed  m echan ism  o f  cyclisa tion  involved  
bringing the tw o  sites  o f  reaction into proxim ity by Ji-orbital 
stack in g  in teraction s b etw een  the electron rich guaiacol (2- 
m eth o x y p h en o l) ring and the electron  deficien t o-fluoro- 
nitrophenyl r in g .15 H ow ever, m acrocycle  form ations o f  this 
type h ave recently  been  dem onstrated to proceed in good  yield  
w hen the aryl hydroxy  group is replaced by an alkyl hydroxy  
group, p rov in g  that su ch  Jt-Jt interactions are not necessary for 
su cc ess fu l c y c lisa tio n .24 A s the isolated  y ield s are high, this 
practical approach by arom atic n u cleop h ilic  substitution (intra­
m olecular S N/A r reaction) shou ld  find ready app lication  in the 
syn ih csis o f  natural products and their a n a logu es w ith particular  
reference to  c y c lic  sperm id ine and sp erm in e  a lk a lo id s o f  the 
cod on ocarp in c 6 and cad ab ic in e  8  c la s se s .
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